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ABSTRACT	
Numerous	pathological	amyloid	proteins	spread	from	cell-to-cell	during	
neurodegenerative	disease,	facilitating	the	propagation	of	cellular	pathology	and	
disease	progression.	Understanding	the	mechanism	by	which	disease-associated	
amyloid	protein	assemblies	enter	target	cells	and	induce	cellular	dysfunction	is	
therefore	key	to	understanding	the	progressive	nature	of	such	neurodegenerative	
proteinopathies.	In	this	study,	we	utilized	an	imaging-based	assay	to	monitor	the	ability	
of	disease-associated	amyloid	assemblies	to	induce	the	rupture	of	intracellular	vesicles	
following	endocytosis,	as	well	as	to	elucidate	the	cellular	consequences	of	this	damaging	
mechanism	of	invasion.	We	observed	that	the	ability	to	induce	vesicle	rupture	is	a	
conserved	feature	of	fibrillar	amyloid	assemblies	of	a-synuclein,	tau,	and	polyglutamine-
expanded	huntingtin.	In	the	case	of	a-synuclein	amyloid	assemblies,	we	determined	
that	Serine	129	phosphorylation	and	strain	conformation	dictate	the	potency	of	
endocytic	vesicle	rupture.	We	also	demonstrated	that	vesicles	ruptured	by	a-synuclein	
are	lysosomes,	and	that	these	damaged	vesicles	are	targeted	to	the	autophagic	
degradation	pathway.	We	observed	that	vesicles	ruptured	by	a-synuclein	can	
accumulate	and	fuse	into	large,	intracellular	structures	resembling	Lewy	bodies	in	vitro,	
and	showed	that	the	same	markers	of	vesicle	rupture	surround	Lewy	bodies	in	brain	
sections	from	PD	patients.	These	data	underscore	the	importance	of	this	conserved
		xxvi	
endocytic	vesicle	rupture	event	as	a	damaging	mechanism	of	cellular	invasion	by	
amyloid	assemblies	of	multiple	neurodegenerative	disease-associated	proteins,	and	
suggest	that	proteinaceous	inclusions	such	as	Lewy	bodies	form	as	a	consequence	of	
continued	fusion	of	autophagic	vesicles	in	cells	unable	to	degrade	ruptured	vesicles	and	
their	amyloid	contents.		
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CHAPTER	ONE	
REVIEW	OF	LITERATURE	
Introduction	
	 Neurodegenerative	diseases	represent	one	of	the	most	formidable	challenges	
facing	biomedical	science	and	medicine.	Despite	intensive	study	and	significant	
advances	in	understanding	of	disease	pathology	and	pathogenesis,	patients	afflicted	by	
diseases	such	as	Alzheimer’s	disease	(AD),	Parkinson’s	disease	(PD),	Huntington’s	
disease	(HD),	amyotrophic	lateral	sclerosis	(ALS),	or	Creutzfeldt-Jakob	disease	(CJD)	are	
only	treated	symptomatically,	as	no	disease-modifying	therapy	exists	to	target	the	
etiology	of	these	diseases.		
	 Despite	tremendous	heterogeneity	in	the	spectrum	of	clinical	symptoms	
resulting	from	dysfunction	and	degeneration	of	the	central	nervous	system	(CNS)	in	
these	diseases,	each	similarly	exhibit	pathological	accumulation	of	misfolded	proteins	
into	amyloid,	a	term	referring	to	insoluble	protein	aggregates	of	a	fibrillar,	b-sheet-rich	
structure.	Because	each	disease	is	characterized	and	defined	by	the	aggregation	of	a	
specific	disease-related	protein,	these	disorders	are	collectively	known	as	
proteinopathies,	and	the	research	community	has	focused	on	understanding	the	
mechanisms	by	which	specific	proteins	become	misfolded	and	ultimately	cause	
neuronal	dysfunction	and	death.	Intriguingly,	an	explosion	of	insight	into	the	
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pathogenesis	of	neurodegenerative	proteinopathies	has	grown	from	an	idea	that	was	
once	considered	heretical.		
	 In	1982,	Stanley	B.	Prusiner	first	described	the	concept	of	a	prion,	a	
proteinaceous	infectious	particle	[1],	and	determined	that	a	protein	alone	was	the	
etiological	agent	of	transmissible	spongiform	encephalopathies	(TSEs)	such	as	CJD	in	
humans,	scrapie	in	sheep	and	goats,	and	bovine	spongiform	encephalopathy	(BSE)	in	
cows.	The	idea	that	a	misfolded	protein	aggregate	could	occupy	the	same	infectious	
domain	previously	thought	to	be	only	that	of	bacteria,	viruses,	fungi,	protozoa,	and	
helminths	was	just	as	much	controversial	as	it	was	groundbreaking	[2].	In	the	years	since	
this	discovery,	the	list	of	proteins	that	behave	in	a	similar	fashion	to	CJD	prions	in	
converting	from	a	normal,	soluble	form	to	a	disease-associated,	insoluble	amyloid	form	
and	amplifying	through	templated	recruitment	of	additional	soluble	counterparts	has	
grown	to	encompass	b-amyloid	(Ab)	and	tau	in	AD,	a-synuclein	(a-syn)	in	PD,	
polyglutamine-rich	huntingtin	(HTTExon1-Q³37)	in	HD,	and	TAR	DNA-binding	protein-43	
(TDP-43)	and	superoxide	dismutase	1	(SOD-1)	in	ALS,	among	others	[3].	Considering	
neurodegenerative	amyloid	proteins	as	“prion-like”	in	their	aggregation	behavior	has	
not	only	yielded	new	knowledge	of	disease	mechanisms,	but	also	led	to	novel	avenues	
of	exploration	for	therapeutic	development.		
	 In	addition	to	their	misfolded	amyloid	structure,	another	key	feature	of	all	prions	
is	their	self-propagation	between	affected	and	naïve	neuronal	cells	and	brain	regions,	
and	ultimately	their	transmission	from	one	infected	host	organism	to	another.	While	the	
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“prion-like”	analogy	for	Ab,	tau,	a-syn,	HTTExon1-Q³37,	TDP-43,	and	SOD-1	does	not	
extend	so	far	as	to	say	that	the	neurodegenerative	proteinopathies	caused	by	these	
misfolded	amyloid	proteins	are	transmissible	between	hosts,	the	similarity	with	prions	
spreading	from	cell-to-cell	and	between	different	brain	regions	has	been	demonstrated	
for	each	disease,	suggesting	a	unifying	role	for	prions	in	neurodegenerative	diseases	[3].	
While	insights	into	the	prion-like	behavior	of	amyloid	proteins	will	have	important	
therapeutic	potential	for	preventing	disease	progression,	much	remains	to	be	elucidated	
about	the	mechanisms	by	which	misfolded	amyloid	aggregates	corrupt	their	soluble	
counterparts,	disrupt	cellular	homeostasis,	and	propagate	their	infectious	pattern	of	
protein	misfolding.		
	 In	seeking	to	understand	amyloid	protein	propagation	more	completely,	and	
elucidate	the	specific	steps	in	the	life	cycle	of	cellular	infection	that	allow	this	process	to	
occur,	insights	can	be	gained	by	examining	other	paradigms	of	infection	in	different	
contexts.	In	the	situation	of	a-syn	in	PD,	it	is	known	that	the	process	of	aggregate	
cellular	entry	resembles	the	infectious	mechanism	of	cellular	invasion	by	some	bacteria	
and	viruses,	which	escape	from	the	endocytic	vesicle	by	inducing	membrane	rupture	[4].	
However,	specific	factors	that	determine	the	potency	of	this	a-syn	cellular	invasion	
mechanism	are	unknown.	Furthermore,	whether	amyloid	assemblies	of	other	
neurodegenerative	disease-associated	proteins	are	capable	of	invading	target	cells	in	
this	manner	remains	to	be	elucidated,	as	does	the	effect	of	this	damaging	mechanism	of	
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entry	on	cellular	homeostatic	processes,	aggregate	cell-to-cell	propagation,	and	
inflammatory	responses.		
The	studies	discussed	in	this	dissertation	focus	on	endocytic	vesicle	rupture	as	a	
mechanism	of	cellular	invasion	for	several	neurodegenerative	disease-related	proteins,	
focusing	for	a-syn	aggregates	on	both	specific	protein	modifications	that	influence	
vesicle	rupture	potency	as	well	as	the	effects	of	a-syn-induced	vesicle	rupture	on	
cellular	homeostasis	and	aggregate	propagation.	A	more	complete	appreciation	of	how	
amyloid	protein	aggregates	invade	target	cells	and	propagate	their	misfolding	in	a	prion-
like	manner	will	aid	in	the	development	of	novel	disease-modifying	therapies	to	benefit	
millions	of	patients	worldwide.		
The	Prion	Principle	of	Infectious	Proteinopathy	
Protein	as	Infectious	Agent.	
At	the	center	of	Stanley	Prusiner’s	definition	of	a	prion	is	the	fact	that	a	protein	
alone	is	the	sole	infectious	agent	causing	TSEs	[1].	There	are	several	unique	features	of	
prions	that	confer	this	infectious	potential.	When	the	scrapie-associated	prion	protein	
PrPSc	was	isolated	from	infected	animals	[5],	it	became	known	that	this	protein	is	highly	
resilient	against	proteolytic	digestion	[6],	indicating	that	it	is	composed	of	stable	protein	
aggregates	with	few	enzymatic	digestion	sites	accessible	in	its	assembled	form.	
Furthermore,	this	aggregated,	protease-resistant	characteristic	of	PrPSc	is	necessary	to	
maintain	its	infectious	capability,	as	prolonged	proteolytic	digestion	or	disaggregation	
procedures	sterilize	prions	and	abolish	infectivity	[6,	7].	As	researchers	sought	to	learn	
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more	about	the	nature	and	source	of	prions,	a	startling	discovery	was	that	prion	protein	
(PrP)	is	encoded	by	a	normal	cellular	gene	(PRNP)	in	the	host,	and	because	this	gene	and	
protein	product	are	not	uniquely	associated	with	infection,	the	prion	infectious	agent	
was	no	longer	considered	to	be	a	foreign	entity	[8-10].	Hence	two	different	forms	of	PrP	
exist,	a	normal	“cellular”	form	(PrPC)	that	is	completely	degraded	upon	protease	
digestion	and	a	disease	(“scrapie”)-associated	aggregated	form	(PrPSc)	that	is	resistant	to	
protease	digestion.	Because	the	primary	structure	of	PrP	encoded	by	PRNP	is	the	same	
in	healthy	and	infected	animals,	the	differences	between	PrPC	and	PrPSc	are	due	to	post-
translational	events	[10].	PrPC	is	composed	mainly	of	a-helix	(42%)	and	has	little	b-sheet	
secondary	structure	(3%),	wheras	PrPSc	has	a	much	higher	b-sheet	content	(43%)	and	a	
lower	a-helical	structure	(30%)	[11].	Limited	digestion	of	PrPSc	by	proteinase	K	produces	
an	N-terminally	truncated	form	known	as	PrP27-30,	named	for	the	molecular	weight	of	
this	protease-resistant	core	present	in	infectious	preparations,	which	also	consists	
mainly	of	b-sheet	secondary	structure	(54%)	with	low	a-helical	content	(21%)	and	is	
known	to	polymerize	into	rod-shaped	amyloid	fibrils	as	seen	in	PrP	amyloid	plaques	[11,	
12].	These	structural	studies	brought	about	the	idea	that	conversion	of	the	precursor	
PrPC	to	PrPSc	involves	posttranslational	modification	during	which	the	protein	becomes	
both	enriched	in	beta-sheet	structure	and	resistant	to	limited	proteolysis,	and	is	then	
capable	of	producing	infection	because	of	these	characteristics.		
Further	confirmation	of	the	protein-only	hypothesis	is	demonstrated	by	
examining	different	forms	of	disease.	Although	transmissible	forms	of	prion	diseases	
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may	be	most	well-known,	sporadic	CJD	with	no	known	cause	other	than	the	
hypothesized	spontaneous	misfolding	of	PrPC	into	PrPSc	represents	85%	of	cases,	and	
over	40	different	mutations	of	PRNP	are	known	to	cause	genetic	prion	disease	[2].	All	
families	affected	by	heritable	forms	of	prion	diseases	exhibit	an	earlier	age	of	onset	and	
longer	duration	of	illness	than	sporadic	cases	[13].	One	such	form	of	heritable	prion	
disease	is	known	as	Gerstmann-Straussler-Scheinker	(GSS)	syndrome,	wherein	affected	
family	members	inherit	a	leucine	to	proline	substitution	at	PrP	codon	102	in	an	
autosomal-dominant	fashion,	leading	to	the	development	of	PrP27-30	accumulation	and	
PrP-immunoreactive	amyloid	plaques	in	the	brain	[14].	Transgenic	animal	models	have	
also	illuminated	the	proteinaceous	source	of	prion	diseases.	One	study	utilized	mice	
expressing	two	point	mutations	in	mouse	PrP	affecting	the	structure	of	its	globular	
domain	to	demonstrate	that	these	genetic	alterations	in	PrP	result	in	a	fully-penetrant	
lethal	spongiform	encephalopathy	with	cerebral	PrP	plaques	[15].	These	findings	
indicate	that	infectious	prion	diseases	can	also	be	genetic	in	nature,	and	suggest	that	
mutations	in	the	PRNP	gene	may	cause	prion	disease	by	facilitating	conversion	of	the	
protein	into	the	prion	state.		
Template	for	Misfolding.	
Another	unique	feature	of	prions	that	defines	their	infectious	nature	is	the	ability	
of	misfolded,	aggregated	PrPSc	to	serve	as	a	template	and	trigger	for	the	further	
misfolding	of	PrPC,	facilitating	amplification	of	the	prion	state	and	propagation	of	its	
misfolded	structure	through	naïve	counterparts.	This	templated	conversion	of	PrPC	by	
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PrPSc	is	illustrated	profoundly	in	transgenic	mice	expressing	both	hamster	and	mouse	
prion	protein,	where	inoculation	with	hamster	prions	greatly	expands	the	number	of	
hamster	prions	but	not	mouse	prions,	and	vice	versa	with	inoculation	of	mouse	prions	
[16].	This	observation	reveals	a	species	specificity	of	prion	infectivity	dictated	by	the	PrP	
sequence,	and	indicates	that	interactions	between	PrPSc	and	homologous	PrPC	initiate	
prion	synthesis.	Direct	evidence	that	this	interaction	promotes	PrPSc	production	is	seen	
when	radiolabeled	PrPC	is	incubated	with	PrPSc,	resulting	in	the	formation	of	protease-
resistant	radiolabeled	PrP,	indicating	that	the	protease-resistant	properties	of	PrPSc	
were	imparted	to	incorporating	PrPC	counterparts	[17].	Dramatically,	this	PrPSc-
templated	conversion	of	PrPC	into	additional	PrPSc	is	necessary	for	the	development	of	
clinical	disease	and	neuronal	death,	as	PrPC-deficient	mice	are	resistant	to	prion	
diseases	[18-20]	and	only	grafted	neurons	overexpressing	PrPC	incur	cellular	damage	
when	implanted	into	the	brains	of	infected	PrPC-deficient	mice	[21].	This	latter	finding	
demonstrates	that	PrPSc	alone	is	not	neurotoxic,	but	must	interact	with	expressed	PrPC	
and	template	its	conversion	into	PrPSc	for	neuronal	death	to	occur.	In	addition	to	
protease	resistance,	subtle	conformational	details	of	PrPSc	seeds	are	templated	onto	the	
incorporating	naïve	PrPC	proteins,	as	evidenced	by	the	recapitulation	of	the	same	fully	
penetrant	lethal	spongiform	changes	induced	by	mutant	PrP	when	subsequently	
inoculated	into	mice	overexpressing	WT	PrP,	and	then	from	these	mice	into	normal	WT	
mice	[15].	Structural	studies	of	infectivity	and	PrPC	to	PrPSc	conversion	suggest	that	the	
PrP	aggregates	that	most	potently	perform	these	activities	are	17-27	nm	in	size	(300-
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600	kilodalton	(kD),	14-28	PrP	molecules),	not	larger	fibrils	or	smaller	oligomers	(less	
than	or	equal	to	5	PrP	molecules)[22].	
Perhaps	the	strongest	support	of	the	protein-only	hypothesis	comes	from	the	
induction	of	prion	disease	in	vivo	from	PrPSc	generated	in	vitro.	Soto	and	colleagues	
developed	a	system	whereby	PrPSc	originally	isolated	from	an	infected	hamster	is	
amplified	in	vitro	through	successive	cycles	of	sonication	and	PrPC	to	PrPSc	conversion	
steps	[23,	24].	This	process,	termed	protein	misfolding	cyclic	amplification	(PMCA),	
exploits	the	templated	misfolding	and	seeding	property	of	prion	proteins	by	
fragmenting	PrPSc	aggregates	into	smaller	seeds	that	can	continue	to	amplify	individually	
upon	co-incubation	with	PrPC,	resulting	in	a	PCR-like	enrichment	of	PrPSc	in	vitro	that	can	
be	used	as	an	inoculum	in	vivo.	The	in	vitro	generated	PrPSc	has	been	shown	to	be	
similar	biochemically	and	structurally	to	the	PrPSc	isolated	from	infected	hamsters,	and	
upon	inoculation	of	wild-type	(WT)	hamsters	with	in	vitro	PrPSc,	prion	disease	is	induced	
identical	to	the	disease	induced	by	PrPSc	isolated	from	infected	brain	[24].	This	process	
of	PrPSc	fragmentation	into	multiple	smaller	seeds	that	independently	amplify	may	also	
be	important	for	authentic	prion	disease,	and	may	represent	a	mechanism	whereby	
even	slowly	growing	PrPSc	aggregates	can	have	a	widespread	physiological	impact	[25].		
Propagation.	
	 While	the	propagation	of	protein	misfolding	occurs	due	to	templated	conversion	
of	PrPC	into	PrPSc,	prions	are	also	capable	of	physically	propagating	between	cells	and	
even	between	host	organisms	to	spread	infection.	While	spreading	between	cells	has	
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been	demonstrated	for	misfolded	aggregates	of	amyloid	proteins	in	many	
neurodegenerative	diseases,	bringing	about	the	“prion-like”	analogy,	only	prions	have	
been	demonstrated	to	be	transmissible	between	hosts.	One	form	of	infectious	human	
prion	disease	is	known	as	kuru,	and	was	transmitted	by	ritualistic	cannibalism	in	New	
Guinea	where	people	ate	the	brains	of	their	dead	relatives	in	an	attempt	to	immortalize	
them	[26].	Iatrogenic	transmission	of	CJD	has	been	documented	through	the	use	of	
contaminated	neurosurgical	instruments	[27,	28]	or	human	growth	hormone	derived	
from	cadaveric	pituitary	extracts	[29],	or	as	a	result	of	corneal	transplantation	[30]	or	
dura	mater	grafting	[31].	Finally,	another	form	of	CJD	known	as	variant	CJD	(vCJD)	arose	
through	dietary	exposure	to	prion-contaminated	beef	products	from	cattle	infected	with	
BSE,	commonly	known	as	“mad	cow”	disease	[32-35].	Variant	CJD	has	even	been	
transmitted	through	a	blood	transfusion	from	a	donor	who	subsequently	developed	
vCJD	[36].	These	examples	of	disease	transmission	due	to	propagation	of	prions	
illustrate	the	paradigm-shifting	nature	of	Stanley	Prusiner’s	definition,	as	they	represent	
the	only	proteinaceous	particles	capable	of	transmitting	neurodegenerative	disease	
between	hosts.		
	 The	spreading	of	prions	between	cell	populations,	organ	systems,	and	brain	
regions	has	been	intensely	investigated.	Neuronal	prion	spreading	between	
interconnected	brain	regions	was	shown	following	retinal	inoculation,	with	subsequent	
progressive	colonization	of	the	entire	visual	system	from	superior	colliculus	to	lateral	
geniculate	and	terminating	in	the	optical	cortex	[37].	When	prions	are	taken	up	
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peripherally,	as	in	the	case	of	non-iatrogenic	infectious	transmission,	prions	have	been	
shown	to	expand	and	neuroinvade	by	way	of	the	lymphohematopoietic	system,	
particularly	by	interacting	with	differentiated	B	cells	[38].	The	spleen	seems	to	represent	
an	extraneuronal	reservoir	for	prions,	whose	arrival	there	depends	on	components	of	
the	lymphohematopoietic	system	such	as	B	cells;	PrP	transit	into	the	spleen	and	further	
neuroinvasion	requires	host	expression	of	PrP	presumably	because	of	its	role	as	a	
substrate	for	templating	of	further	prions	[39].	Once	the	splenic	compartment	has	been	
colonized,	prions	exploit	an	interaction	between	follicular	dendritic	cells	and	splenic	
sympathetic	nerves	to	invade	these	peripheral	nerve	cells	and	eventually	gain	access	to	
the	CNS	[40,	41].	These	steps	along	the	pathway	of	prion	spreading	in	the	periphery	or	
in	the	nervous	system	represent	attractive	therapeutic	targets	for	preventing	the	spread	
of	infection	and	the	onset	of	neurologic	symptoms.			
	 While	some	knowledge	has	been	gained	regarding	the	specific	cellular	
mechanisms	of	prion	cell-to-cell	propagation,	much	remains	to	be	elucidated	about	the	
complete	life	cycle	of	cellular	infection	[42].	While	endogenous	PrPC	is	known	to	localize	
to	the	plasma	membrane,	its	localization	there	is	not	required	for	exogenous	PrPSc	
binding	or	internalization	[43-45].	Instead,	incoming	PrPSc	interacts	with	
glycosaminoglycans	(GAGs)	at	the	cell	surface	that	facilitate	its	binding,	and	is	
internalized	via	nonspecific	endocytic	routes	such	as	pinocytosis	or	transcytosis	into	
vesicles	positive	for	markers	of	late	endosomes	or	lysosomes,	but	not	synaptic,	early	
endocytic,	or	raft-derived	vesicles	[43,	44].	This	internalized	PrPSc	is	then	transported	
		
11	
within	the	infected	cell	along	neurites	to	positions	of	intercellular	contact,	perhaps	
facilitating	cell-to-cell	movement.	Cellular	uptake	can	be	a	rapid	process,	within	2	hours	
of	exposure,	but	may	not	occur	for	all	cells	equivalently,	as	uptake	depends	on	both	the	
membrane	microenvironment	and	host	cell-specific	factors	encountered	upon	binding,	
as	well	as	the	size	of	the	aggregates	themselves,	with	smaller	aggregates	more	
efficiently	taken	up	than	larger	ones	[45].	When	membrane-associated	PrPC	encounters	
exogenous	PrPSc,	pathological	conversion	of	membrane-associated	PrPC	by	the	infecting	
PrPSc	occurs	within	minutes	at	the	cell	surface	in	lipid	rafts,	followed	by	endocytosis	of	
the	newly	formed	PrPSc	into	early	endosomes	and	either	recycling	to	the	plasma	
membrane	or	retrograde	transport	to	the	Golgi	and	eventual	lysosomal	degradation,	the	
main	degradative	process	at	this	early	stage	of	infection	[46].		
Once	successful	infection	of	a	target	cell	has	been	established,	and	replicating	
prions	evade	degradative	processes	as	they	multiply,	their	trafficking	to	additional	cells	
has	been	shown	to	occur	through	multiple	mechanisms.	Cell-to-cell	spreading	is	
facilitated	by	cell-to-cell	contact,	and	tunneling	nanotubes	(TNTs)	allow	transfer	of	both	
exogenous	and	endogenous	PrPSc	between	infected	and	naïve	neuronal	cells	or	from	
infected	dendritic	cells	to	neurons	as	relevant	for	neuroinvasion	from	peripheral	
lymphoid	organs	[47,	48].	Significantly,	because	of	their	nature	as	a	transient	direct	
conduit	between	the	cytoplasm	of	interconnected	cells,	TNTs	may	allow	more	efficient	
transmission	of	endogenous	PrPSc,	which	may	have	fewer	options	for	cellular	release	
and	intercellular	transfer	compared	to	internalized	exogenous	PrPSc	[48].	In	addition	to	
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transferring	through	direct	cell-to-cell	contacts,	both	PrPC	and	PrPSc	are	known	to	be	
released	into	the	extracellular	environment	from	naïve	and	infected	neuronal	cells,	
respectively,	in	association	with	exosomes,	which	can	then	efficiently	initiate	infection	in	
uninfected	cells	[49,	50].	Learning	more	about	the	mechanisms	of	prion	transmission	
between	hosts	will	alleviate	public	health	concerns,	and	elucidating	specific	steps	in	the	
pathway	of	intracellular	and	intercellular	infection	may	allow	therapeutic	development	
for	prions	and	other	neurodegenerative	disease-related	amyloid	proteins	that	share	the	
prion-like	ability	to	propagate	between	cells	and	brain	regions.		
Strains.	
	 Upon	pathological	examination	of	infected	brain	tissue,	all	forms	of	human	prion	
disease	exhibit	PrP	deposition,	astrocytic	gliosis,	and	prominent	vacuolation	of	neural	
tissue,	the	characteristic	appearance	of	which	led	to	the	spongiform	descriptor	of	this	
group	of	encephalopathies	[2].	Despite	sharing	a	similar	pathological	appearance	and	
the	same	misfolded	protein	as	the	etiological	agent,	TSEs	differ	in	phenotypic	
characteristics	such	as	incubation	time,	clinical	signs	of	disease,	brain	regions	and	cell	
types	affected,	and	vacuolation	and	protein	deposition	patterns	[51,	52].	When	different	
phenotypes	of	disease	arise	from	inoculation	with	different	prion	preparations,	despite	
precisely	controlling	for	parameters	such	as	prion	titer,	tissue,	infection	route,	PrP	
genotype,	age,	gender,	and	immune	system	status,	these	different	disease	phenotypes	
define	unique	prion	strains	[51].	This	strain	phenomenon	was	first	observed	when	
animals	infected	with	the	same	inoculum	developed	prion	disease	with	differing	clinical	
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features	[53,	54],	and	subsequently	these	observed	differences	in	the	localization	and	
appearance	of	CNS	spongiform	degeneration	are	the	most	well-accepted	criteria	to	
distinguish	strains	[55,	56].	True	to	the	templating	nature	of	prion	propagation,	these	
distinguishing	phenotypic	characteristics	of	different	prion	strains	are	faithfully	
propagated	to	other	infected	animals	upon	serial	passage	[57].	Indeed,	the	
recapitulation	of	strain-specific	pathology	allowed	the	identification	of	vCJD	as	the	
human	counterpart	of	BSE,	as	characterization	of	the	new	vCJD	pathology	demonstrated	
features	distinct	from	sporadic	CJD	but	similar	to	BSE	[32-35].	Strain-specific	
accumulation	in	distinct	brain	regions	has	been	demonstrated	using	histoblot	
quantification	of	prion	deposition	[58,	59],	and	immunohistochemistry	studies	have	
revealed	strain-specific	cell	type	tropism	[60].	While	identifying	induction	of	spongiform	
degeneration	in	specific	brain	regions	has	been	a	reliable	indicator	of	prion	strain	
differences,	this	approach	is	limited	because	prions	can	also	accumulate	in	brain	regions	
where	overt	degeneration	is	not	observed,	and	specific	cellular	or	structural	parameters	
that	further	distinguish	prion	strains	and	that	may	dictate	cell	type	and	brain	region	
tropism	cannot	be	elucidated	in	this	fashion.		
	 	At	the	structural	level,	prion	strains	have	been	distinguished	from	one	another	
through	biochemical	properties	such	as	epitope	accessibility	for	antibody	binding,	
differential	sensitivity	to	proteinase	K	digestion,	and	variable	sedimentation	and	gel	
electrophoretic	properties	[61,	62].	These	results,	in	addition	to	the	observation	that	
strain-specific	differences	in	gel	migration	properties	were	preserved	through	animal	
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transmission	[63]	have	led	to	the	view	that	strain	diversity	is	encoded	by	differences	in	
PrPSc	conformation	that	serve	as	unique	templates	for	the	corruption	of	expressed	PrPC.	
This	structural	heterogeneity	of	PrPSc	has	been	seen	in	electron	microscopic	(EM)	
studies	where	fibrillar	protofilaments	of	different	strains	exhibited	different	widths	and	
periodicities	[64],	or	when	differential	immunoreactivity	is	observed	between	strains	
upon	incubation	under	denaturing	conditions	[65].	Another	distinguishing	factor	
between	various	prion	strains	is	their	conformational	stability,	their	relative	propensity	
for	spontaneous	disassociation	or	fragmentation,	although	there	is	some	debate	about	
whether	decreasing	conformational	stability	results	in	a	shortening	or	lengthening	of	
disease	incubation	time	[25,	66,	67].	Similar	distinguishing	features	have	been	observed	
between	prion	strains	produced	entirely	in	vitro	from	bacterially-derived	recombinant	
PrP,	further	highlighting	the	idea	that	strain	phenotypic	diversity	results	from	
differences	in	protein	aggregate	conformation	[66,	68-70].	Elucidating	the	structural	
differences	that	distinguish	different	prion	strains	and	dictate	their	toxicity,	seeding,	and	
propagation	properties	may	elucidate	the	underpinnings	of	differing	disease	phenotypes	
and	highlight	opportunities	for	inhibiting	or	preventing	disease	onset	and	progression.		
Alpha-Synucleinopathies	
Clinical	Features.	
	 PD,	Dementia	with	Lewy	bodies	(DLB),	and	multiple	system	atrophy	(MSA)	are	all	
neurodegenerative	proteinopathies	that	exhibit	aggregation	of	a-syn,	and	hence	are	
named	a-synucleinopathies.	PD	is	the	most	common	and	well-known	a-
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synucleinopathy,	first	described	by	James	Parkinson	in	1817	in	his	Essay	on	the	Shaking	
Palsy	[71].	Parkinson	described	the	essential	motor	symptoms	of	the	“paralysis	agitans”	
disease	that	would	later	bear	his	name,	noting	an	“involuntary	tremulous	motion,	with	
lessened	muscular	power,	in	parts	not	in	action	and	even	when	supported”.	He	also	
described	“a	propensity	to	bend	the	trunk	forward,	and	to	pass	from	a	walking	to	a	
running	pace:	the	sense	and	intellects	being	uninjured.”	The	essential	characteristics	of	
the	disease	were	later	refined	by	Jean-Martin	Charcot,	the	father	of	modern	neurology,	
who	named	the	disorder	Parkinson’s	disease	and	clearly	described	its	characteristic	
bradykinesia,	or	slowness	of	movement,	as	distinct	from	muscle	weakness,	noting	“a	
slowness	in	execution	of	movement	rather	than	real	weakness”	[72].	Charcot	used	the	
name	Parkinson’s	disease	rather	than	paralysis	agitans	or	shaking	palsy	because	he	
recognized	that	PD	patients	are	not	very	weak	and	do	not	necessarily	have	a	tremor	
[73].	The	Parkinson’s	Disease	Foundation	estimates	that	as	many	as	1	million	Americans	
and	more	than	10	million	people	worldwide	are	currently	living	with	PD,	although	
prevalence	rates	are	projected	to	greatly	increase	as	the	population	continues	to	age	
[74].	PD	prevalence	in	industrialized	countries	is	estimated	at	0.3%	of	the	entire	
population	and	about	1%	of	people	over	60	years	of	age	[75].	Age	is	known	to	be	the	
greatest	risk	factor	for	the	development	of	PD,	as	onset	is	rarely	before	age	50	and	
prevalence	and	incidence	increase	nearly	exponentially	with	age,	peaking	after	age	80	
[75-78].	The	incidence	of	PD	is	8-18	per	100,000	person-years	[75].	Gender	and	ethnicity	
also	affect	rates	of	PD,	with	a	3:2	higher	prevalence	of	men	affected	than	women	and	
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incidence	highest	among	Hispanics,	then	non-Hispanic	Whites,	Asians,	and	Blacks	[77,	
79].	As	the	second-most	common	neurodegenerative	disease	and	the	most	common	
movement	disorder,	PD	represents	a	significant	burden	of	morbidity	and	mortality	for	
an	aging	population.		
	 Because	there	is	no	definitive	test	for	the	diagnosis	of	PD,	the	disease	must	be	
diagnosed	based	on	clinical	criteria	which	differ	between	PD,	DLB,	and	MSA.	The	
International	Parkinson	and	Movement	Disorder	Society	(MDS)	Clinical	Diagnostic	
Criteria	for	Parkinson’s	disease	(MDS-PD	Criteria)	place	the	motor	syndrome	at	the	
center	of	disease	diagnosis,	characterized	by	bradykinesia	and	either	rigidity,	resting	
tremor,	or	both	[80].	These	characteristic	motor	features	result	from	the	death	of	
dopaminergic	neurons	in	the	substantia	nigra	pars	compacta	(SNpc),	a	hallmark	feature	
of	PD	observable	at	autopsy	even	at	the	gross	anatomical	level	due	to	the	loss	of	the	
dark	neuromelanin	“black	substance”	pigment	that	gives	the	substantia	nigra	its	name	
(Figure	1).	Without	the	input	of	dopamine	(DA)	from	nigral	projections	to	the	striatum,	
the	ability	of	the	basal	ganglia	circuitry	to	control	normal	movement	is	compromised,	
resulting	in	the	aforementioned	motor	manifestations	of	PD	[81].	By	the	time	these	
parkinsonian	motor	symptoms	manifest,	there	has	already	been	at	least	a	70%	decrease	
in	striatal	DA,	an	amount	that	will	continue	to	decrease	over	time	as	the	disease	
progresses	[82].	In	addition	to	these	cardinal	signs	of	PD,	loss	of	postural	reflexes,	or	the	
inability	to	maintain	balance,	is	also	considered	a	hallmark	of	PD	[83].	Although	
substantial	heterogeneity	can	exist	in	the	clinical	phenotype	of	PD,	other	secondary		
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Figure	1.	Degeneration	of	the	SNpc	in	PD.	Gross	unstained	cross	section	of	human	
midbrain	in	normal	case	(left)	and	in	PDD	(right).	Normal	case	(left)	from	74-year	old	
female	with	cause	of	death	as	multiple	myeloma.	PDD	case	(right)	from	68-year	old	male	
with	pathologically	confirmed	LBs	in	substantia	nigra	and	in	the	cingulate	cortex,	in	the	
absence	of	diffuse	LB	disease.	Neuromelanized	dopaminergic	neurons	in	SNpc	visible	
dorsal	to	cerebral	peduncles,	seen	best	in	normal	case.	Neuromelanin,	a	byproduct	of	
DA	synthesis,	is	responsible	for	the	black	pigment	which	gives	the	substantia	nigra	its	
name,	which	in	Latin	means	“black	substance”.	In	the	case	of	PDD,	loss	of	neuromelanin	
results	in	nigral	pallor	(arrows),	indicating	dopaminergic	degeneration.	(Image	courtesy	
of	John	Lee,	MD,	PhD,	used	with	permission).	
	
motor	features	may	include	hypomimia	(masked	facies),	dysarthria	(slow	or	slurred	
speech),	dysphagia	(difficulty	swallowing),	micrographia	(small	handwriting),	shuffling	
gait,	festination	(quickening	and	shortening	of	strides),	freezing,	or	dystonia	(involuntary	
muscle	contractions	causing	repetitive	or	twisting	movements)	[83].		
In	addition	to	these	symptoms	affecting	movement,	it	is	now	widely	accepted	
that	PD	patients	exhibit	a	variety	of	non-motor	symptoms,	often	preceding	the	onset	of	
the	motor	syndrome	by	months	to	decades	and	persisting	for	the	duration	of	the	
disease	[84-87].	Dysfunction	of	the	autonomic	nervous	system	is	commonly	experienced	
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as	evidenced	by	symptoms	such	as	constipation,	postural	hypotension,	excessive	
sweating	or	salivation,	bladder	irritability,	or	urinary	urgency	[88].	Anosmia	(loss	of	the	
sense	of	smell)	is	so	often	associated	with	PD	that	its	symptomatic	presence	constitutes	
a	supportive	criterion	in	the	MDS-PD	Criteria	alongside	resting	tremor	and	
responsiveness	to	dopaminergic	medication	[80].	PD	can	also	cause	rapid	eye	
movement	(REM)	sleep	behavioral	disorder	(RBD)	where	patients	act	out	their	dreams	
[85,	88].	PD	patients	also	experience	neuropsychiatric	symptoms,	with	anxiety	present	
to	varying	degrees	in	45%	of	PD	patients	and	depression	occurring	in	around	35%	of	
patients	[89-91].	Finally,	cognitive	decline	leading	to	dementia	commonly	occurs	in	PD,	
seen	in	46%	of	PD	patients	10	years	after	diagnosis	and	83%	of	patients	20	years	after	
diagnosis	[92,	93].	Although	in	the	past	the	presence	of	dementia	or	the	temporal	
relationship	of	its	onset	to	the	onset	of	parkinsonian	symptoms	was	used	to	exclude	a	
diagnosis	of	PD	and	suggest	separate	disorders	of	PD	dementia	(PDD)	or	DLB	[94,	95],	
these	conditions	are	considered	by	many	to	be	part	of	the	same	pathological	spectrum,	
and	the	MDS-PD	Criteria	considers	DLB	to	be	a	subtype	of	PD	[80].		
Although	treatment	of	the	underlying	neurodegenerative	process	does	not	exist,	
patient	quality	of	life	can	be	significantly	improved	for	many	years	with	symptomatic	
therapies.	The	most	effective	medication	available	for	treating	the	motor	symptoms	of	
PD	is	levodopa	(L-DOPA),	a	DA	precursor,	intended	to	more	easily	facilitate	DA	synthesis	
in	degenerating	dopaminergic	neurons	[96].	Additionally,	DA	agonists	can	be	used	to	
stimulate	DA	receptors,	and	monoamine	oxidase	type	B	inhibitors	(MAOBIs)	can	be	used	
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to	maintain	as	high	a	level	of	endogenous	DA	as	possible	by	preventing	its	catabolism	
[96].	Eventually,	however,	these	treatments	begin	to	fail	when	patients	report	that	the	
effects	are	“wearing	off”,	not	lasting	until	the	next	dose,	and	eventually	patients	
experience	marked	“on-off”	motor	fluctuations	with	some	doses	being	completely	
ineffective	[88].	In	addition,	when	patients	have	been	taking	L-DOPA	for	many	years,	
they	can	begin	to	experience	involuntary	movements	called	L-DOPA-induced	dyskinesias	
that	can	be	debilitating.	As	dopaminergic	degeneration	proceeds	inexorably,	patients	
then	face	the	challenging	decision	to	either	remain	on	L-DOPA	to	experience	its	limited	
benefits	despite	the	debilitating	dyskinesias	or	reduce	their	dose	of	L-DOPA	resulting	in	
a	concomitant	reduction	of	dyskinesia	severity	but	an	increase	in	time	spent	in	an	“off”	
state,	often	one	of	the	most	frightening	PD	symptoms	[88].	This	may	be	the	point	when	
patients	opt	for	symptomatic	surgical	intervention	through	deep	brain	stimulation	
(DBS),	where	adjustable	implanted	electrodes	utilize	high	frequency	electrical	
stimulation	of	brain	regions	such	as	the	subthalamic	nucleus	(STN)	and	globus	pallidus	
internus	(GPi)	to	improve	motor	features	and	allow	for	a	reduction	in	L-DOPA	dosage	
[97].	Although	almost	a	quarter	of	patients	have	a	good	outcome	at	10	years	after	
diagnosis,	living	free	of	dementia	or	postural	instability	[92],	these	symptoms	become	
more	prevalent	and	severe	in	the	end	stages	of	the	disease,	and	postural	instability	and	
hypotension	can	cause	especially	severe	complications	for	patients,	with	81%	
experiencing	falls	and	23%	sustaining	fractures	by	15	years	after	diagnosis	[98].	Despite	
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these	end-stage	challenges,	PD	is	a	substantial	contributor	to	death	in	only	20%	of	
patients,	with	the	most	common	cause	instead	being	pneumonia	[92].		
Multiple	system	atrophy	is	known	as	a	distinct	a-synucleinopathy	from	PD	
because	of	the	differences	exhibited	in	the	spectrum	of	patient	symptoms.	The	average	
age	of	onset	is	younger	for	MSA	compared	to	PD,	54	compared	to	68,	and	is	generally	
considered	to	evolve	much	more	quickly	than	PD	[88,	92,	99].	Autonomic	dysfunction	
features	prominently	in	MSA	along	with	parkinsonism,	but	significant	cerebellar	
dysfunction	may	also	be	present	as	distinct	from	PD	[100],	and	MSA	patients	may	not	
respond	as	well	as	PD	patients	to	L-DOPA.	MSA	is	also	less	common	than	PD,	with	a	
prevalence	of	4.4	per	100,000	person-years	[101].	While	both	PD	and	MSA	exhibit	
dopaminergic	degeneration	of	the	SNpc,	histopathologic	examination	on	autopsy	is	the	
most	reliable	way	to	distinguish	these	disorders,	as	the	characteristic	signature	of	a-syn	
aggregates	differs	between	the	two	disorders.		
Lewy	Bodies.	
	 	The	histopathologic	hallmark	of	a-synucleinopathies	was	first	described	in	1912	
by	Fritz	Heinrich	Lewy	when	he	observed	neuronal	inclusions	in	the	dorsal	motor	
nucleus	of	the	vagus	nerve,	the	basal	nucleus	of	Meynert,	the	globus	pallidus,	and	the	
thalamus	of	a	PD	patient	[102,	103].	These	neuronal	inclusions	were	later	given	the	
name	“Lewy	bodies”	(LBs)	by	Konstantin	Tretiakoff	who	reported	in	his	doctoral	
dissertation	the	presence	of	“corps	de	Lewy”	in	the	substantia	nigra,	noting	a	
degeneration	of	the	substantia	nigra	in	PD	and	postulating	a	connection	between	this	
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nigral	cell	loss	and	the	characteristic	symptoms	of	rigidity	and	tremor	seen	in	PD	[104,	
105].	LBs	have	subsequently	been	identified	as	widely	distributed	throughout	multiple	
tissues	[106].	In	the	central	nervous	system	(CNS),	in	addition	to	the	areas	discovered	by	
Lewy	and	Tretiakoff	mentioned	above,	LBs	have	been	found	in	the	olfactory	bulb,	
hypothalamus,	posterior	pituitary,	locus	ceruleus,	dorsal	raphe	nucleus,	cerebellum,	
amygdala,	and	the	cerebral	cortex	[106].	Beyond	the	CNS,	LBS	have	been	identified	in	
multiple	areas	of	the	peripheral	nervous	system	(PNS)	such	as	sympathetic	ganglia	and	
enteric	neurons,	and	in	tissues	as	diverse	as	heart,	pelvic	organs,	adrenal	medulla,	
salivary	gland,	and	skin	[106].	This	widespread	LB	distribution	underscores	the	
multisystem	nature	of	PD	and	a-synucleinopathies	in	general,	which	is	also	evident	by	
the	diversity	of	symptoms	experienced	by	patients.		
Classical,	brainstem-type	LBs	are	seen	by	light	microscopic	examination	of	
hematoxylin	and	eosin	(H&E)-stained	sections	as	intracytoplasmic,	single	or	multiple,	
spherical	or	elongated,	eosinophilic	masses	possessing	a	dense	core	and	a	lighter	
peripheral	halo	[106]	(Figure	2A).	Antibodies	for	ubiquitin	were	initially	used	as	the	most	
useful	marker	of	LBs	since	the	fibrillar	components	comprising	their	ultrastructure	were	
known	to	be	heavily	ubiquitinated	[107,	108],	but	the	discovery	of	insoluble	a-syn	fibrils	
as	the	main	proteinaceous	component	of	LBs	led	to	staining	for	a-syn	replacing	staining	
for	ubiquitin	as	the	most	sensitive	and	preferred	method	of	detection	for	LBs	[109-111].	
Additionally,	insoluble	a-syn	fibrillar	aggregates	were	also	identified	as	the	main	
component	of	glial	cytoplasmic	inclusions	(GCIs),	or	Papp-Lantos	bodies,	present		
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Figure	2.	Demonstration	of	Lewy	bodies	in	SNc	dopaminergic	neurons	in	sporadic	PD.	
Conventional	haematoxylin	(blue)	and	eosin	(pink)	histological	staining	(A)	reveals	a	
spherical	Lewy	body	(arrow)	in	SNc	dopamine	neurons	with	a	distinct	central	core	and	a	
peripheral	halo.	Electron	micrograph	of	a	Lewy	body	(B)	reveals	that	the	core	(c)	
contains	granular	material	and	the	outer	halo	(h)	is	composed	of	radiating	filaments.	A	
standard	immunohistochemical	protocol	shows	two	Lewy	bodies	(arrow)	with	ubiquitin	
concentrated	in	the	core	(C)	and	two	Lewy	bodies	(arrow)	with	a-synuclein	
concentrated	in	the	halo	(D).	Reprinted	from	The	Lancet	Neurology,	Volume	3,	Issue	8,	C	
Warren	Olanow,	Daniel	P	Perl,	George	N	DeMartino,	Kevin	St	P	McNaught,	Lewy-body	
formation	is	an	aggresome-related	process:	a	hypothesis,	Page	496-503	(Reference	118),	
Copyright	2004,	with	permission	from	Elsevier	(License	Number	4057260798096).	
http://www.sciencedirect.com/science/journal/14744422.		
	
exclusively	in	oligodendrocytes	that	specifically	characterize	MSA	pathology	[112-114].	
This	difference	in	localization	of	neuronal	LBs	in	PD	and	oligodendroglial	LBs	in	MSA	
allows	these	two	disorders	to	be	definitively	distinguished	by	pathological	examination,	
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in	combination	with	the	differences	in	clinical	phenotype.	Not	only	was	the	a-syn	
protein	identified	in	all	LBs	from	the	diverse	tissues	they	inhabit	and	diseases	they	
characterize,	a-syn	was	not	identified	as	a	component	of	other	neuronal	or	glial	
inclusions	characteristic	of	other	diseases	such	as	AD,	motor	neuron	disease,	or	triplet-
repeat	diseases	[115].		It	was	subsequently	found	that	the	insoluble	a-syn	fibrils	
comprising	the	LB	were	the	substrate	for	ubiquitination	[116],	although	not	all	LBs	
exhibit	the	same	a-syn/ubiquitin	labeling	pattern;	some	LBs	show	a-syn	and	ubiquitin	
evenly	distributed	and	overlapping	homogenously	across	the	inclusion	body,	while	
others	appear	in	a	concentric	pattern	where	a-syn	is	concentrated	peripherally	and	
ubiquitin	inhabits	the	central	core	region	[117]	(Figure	2C-D).	This	appearance,	where	
insoluble	a-syn	fibrils	segregate	to	the	periphery	of	LBs,	agrees	with	electron	
microscopic	examination	of	LBs	demonstrating	an	outward-radiating	filamentous	halo	
surrounding	a	dense	granular	core	[118]	(Figure	2B),	and	is	consistent	with	the	
hypothesis	that	insoluble	a-syn	is	continually	deposited	into	LB	inclusions	[117].		
An	important	advance	came	when	phosphorylation	was	identified	as	a	key	post-
translational	modification	(PTM)	of	a-syn	fibrils	enriched	in	LB	inclusions.	Almost	90%	of	
a-syn	present	in	LBs	was	shown	to	be	extensively	and	selectively	phosphorylated	at	
Serine	129	(pS129),	whereas	only	5%	of	a-syn	in	unaffected	brain	tissue	is	similarly	
modified	[119-122].	Many	other	LB	components	have	been	identified	including	PD-
linked	gene	products	in	addition	to	a-syn	such	as	DJ-1,	leucine-rich	repeat	kinase	2	
(LRRK2),	parkin,	and	phosphatase	and	tensin	homolog	(PTEN)-induced	putative	kinase	1	
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(PINK1),	as	well	as	lipids,	kinases,	mitochondria-related	proteins,	and	molecules	involved	
in	protein	folding,	membrane	trafficking,	oxidative	stress,	the	ubiquitin-proteasome	
system,	autophagy,	and	aggresome	formation	[106,	117,	123].	This	list	of	components	
can	give	clues	to	the	pathological	mechanisms	leading	to	LB	formation.	
	 It	was	originally	believed	that	LBs,	as	the	histopathologic	hallmark	of	PD	and	
other	a-synucleinopathies,	are	directly	toxic	to	the	cells	that	contain	them,	and	their	
formation	led	to	neurodegeneration.	More	recently,	however,	LB	formation	has	been	
considered	a	protective	mechanism	which	may	occur	when	the	cell	is	overwhelmed	by	
accumulating	protein	aggregates	that	are	unable	to	be	effectively	refolded	by	
chaperones	or	cleared	by	proteasomal	or	autophagic	mechanisms	[118,	124].	As	part	of	
the	cellular	response	to	protein	misfolding	and	to	better	facilitate	degradation	and	
cellular	protection	from	aggregate	toxicity,	aggregates	can	be	specifically	delivered	to	
proteinaceous	perinuclear	inclusion	bodies	called	aggresomes	formed	at	the	
centrosome	by	dynein-dependent	retrograde	transport	on	microtubules	[118,	124].	The	
prevailing	hypothesis	by	Kopito,	Olanow	and	others	regarding	LB	formation	as	an	
aggresome-related	process	proposes	that	trafficking	to	the	perinuclear	aggresome	
occurs	when	cellular	quality	control	mechanisms	such	as	chaperones	or	proteasomes	
are	overwhelmed	and	become	unable	to	cope	with	the	increasing	burden	of	misfolded	
protein	“waste”	[118,	124].	Hence	the	aggregate	accumulation	that	is	represented	by	
inclusion	formation	serves	to	concentrate	these	misfolded	proteins	and	increase	the	
efficiency	of	their	capture	by	autophagic	degradative	mechanisms	which	properly	
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“recycle”	components	of	this	waste	for	other	cellular	purposes	[118,	124].	It	is	only	
when	their	recycling	capacity	also	becomes	overwhelmed	and	fails	that	aggresomes	
become	cellular	“junkyards”	where	continual	deposition	of	misfolded	protein	waste	
serves	to	protect	the	cell	from	further	aggregate	toxicity	but	consequentially	promotes	
abnormal	growth	and	persistence	of	proteinaceous	inclusions	[118,	124].		
	 This	aggresome	hypothesis	is	supported	by	studies	of	the	stages	of	LB	
development.	a-syn	in	LB-related	pathology	first	becomes	evident	as	diffuse	or	granular	
neuronal	cytoplasmic	staining	in	otherwise	morphologically	normal-looking	cells,	but	
can	then	begin	to	form	thread-like	or	dot-like	structures	that	first	appear	in	neurites	
(Lewy	neurites,	LNs)	and	eventually	inhabit	the	perikarya	[106,	125,	126].	This	pattern	
gives	way	via	coalescence	and	incorporation	of	p62,	ubiquitin,	and	other	components	
first	to	irregularly	shaped,	uneven	staining	in	neurons	that	are	often	poorly	pigmented,	
indicating	early	cellular	dysfunction,	and	then	to	discrete	staining	corresponding	to	well-
defined	pale	bodies	(PBs)	which	are	less	eosinophilic	than	classical	LBs	and	do	not	
exhibit	a	halo	[106,	126,	127].	PBs	are	known	to	be	composed	of	sparse	granular	and	
vesicular	structures	among	a-syn	filaments,	corresponding	to	observations	that	early	
stages	of	inclusion	formation	involve	clustering	of	a-syn-associated	vesicles	[128]	as	well	
as	enrichment	and	aggregation	of	lysosomes	and	mitochondria	in	the	juxtanuclear	
inclusion	body	that	suggest	an	ongoing	cellular	degradation	effort	[129].	PBs	
occasionally	display	condensations	or	one	or	more	small	LBs	at	their	periphery,	
eventually	developing	into	ring-like	classic	LBs	through	a	compaction	mechanism	[106,	
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126].	Despite	expressing	the	autophagic	marker	microtubule-associated	protein	1A/1B-
light	chain	3	(LC3)	[130-133],	exhibiting	lysosome-associated	membrane	protein	2	
(LAMP2)	expression	at	the	periphery	[133],	and	containing	lysosomal	enzymes	such	as	
cathepsins	[131,	134]	and	glucocerebrosidase	[135],	LB	inclusions	are	associated	with	
the	accumulation	of	abnormal	autophagosomes	and	lysosomes	consistent	with	
aggresomes	failing	to	fulfill	their	degradative	intention	[131,	134].	Much	debate	exists	
regarding	the	role	of	ubiquitination	and	S129	phosphorylation	in	LB	inclusion	formation,	
as	studies	have	demonstrated	conflicting	reports	on	whether	these	PTMs	occur	at	early	
stages	of	protein	aggregation	to	promote	inclusion	formation,	or	happen	after	inclusion	
formation	has	already	occurred	and	thus	represent	a	cellular	attempt	to	mark	these	
inclusions	for	degradation	[119,	136-138].	Evidence	that	LB	inclusion	formation	may	
represent	a	protective	cellular	response	was	also	seen	when	a	potential	therapeutic	
compound	that	promotes	inclusion	formation	in	cellular	models	of	PD	and	HD	
prevented	dysfunction	and	toxicity	associated	with	misfolded	protein	aggregates,	
supporting	the	idea	that	promoting	inclusion	formation	to	potentially	boost	cellular	
mechanisms	of	degradation	may	represent	a	viable	treatment	approach	for	patients	
[139].		
a-Synuclein	Physiological	Function.	
	 a-syn	is	a	140	amino-acid	protein	that	was	first	identified	with	an	antibody	
against	synaptic	vesicles	from	the	electromotor	nucleus	of	Torpedo	californica;	its	
localization	to	the	synapse	and	the	nuclear	envelope	result	in	the	name		
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Figure	3.	Human	ASYN.	Scheme	representing	the	structure	of	human	ASYN	with	the	
three	distinct	domains	(N-terminal,	NAC	and	C-terminal).	Amino	acid	residues	are	
indicated	in	the	bottom.	Brown	bars	inside	protein	domains	represent	the	imperfect	
hexameric	KTKEGV	repeats.	Arrows	indicate	the	sites	of	phosphorylation	and	the	broken	
lines	show	the	mutated	sites.	Adapted	and	reprinted	from	PLoS	Genetics,	Volume	10,	
Issue	11,	Diana	F.	Lazaro,	Eva	F.	Rodrigues,	Ramona	Langohr,	Hedieh	Shahpasandzadeh,	
Thales	Ribeiro,	Patrıcia	Guerreiro,	Ellen	Gerhardt,	Katharina	Krohnert,	Jochen	Klucken,	
Marcos	D.	Pereira,	Blagovesta	Popova,	Niels	Kruse,	Brit	Mollenhauer,	Silvio	O.	Rizzoli,	
Gerhard	H.	Braus,	Karin	M.	Danzer,	Tiago	F.	Outeiro,	Systematic	Comparison	of	the	
Effects	of	Alpha-synuclein	Mutations	on	Its	Oligomerization	and	Aggregation,	e1004741,	
doi:10.1371/journal.pgen.1004741	(Reference	256),	Copyright	2014,	reproduced	under	
the	terms	of	the	Creative	Commons	Attribution	License.		
	
“synuclein”	[140].	Homologs	to	the	Torpedo	synuclein	protein	were	then	identified	in	rat	
and	human	brain,	as	were	two	other	members	of	a	synuclein	family	of	proteins,	thus	
giving	rise	to	the	names	a-,	b-,	and	g-synuclein	for	these	individual	isoforms	[140-142].	
At	the	time	a-syn	was	identified	in	human	brain,	its	full-length	sequence	was	
determined	to	be	identical	to	the	previously-identified	precursor	of	the	non-Ab	
component	(NACP)	[142],	the	name	of	which	is	derived	from	its	cleaved	fragment,	later	
determined	to	correspond	with	amino	acid	residues	61-95	of	a-syn	(Figure	3),	the	non-
Ab	component	(NAC)	of	AD	amyloid	plaques	[143].	Studies	of	NACP,	equivalent	to	full-
length	a-syn,	confirmed	its	association	with	synaptic	vesicles	at	the	presynaptic	terminal	
[142,	144].	The	human	a-syn	gene,	SNCA,	maps	to	chromosome	4q21.3-q22	[145,	146],	
and	while	a-syn	protein	expression	has	been	detected	in	non-neural	tissues	such	as	red	
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blood	cells	(RBCs)	[147],	it	is	abundantly	expressed	mainly	in	the	nervous	system	where	
it	comprises	an	estimated	one	percent	of	total	protein	in	soluble	cytosolic	brain	
fractions	[144].	While	the	endogenous	state	of	a-syn	has	been	the	subject	of	much	
debate,	as	some	have	suggested	a	native	helically-folded	tetramer	as	the	normal	form	of	
a-syn	[148],	most	findings	agree	that	the	native	form	of	a-syn	is	an	unfolded,	
unstructured	monomer	[149,	150].		
Despite	this	debate	about	its	native	state,	numerous	findings	clearly	reveal	that	
the	first	~100	amino	acids	in	the	N-terminus	of	a-syn,	which	contain	seven	imperfect	11-
residue	repeats	with	a	highly	conserved	hexameric	KTKEGV	motif	(Figure	3),	mediate	a	
structural	transition	from	natively	unfolded	to	an	amphipathic	a-helix	upon	association	
with	lipid	membranes	[140,	143,	151-153].	a-syn	can	adopt	two	distinct	a-helical	
conformations	in	association	with	lipids	depending	on	the	lipid	composition	or	charge	or	
on	the	diameter	of	the	vesicle.	In	one	conformation,	two	curved	a-helical	regions,	from	
Valine	3-Valine	37	and	from	Lysine	45-Threonine	92,	are	separated	by	a	short	linker	
region	and	have	an	antiparallel	arrangement	resembling	a	broken	or	bent	a-helix	or	an	
a-helix	horseshoe	[154-157].	This	conformation	has	been	proposed	for	interactions	
between	a-syn	and	smaller-diameter,	highly-curved	vesicles	for	which	a-syn	has	a	
preferential	affinity	[151,	155,	156,	158].	In	another	conformation,	an	extended,	
uninterrupted	curved	a-helix	spans	a	similar	stretch	of	N-terminal	amino	acids	as	for	the	
two	a-helices	in	the	previous	conformation	[156,	157].	This	conformation	is	preferable	
for	interaction	between	a-syn	and	larger-diameter	vesicles,	although	the	two	a-syn	
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conformations	may	also	co-exist	within	the	same	vesicle	[155-157].	In	both	
conformations,	the	C-terminal	part	of	a-syn,	from	Aspartic	acid	98	to	Alanine	140	
(Figure	3),	is	highly	charged	and	mobile	and	does	not	associate	with	lipids,	remaining	
free	and	unfolded	[152,	155].	The	N-terminal	a-helical	region	of	a-syn	is	key	for	
anchoring	the	protein	to	lipid	bilayers	[159],	possibly	through	interactions	with	lipid	
rafts	or	ganglioside	GM1	[160,	161].	The	various	conformational	transitions	between	
natively	unfolded	and	multiple	a-helical	structures	are	encoded	within	the	a-syn	amino	
acid	sequence	and	can	be	triggered	and	tuned	by	lipid	composition	and	charge	as	well	
as	membrane	curvature	[158,	162].		
	 The	membrane	binding	capacity	of	the	a-syn	protein	is	crucial	for	its	cellular	
function.	a-syn	knockout	(KO)	mice	are	viable	and	are	largely	normal	in	their	brain	
architecture,	cell	bodies,	fibers,	and	synapses,	but	exhibit	increased	DA	release	with	
some	stimuli	and	a	deficiency	of	undocked	presynaptic	vesicles	in	the	reserve	pool,	
pointing	to	a	role	for	a-syn	as	a	pre-synaptic	regulator	of	vesicle	mobilization	and	DA	
neurotransmission	[163-165].	Through	its	binding	affinity	for	membranes	of	high	
curvature,	a-syn	is	targeted	to	negatively-charged	endocytic	or	post-Golgi	vesicles	[166],	
possibly	through	interacting	with	membrane-associated	GTP-bound	Rab3a	rather	than	
cytosolic	GDP-Rab3a	[167].	In	line	with	a	role	in	vesicle	trafficking,	the	synuclein	family	is	
required	for	the	fast	kinetics	of	synaptic	vesicle	endocytosis	[168],	and	has	been	shown	
to	induce	the	clustering	of	synaptic	vesicles	[169].	Furthermore,	a-syn	has	been	shown	
to	act	as	a	chaperone	for	the	folding	and	refolding	of	soluble	N-ethylmaleimide–
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sensitive	factor	attachment	protein	receptor	(SNARE)	proteins,	binding	to	
synaptobrevin-2/vesicle-associated	membrane	protein	2	(VAMP2)	and	promoting	
assembly	of	the	SNARE	complex	[170,	171].	This	function	is	clearly	important	for	proper	
neuronal	homeostasis,	as	KO	mice	lacking	the	synuclein	family	develop	neurological	
impairments	with	age	and	died	prematurely	[171].	Recently,	additional	functions	have	
been	proposed	for	a-syn	that	do	not	necessarily	involve	its	lipid-binding	functionality.	a-
syn	can	bind	to	tubulin	to	facilitate	microtubule	nucleation	and	increase	growth	rate	and	
catastrophe	[172],	and	a-syn	can	also	interact	with	ATP	synthase	in	mitochondria	to	
increase	efficiency	of	ATP	synthesis	[173].	While	the	function	of	a-syn	is	still	
incompletely	understood,	and	its	role	is	continuing	to	be	elucidated	[174],	it	clearly	
influences	very	important	cellular	processes,	leading	some	to	hypothesize	that	a-syn-
induced	pathology	may	be	a	toxic	combination	of	the	gain-of-function	induced	by	a-syn	
aggregation	and	the	loss-of-function	caused	by	displacement	from	its	native	role	
following	sequestration	into	insoluble	protein	aggregates	[175,	176].	
a-syn	Pathological	Aggregation.	
	 Characterization	and	process.	To	learn	more	about	how	the	a-syn	protein	
aberrantly	abandons	its	native	conformation	and	role	to	become	an	aggregated,	
insoluble	fibrillar	component	of	LB	inclusions,	researchers	have	focused	on	
characterizing	a-syn	aggregates	from	human	brain	and	in	vitro	systems	and	on	modeling	
the	aggregation	process.	Characterizing	a-syn	aggregates	found	in	patients	has	yielded	
many	clues	as	to	the	mechanisms	of	fibril	and	inclusion	formation.	In	addition	to	the	
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fibrillar	composition	and	detergent	insolubility	identified	from	studies	of	LB	inclusions	in	
situ,	a-syn	fibrils	isolated	from	brains	of	patients	are	partially	resistant	to	proteinase	K	
digestion	[177]	and	exhibit	a	consistent	orientation	of	monomeric	constituents	as	
evidenced	by	antibodies	against	the	C-terminal	region	labeling	filaments	along	their	
entire	length	whereas	antibodies	for	the	N-terminal	region	label	only	one	filament	end	
[178].	In	addition	to	the	filamentous	a-syn	pathology	observed	in	LBs,	smaller	pre-
fibrillar	a-syn	oligomers	have	been	identified	in	brains	of	transgenic	mice	expressing	
human	a-syn	prior	to	neurological	symptom	onset;	as	opposed	to	a-syn	fibrils,	these	
oligomers	are	detergent-soluble,	proteinase	K-sensitive,	and	are	found	both	in	regions	
containing	LB	inclusions	as	well	as	histologically	unaffected	regions	[179].	However,	
oligomers	from	inclusion-bearing	regions	accelerate	in	vitro	a-syn	aggregation	and	
cause	neurodegeneration,	while	oligomers	from	unaffected	regions	are	not	toxic	and	
delay	in	vitro	a-syn	aggregation	[179].	These	various	properties	unique	to	a-syn	
oligomers	and	distinct	from	native	and	fibrillar	a-syn	suggest	that	oligomers	represent	a	
separate	a-syn	species	that	may	evolve	from	monomer	and	develop	into	more	mature	
fibrils	and	inclusions,	and	further	imply	that	different	functional	conformations	of	
oligomers	may	exist,	each	with	their	own	specific	cellular	consequences.	Employing	the	
proximity	ligation	assay	(PLA)	for	the	specific	detection	of	oligomeric	forms	of	a-syn	in	
human	brain	revealed	previously	unrecognized	extensive	diffuse	deposition	of	a-syn	
oligomers,	often	in	brain	areas	mildly	affected	by	PD,	and	preferentially	labeling	early-
stage,	diffuse	or	loosely	compacted	lesions	such	as	PBs	rather	than	more	heavily	
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compacted	mature	LBs	[180].	These	findings	indicate	that	oligomeric	forms	of	a-syn	
may	precede	the	development	of	classical	PD	pathology,	and	in	demonstrating	that	
oligomeric	a-syn	exhibits	an	intermediate	proteinase	K	resistance	different	from	the	
proteinase	K	sensitivity	of	native	a-syn	and	resistance	of	a-syn	in	LBs,	this	work	
supports	the	view	that	oligomers	represent	an	a-syn	species	distinct	from	native	and	
fibrillar	forms	[180].	These	studies	of	brain-derived	a-syn	aggregates	illuminate	
potential	mechanisms	of	a-syn	aggregation	in	authentic	disease	processes,	and	are	
essential	to	establish	the	physiological	relevance	of	in	vitro	characterization	methods.		
	 Studies	of	a-syn	aggregation	from	in	vitro	experiments	or	molecular	simulations	
have	highlighted	the	essential	role	of	the	central	hydrophobic	domain	of	a-syn,	known	
as	NAC	for	its	accumulation	as	the	non-Ab	component	of	amyloid	plaques	in	AD,	in	
promoting	the	aggregation	process.	Although	native,	monomeric	a-syn	is	essentially	
disordered,	studies	of	its	conformation	under	physiological	cell	conditions	have	
demonstrated	that	the	central	hydrophobic	NAC	domain	is	shielded	from	exposure	to	
the	cytoplasm,	perhaps	counteracting	spontaneous	aggregation	[181].	However,	
molecular	simulations	have	revealed	that	a-syn	can	sample	conformations	that	place	
the	NAC	domain	in	a	solvent	exposed	and	extended	conformation	that	can	form	cross-b	
structure,	and	that	frequent	long-range	contacts	formed	between	the	a-syn	N-and	C-
termini	promote	this	solvent-exposed	orientation	of	the	NAC	domain	[182]	(Figure	4).	In	
addition	to	spontaneous	conformational	changes	into	aggregation-prone	states,	
decreasing	pH	or	increasing	temperature	have	been	shown	to	transform	a-syn	into	a		
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Figure	4.	Protein	misfolding	and	aggregation	into	infectious	fibrillar	assemblies.	
Natively	unfolded	polypeptide	chain	(sphere)	undergoes	conformational	changes	that	
lead	to	distinct	abnormal	(cube	or	cylinder)	forms.	The	rates	depend	on	the	propensity	
of	the	polypeptide	to	populate	a	given	conformation.	According	to	the	“template	
assistance”	model,	the	abnormal	folding	intermediates	interact	with	the	native	form	of	
the	infectious	protein	and	convert	it	into	abnormal	forms.	The	distinct	abnormal	forms	
of	the	polypeptide	interact	transiently	with	like	conformers	and	establish	longitudinal	or	
lateral	interactions	following	the	“seeded	polymerization”	model.	The	oligomeric	
species	are	unstable	and	dissociate	because	the	inter-molecular	interactions	do	not	
outweigh	the	entropic	cost	of	binding.	Once	longitudinal	and	lateral	interactions	have	
been	established	between	abnormal	forms	of	the	polypeptide,	distinct	stable	seeds	are	
formed	(in	brackets).	These	seeds	grow	indefinitely	by	incorporation	of	like	molecules,	
yielding	fibrils	of	distinct	physical	properties.	The	different	fibrils	can	break	into	smaller	
fragments	because,	amongst	other	things,	of	Brownian	movement.	The	rate	of	breakage	
depends	on	the	number	of	bonds	established	between	the	molecules.	Each	resulting	
fragment	acts	as	seed.	Reprinted	from	Journal	of	Parkinson’s	Disease,	Volume	5,	Ronald	
Melki,	Role	of	Different	Alpha-Synuclein	Strains	in	Synucleinopathies,	Similarities	
with	other	Neurodegenerative	Diseases,	Pages	217-227,	doi:	10.3233/JPD-150543	
(Reference	304),	Copyright	2015,	reproduced	under	the	terms	of	the	Creative	Commons	
Attribution	Non-Commercial	License.		
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partially	folded	conformation	[183],	and	native	interactions	between	a-syn	and	lipids	at	
the	plasma	membrane	or	on/in	vesicles	or	exosomes	may	also	promote	its	initial	
misfolding	and	aggregation	[184-187].	Finally,	abnormal	cytosolic	interactions	between	
a-syn	and	histones	released	from	nuclei	due	to	disruption	of	nuclear	membrane	
integrity	during	apoptosis	may	also	contribute	to	de	novo	aggregation	of	a-syn	[188,	
189].		
While	the	specific	events	leading	to	initial	a-syn	misfolding	remain	to	be	
elucidated,	the	NAC	domain	clearly	plays	an	integral	role	in	aggregation,	as	a	12-amino	
acid	stretch	(Valine	71-	Valine	82)	in	the	middle	of	this	hydrophobic	region	is	necessary	
and	sufficient	for	fibrillization	[190].	Introduction	of	a	single	charged	amino	acid	into	this	
12-amino	acid	stretch	significantly	slows	aggregation,	deletion	of	this	stretch	completely	
abolishes	aggregation,	and	synthetic	peptides	of	these	12	amino	acids	are	sufficient	to	
form	filaments	in	vitro	which	promote	the	aggregation	of	full-length	a-syn	[190].	Even	a	
deletion	of	two	amino	acids,	Alanine	76	and	Valine	77,	dramatically	impairs	fibril	
polymerization	due	to	the	combination	of	the	location	and	hydrophobicity	of	these	
residues	within	the	a-syn	protein	sequence	as	key	factors	contributing	to	its	aggregation	
propensity	[191].	Crystals	formed	of	amino	acid	residues	Glycine	68	to	Alanine	78	in	the	
NAC	region	were	used	for	structure	determination	by	micro-electron	diffraction,	
revealing	protofibrils	built	of	pairs	of	face-to-face	b-sheets,	a	pattern	very	similar	to	
fibrils	of	full-length	a-syn	[192],	known	to	contain	parallel-in-register	b-sheets	and	
hydrophobic	core	residues	[193].	The	hydrophobic	NAC	region	comprises	the	highly-
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ordered	core	of	a-syn	fibrils,	and	while	the	N	and	C	termini	are	unfolded	and	proteinase	
K	sensitive	in	the	fibrillar	state,	the	NAC	domain	imparts	its	proteinase	K	resistance	to	
the	larger	fibrils	[177,	194].	In	vitro	studies	of	a-syn	aggregation	are	made	possible	
through	the	propensity	of	the	a-syn	protein	to	form	filaments	resembling	those	isolated	
from	diseased	brain	[195],	as	well	as	by	amyloidogenic	dyes	such	as	Thioflavin	T	(ThT)	or	
K114	that	allow	quantitative	monitoring	of	a-syn	fibril	formation	through	their	amyloid-
sensing	fluorescence	[196].	These	studies	have	resulted	in	molecular	insights	that	have	
informed	research	efforts	to	better	model	the	stages	of	the	aggregation	process	from	
monomer	to	LB	inclusion.		
Following	the	first	step	in	the	aggregation	process,	the	conversion	of	the	native	
unfolded	a-syn	monomer	to	an	aggregation-competent	form	[183],	the	next	step	
involves	the	misfolded	monomer	serving	as	a	nucleus	and	template	for	the	further	
misfolding	of	additional	soluble	a-syn	counterparts	that	become	recruited	to	the	seed	
nucleus	[197,	198]	(Figure	4).	This	nucleation-dependent	growth	is	known	to	follow	first-
order	kinetics	with	respect	to	a-syn	concentration	and	to	occur	via	a	stop-and-go	
mechanism,	either	extending	at	a	homogenous	rate	or	stopping	for	variable	intervals	
[197,	199].	When	pre-formed	seeds	of	fibrillar	a-syn	are	exogenously	introduced	into	
cultured	neuronal	cells,	these	seeds	are	taken	up	into	target	cells	by	adsorptive-
mediated	endocytosis	and	trigger	intracellular	a-syn	aggregation	by	recruiting	
expressed	a-syn	into	insoluble,	hyperphosphorylated,	and	ubiquitinated	inclusions	that	
resemble	LBs	and	LNs	in	PD	[200-204].	These	findings	demonstrate	that	once	the	
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internalized	misfolded	a-syn	pre-formed	fibril	encounters	the	cytosolic	expressed	a-syn,	
it	serves	as	a	template	for	the	conversion	of	native	a-syn	into	its	same	misfolded	
conformation,	an	event	which	triggers	fibril	growth	and	eventual	inclusion	formation.	
Furthermore,	this	seeding	process	eliminates	the	lag	phase	of	aggregate	growth	
dependent	on	the	slow,	energetically-unfavorable	conversion	of	native	to	aggregation-
competent	a-syn	monomer,	and	dramatically	accelerates	fibril	formation	[197,	205].	
Amyloid	self-replication	through	this	seeding	process	has	been	shown	to	be	tightly	
dependent	on	the	molecular	sequence	compatibility	between	the	fibrillar	seed	and	the	
native	protein,	such	that	cross-seeded	aggregation	between	human	and	mouse	a-syn	is	
bi-directionally	restricted	[206].	In	a	direct	analogy	to	prion	infectivity,	seeding	of	the	
misfolded	a-syn	conformation	by	exogenous	a-syn	aggregates	is	the	basis	for	
amplification	and	transmission	of	a-syn	misfolding.	
As	the	initial	misfolded	a-syn	monomeric	seed	nucleus	grows	by	recruiting	
additional	soluble	a-syn	monomers,	the	growing	aggregate	is	now	considered	an	
oligomer,	a	term	encompassing	a	wide	variety	of	a-syn	aggregates	but	defined	simply	by	
a	composition	of	multiple	a-syn	monomers,	as	few	as	two	or	as	many	as	a	hundred	or	
more	[205,	207].	Oligomers	exhibit	an	intermediate	b-sheet	content	between	that	of	
monomers	and	fibrils,	and	may	initially	be	somewhat	disordered	structures	that	
undergo	slow	conversion	to	more	compact	proteinase-K	resistant	oligomers	[207-209].		
Oligomers	can	then	undergo	another	conversion	to	more	mature	fibrils	that	can	
elongate	by	further	monomeric	addition,	indicating	that	oligomers	represent	a	
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continuum	of	species	ranging	from	unstable	low	molecular	weight	particles	to	stable	
elongated	oligomers	to	mature	fibrils	[209,	210]	(Figure	4).	The	prion-like	capacity	of	a-
syn	aggregates	to	seed	further	a-syn	misfolding	can	occur	at	any	stage	along	this	
continuum,	with	aggregation-competent	monomers,	various	forms	of	oligomers,	and	
fibrils	all	demonstrating	seeding	activity,	albeit	to	varying	degrees.	The	a-syn	fibrillar	
conformation	is	regarded	as	most	effective	for	seeding,	and	if	larger	amyloid-like	fibrils	
are	fragmented	into	smaller	components	of	50	nm	or	less	that	maintain	the	b-sheet-rich	
composition	characteristic	of	fibrillar	architecture,	these	short,	fragmented	fibrils	most	
efficiently	promote	cellular	accumulation	of	pS129	a-syn	and	represent	the	key	
pathogenic	seeds	that	trigger	a-syn	misfolding	[209-211].	Certain	forms	of	larger	stable	
a-syn	oligomers	also	possess	seeding	capacity,	although	to	a	lesser	degree	than	a-syn	
fibrils,	whereas	smaller	more	disordered	unstable	oligomers	are	unable	to	induce	
seeding	and	may	instead	inhibit	fibril	formation	because	their	“off-pathway”	
conformation	does	not	lead	to	fibril	formation	[208,	210].	In	some	circumstances,	larger	
a-syn	fibrils	may	fragment	into	multiple	smaller	fibrillar	or	stable-oligomeric	
components	that	can	each	serve	as	independent	seeds,	representing	a	mechanism	for	
the	amplification	of	misfolding	[207]	(Figure	4).	While	it	seems	feasible	that	even	a	
single	misfolded	a-syn	seed	is	capable	of	nucleation-dependent	growth	and	
amplification	through	fragmentation	and	propagation	resulting	in	an	overall	
acceleration	of	aggregation	and	genesis	of	a-syn-induced	neurodegenerative	pathology,	
other	unknown	factors	may	influence	this	process	such	that	a	sufficiently	high	amount	
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of	a-syn	misfolding	must	occur	for	pathology	to	ensue.	Indeed,	one	study	found	that	a	
very	high	number	of	oligomeric	or	fibrillar	seeds,	on	the	order	of	104,	was	required	for	
efficient	seeding	that	bypasses	the	slow	rate	of	aggregation	through	spontaneous	
primary	nucleation	[209].	Because	much	lower	numbers	of	a-syn	seeds	also	generate	
cellular	dyshomeostasis	by	increasing	reactive	oxygen	species	(ROS),	other	factors	such	
as	cellular	stress	may	be	required	to	synergize	with	seed	concentration	to	achieve	
sufficiently	potent	a-syn	seeding	[209].	The	templated	seeding	ability	of	misfolded	a-
syn	aggregates	plays	an	essential	role	in	disease	pathology,	as	numerous	animal	models	
in	mice,	rats,	and	monkeys	have	demonstrated	that	the	introduction	of	exogenous	
aggregated	a-syn	triggers	the	conversion	and	misfolding	of	endogenous	a-syn	to	an	
aggregated	form	identical	to	the	exogenous	seed,	propagating	and	accelerating	a-syn	
protein	misfolding	pathology	[212-219].		
	 Regulating	factors.	Genetic	variants.	A	major	breakthrough	in	the	understanding	
of	PD	pathogenesis	came	with	the	identification	of	missense	mutations	in	the	a-syn	
protein	that	cause	autosomal-dominant,	early-onset	familial	PD.	These	mutations	
include	A53T	[220],	A30P	[221],	E46K	[222],	and	the	more	recently	identified	G51D	
[223],	H50Q	[224],	A18T	[225],	A29S	[225],	and	A53E	[226].	These	mutations	clearly	
demonstrate,	through	their	recapitulation	of	the	a-syn	LB	pathology	and	PD	motor	
syndrome	characteristic	of	idiopathic	PD,	that	a-syn	misfolding	induced	by	missense	
mutations	cause	PD.	Furthermore,	when	A53T	was	identified	as	the	first	of	what	would	
eventually	become	the	aforementioned	several	known	a-syn	missense	mutations,	a-syn	
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was	soon	after	identified	as	the	main	component	of	LBs,	firmly	establishing	the	a-syn	
protein	as	central	to	PD	pathogenesis.	Additionally,	increasing	the	baseline	level	of	a-
syn	expression	through	SNCA	gene	locus	triplication	or	duplication	also	causes	PD,	
exhibiting	a	clear	a-syn	dose-dependence	for	age	of	onset	and	disease	progression,	with	
triplication	patients	developing	a	rapidly-progressive	PD	much	earlier	than	the	slowly-
progressing,	late	onset	of	PD	in	duplication	patients	[227,	228].	Importantly,	the	
presence	of	a-syn-rich	LB	inclusions	in	these	patients	indicates	that	increasing	the	
expression	level	of	a-syn	promotes	its	pathological	aggregation.	Despite	the	causal	
relationship	between	a-syn	mutation	or	multiplication	and	inherited	PD,	only	10-15%	of	
PD	cases	have	a	familial	cause,	whereas	85-90%	of	cases	are	idiopathic,	exhibiting	
inclusions	of	WT	a-syn	expressed	at	a	normal	level	[229,	230].	The	link	between	a-syn	
and	idiopathic	PD	came	with	genome-wide	association	studies	(GWAS)	that	recognized	
single	nucleotide	polymorphisms	(SNPs)	in	the	SNCA	gene	or	its	promoter	or	enhancer	
elements	that	increase	risk	for	PD	[231-234],	firmly	establishing	the	role	of	a-syn	
pathology	in	all	cases	of	PD,	not	just	rare	familial	forms.	
	 Because	all	familial	missense	mutations	in	the	a-syn	protein	occur	within	the	N-
terminal	amphipathic	a-helical	domain	responsible	for	lipid	binding	(Figure	3),	much	
effort	has	been	made	to	understand	the	effects	of	these	mutations	on	the	membrane	
binding	of	monomeric	and	fibrillar	a-syn	as	well	as	to	establish	a	link	between	these	
missense	substitution	mutations	and	alterations	in	native	protein	function	and/or	
pathological	aggregation.	Despite	early	reports	that	the	A30P	and	A53T	point	mutations	
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had	little	or	no	effect	on	lipid	binding	or	a-helicity	[235,	236],	later	findings	agree	that	
the	A30P	mutant	exhibits	defective	binding	to	phospholipid	membranes	perhaps	
because	of	a	perturbation	in	the	helical	structural	around	the	site	of	the	mutation	[237-
240].	A30P	was	shown	to	interrupt	a	helix	turn,	destabilizing	the	preceding	one	as	well	
as	shifting	the	helix	register	after	the	mutation	disturbing	the	proper	amphipathic	
sequence	of	polar	and	hydrophobic	residues	for	at	least	two	turns	[239].	The	A53T	and	
E46K	mutations,	by	contrast,	exhibit	stronger	interactions	with	lipids	because	of	
stabilizing	hydrogen	bonds	that	form	between	these	protein	variants	and	the	lipid	
bilayer	[238,	240,	241].	Finally,	the	recently	described	G51D	and	A53E	mutations	have	
been	shown	to	exhibit	decreased	lipid	binding	affinity	compared	to	WT,	behaving	
similarly	to	the	A30P	mutation	[242,	243].	Interestingly,	the	weakly-membrane	binding	
A30P	and	G51D	mutants	were	shown	to	populate	an	exposed	membrane-bound	form	
where	the	NAC	domain	is	dissociated	from	the	bilayer	more	than	in	the	WT	form,	
resulting	in	a	greater	membrane-induced	aggregation	propensity	[244].	a-syn	missense	
mutations	clearly	alter	membrane	affinity,	and	may	be	relevant	for	promoting	
pathological	instead	of	native	conformations	and	increasing	susceptibility	to	
aggregation.	
	 Studies	of	the	effects	of	a-syn	mutations	on	aggregation	behavior	paralleled	
investigation	of	WT	a-syn	aggregation,	as	the	discovery	of	the	first	known	mutation,	
A53T,	was	the	first	to	implicate	a-syn	as	the	aggregation-prone	pathogenic	protein	in	
PD.	Early	studies	of	the	in	vitro	aggregation	behavior	of	WT	and	mutant	a-syn	
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demonstrated	their	shared	ability	to	abandon	a	natively	disordered	state	to	self-
aggregate	and	assemble	into	insoluble	filaments	that	resembled	those	in	LB	inclusions,	
and	suggested	that	both	A53T	and	A30P	mutations	accelerated	this	aggregation	process	
[245-247].	Later	findings	then	clarified	the	nuanced	influence	of	these	mutations	on	the	
various	stages	of	the	aggregation	process;	both	A30P	and	A53T	share	the	ability	to	
accelerate	oligomerization	by	consuming	their	component	monomers	faster	than	WT	
monomers,	but	this	translates	into	an	acceleration	of	fibrillization	only	for	A53T,	
whereas	A30P	was	shown	to	ultimately	fibrillize	more	slowly	than	WT	a-syn	[248].	The	
observation	that	A53T	a-syn	accelerates	oligomerization	and	fibrillization	correlates	
with	the	increased	severity	of	disease	experienced	by	transgenic	mice	expressing	A53T	
compared	to	WT	a-syn,	where	A53T	mice	developed	age-dependent	filamentous	
intracytoplasmic	neuronal	a-syn	inclusions,	motor	impairment,	paralysis,	and	death	
[249].	The	E46K	mutation	increases	the	rate	of	a-syn	assembly	to	a	similar	extent	as	the	
A53T	mutation	[241],	and	because	the	artificial	E46A,	E83K,	and	E83A	mutations	exhibit	
a	similar	acceleration,	glutamic	acid	residues	residing	within	N-terminal	KTKEGV	repeats	
critical	for	amphipathic	a-helical	structure	significantly	modulate	a-syn	fibrillar	
assembly	[250].	Additionally,	E46K	fibrils	seeded	aggregation	more	efficiently	than	WT	
fibrils,	whereas	A30P	fibrils	were	less	efficient	seeds	for	aggregation	[251].	The	G51D	
and	A53E	mutations	are	known	to	attenuate	a-syn	aggregation	relative	to	WT	[223,	242,	
243,	252,	253],	whereas	the	H50Q	mutation	accelerates	aggregation	[252,	254,	255].	
While	these	studies	provide	key	insights	into	the	pathogenic	effects	of	these	PD-causing	
		
42	
mutations,	they	are	also	limited	in	their	comparative	value	because	of	variability	in	
approach.	Several	recent	studies	have	sought	to	systematically	compare	the	effects	of	
each	disease-causing	mutation	within	the	same	experimental	system,	either	in	vitro,	
with	cell-free	protein	expression,	or	within	living	cells.	These	studies	have	concluded	
that	a-syn	missense	mutation	does	indeed	significantly	impact	on	seeding	capacity,	
oligomerization,	fibrillization,	and	inclusion	formation,	and	they	reveal	molecular	
insights	into	the	initiation	and	spreading	of	a-syn	aggregation	[256-258].	
	 Serine	129	phosphorylation.	a-syn	undergoes	multiple	PTMs	such	as	
phosphorylation,	ubiquitination,	sumoylation,	acetylation,	nitration,	and	truncation,	but	
S129	phosphorylation	represents	the	modification	most	preferentially	and	consistently	
up-regulated	in	PD	and	other	a-synucleinopathies	[259,	260]	(Figure	3).	a-syn	S129	
phosphorylation	was	first	identified	as	a	constitutive	modification	in	immortalized	cell	
lines	[261],	but	the	discovery	that	S129	phosphorylation	affected	90%	of	insoluble	a-syn	
in	LBs	compared	to	only	5%	of	normal	soluble	a-syn	raised	the	possibility	that	this	
modification	influences	a-syn	aggregation	or	toxicity	[119-122].	Phosphorylation	of	a-
syn	S129	not	only	occurs	in	brains	of	PD	and	MSA	patients	[119-122,	125,	262,	263],	but	
also	in	a-syn	overexpressing	mouse	models	of	PD	and	MSA	[262,	264]	and	in	
dopaminergic	neurons	of	the	monkey	SNpc	with	normal	aging	[265].	While	insoluble	
pS129	a-syn	increases,	the	initially	elevated	levels	of	soluble	a-syn	decrease	over	the	
course	of	PD	[266],	suggesting	that	a-syn	phosphorylation	level	depends	directly	on	the	
amount	of	substrate	available,	where	high	initial	levels	of	soluble	a-syn	enhance	S129	
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phosphorylation	and	consume	soluble	a-syn	into	insoluble	inclusions	[265,	267].	It	
remains	unclear,	however,	if	S129	phosphorylation	is	a	cause	or	a	consequence	of	this	
transition	from	soluble	to	insoluble	a-syn.	The	existence	of	a	low	level	of	normal	soluble	
a-syn	phosphorylated	at	S129	suggests	that	this	LB-associated	form	is	produced	during	
normal	metabolism	of	a-syn	and	may	promote	aggregation	and	inclusion	formation	
[121,	122].	However,	a-syn	could	also	be	phosphorylated	after	fibrillization	or	inclusion	
formation	[122,	268-270]	as	a	mechanism	to	identify	and	promote	the	clearance	of	
misfolded	proteins	[271],	a	possibility	supported	by	the	buildup	of	pS129	a-syn	
following	proteasome	inhibition	and	elevated	autophagic	or	proteasomal	degradation	of	
a-syn	induced	by	overexpressing	specific	kinases	such	as	polo-like	kinase	2	(PLK2)	or	G-
protein-coupled	receptor	kinase	5	(GRK5)	[272-274].	Investigation	into	the	identities	of	
the	responsible	kinases	as	well	as	studies	of	the	influence	of	S129	phosphorylation	on	a-
syn	membrane	binding,	aggregation,	and	toxicity	have	worked	toward	a	higher	level	of	
clarity	regarding	these	two	opposing	possibilities.		
	 When	pS129	was	first	identified	as	an	a-syn	PTM,	it	was	noted	that	this	site	is	
located	within	a	consensus	recognition	sequence	of	casein	kinase	1	(CK1)	[261],	and	it	
was	later	found	that	casein	kinase	2	(CK2)	could	also	be	responsible	for	S129	
phosphorylation	that	increased	under	oxidative	or	proteasomal	stress	[275].	
Additionally,	G-protein-coupled	receptor	kinase	2	and	5	(GRK2,	GRK5)	preferentially	
phosphorylate	a-syn	at	S129	[137,	276,	277].	Finally,	members	of	the	polo-like	kinase	
(PLK)	family	such	as	PLK1,	PLK2,	and	PLK3	are	also	capable	of	a-syn	S129	
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phosphorylation,	and	unlike	other	kinases	that	only	partially	phosphorylate	a-syn	at	
S129,	these	PLK	family	members	induce	complete	phosphorylation	[268,	278].	Studies	of	
PLK2	have	found	an	increased	expression	within	neurons	of	older	monkeys	and	in	a-
synucleinopathy	patient	brains,	perhaps	contributing	to	the	increase	in	pS129	a-syn	
[265,	273].		While	several	responsible	kinases	have	been	identified,	the	overall	effects	of	
their	action	remain	to	be	determined.		
One	tool	to	examine	the	specific	consequences	of	S129	phosphorylation	on	a-
syn	behavior	has	been	in	vitro	biochemical	assays.	In	vitro	studies	of	membrane	binding	
suggest	that	the	pS129	modification	of	WT	a-syn	does	not	perturb	a-syn	membrane	
affinity	[270,	272,	279,	280],	but	S129	phosphorylation	can	increase	membrane	affinity	
of	the	normally	weakly-binding	A30P	a-syn	and	decrease	the	normal	binding	affinity	of	
A53T	a-syn	[272,	280].	These	results	implicate	long-range	interactions	between	pS129	in	
the	unstructured	a-syn	C-terminal	tail	with	the	membrane	binding	ability	of	the	N-
terminal	amphipathic	a-helix	and	the	familial	mutations	that	are	be	present	there	in	
affected	patients	[236,	280].	In	vitro	study	of	the	influence	of	pS129	on	a-syn	
aggregation	has	yielded	inconsistent	results,	with	some	studies	demonstrating	increased	
aggregation	[119,	280],	others	showing	decreased	aggregation	[279],	and	still	others	
showing	no	effect	with	S129	phosphorylation	[281].	These	inconclusive	results	are	
mirrored	by	similarly	varied	findings	when	pS129	levels	are	modulated	in	cells	or	
animals	by	expression	of	kinases	capable	of	performing	S129	phosphorylation.	Some	
findings	using	this	strategy	to	upregulate	pS129	a-syn	demonstrate	an	increase	in	
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aggregation	and	inclusion	formation	[277,	282-284]	while	others	demonstrate	a	
decrease	or	no	effect	[136,	137,	279,	285].	Finally,	utilization	of	artificial	mutants	to	
mimic	(S129D,	S129E)	or	prevent	(S129A)	phosphorylation	at	the	S129	position	generally	
revealed	that	mimicking	pS129	decreases	membrane	affinity	while	preventing	S129	
phosphorylation	has	the	opposite	effect,	indicating	that	pS129	may	decrease	membrane	
binding	[286-288].	These	findings	are	inconsistent	with	those	obtained	by	in	vitro	
methods	perhaps	because	of	the	limited	ability	of	amino	acid	substitutions	to	truly	
mimic	the	effects	of	phosphorylation	or	its	inhibition	on	a-syn	behavior	[279].	
Furthermore,	phosphorylation	mimic	or	null	mutants	had	a	differential	effect	on	a-syn	
aggregation	propensity.	Some	studies	demonstrated	that	preventing	S129	
phosphorylation	with	S129A	expression	rescues	neuronal	loss	caused	by	WT	a-syn	that	
is	capable	of	being	phosphorylated,	whereas	S129D	a-syn	increases	pathology	[137,	
282].	Other	studies	had	the	opposite	finding,	where	S129A	a-syn	caused	severe	
pathology	that	was	absent	or	prevented	with	S129D	a-syn	expression,	and	still	other	
studies	found	no	difference	in	pathology	between	S129A	or	S129D	a-syn	expressing	
systems	[281,	289].	These	various	approaches	to	study	the	consequences	of	S129	
phosphorylation	are	each	limited	in	their	own	way;	biochemical	approaches	omit	
important	cellular	factors	that	impinge	on	phosphorylation	and	aggregation	processes,	
and	model	systems	that	rely	on	kinase	or	a-syn	overexpression	may	be	confounded	by	
potential	off-target	effects.	Nevertheless,	dissecting	the	influence	of	this	highly	
prevalent	S129	phosphorylation	PTM	remains	a	high	priority	for	its	potential	therapeutic	
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implications	to	intervene	on	a	process	that	directly	modulates	a-syn	aggregation	and	
toxicity.	
	 Solution	conditions.	Several	factors	in	the	cytosolic	milieu	of	dopaminergic	
neurons	in	the	SNpc	also	influence	the	tendency	of	a-syn	to	form	insoluble	fibrils	and	
inclusions.	One	factor	present	in	cells	of	this	region	is	DA	itself,	the	synthesis	of	which	is	
required	for	nigrostriatal	signal	transduction.	DA	synthesis	is	known	to	be	highly	
oxidative	in	nature,	and	upon	its	oxidative	ligation	to	a-syn,	DA	inhibits	conversion	of	a-
syn	protofibrils	to	fibrils	resulting	in	accumulation	of	protofibrillar	species	[290].	DA,	L-
DOPA,	other	catecholamines,	and	their	respective	oxidative	breakdown	products	have	
been	shown	to	inhibit	in	vitro	a-syn	fibrillization	or	dissolve	a-syn	fibrils	already	formed	
by	creating	an	environment	where	formation	of	non-amyloidogenic	protofibrils	or	
oligomers	is	favored	over	fibril	formation	[291-294].	In	cellular	models	of	a-syn	
aggregation,	increasing	DA	levels	has	a	similar	effect	as	observed	in	vitro,	inhibiting	
aggregate	formation	and	instead	promoting	formation	of	non-toxic	oligomeric	
intermediates	[294,	295].	These	results	implicate	decreased	DA	levels	in	SNpc	neurons	
as	a	factor	promoting	a-syn	aggregation	in	PD,	which	could	then	result	in	a	positive	
feedback	loop	of	a-syn-induced	dopaminergic	degeneration	and	additional	a-syn	
aggregation	[292].	Moreover,	the	lysosomal	protease	cathepsin	B	(CatB)	triggers	
intracellular	a-syn	aggregate	formation	[296],	as	do	cellular	stressors	such	as	oxidation	
or	cytochrome-c	released	from	mitochondria	[297,	298];	these	factors	would	all	be	
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increased	with	a-syn-mediated	cellular	toxicity,	and	would	feed	into	the	same	positive	
feedback	loop	promoting	a-syn	aggregation.	
	 Finally,	the	morphology	of	a-syn	and	the	aggregates	formed	are	highly	sensitive	
to	solution	conditions	such	as	ionic	strength	and	pH	[299,	300].	At	mildly	acidic	pH	such	
as	would	be	encountered	in	the	environment	of	endosomes	or	lysosomes,	the	rate	of	
secondary	nucleation	processes	such	as	fragmentation	and	surface-assisted	nucleation	
is	dramatically	faster	than	at	physiological	pH,	leading	to	an	increase	in	both	aggregate	
size	as	well	as	total	number	[301].	a-syn	remains	unfolded	at	neutral	pH,	but	acidic	pH	is	
associated	with	rigidification	and	compaction	of	the	highly	hydrophobic	and	negatively-
charged	C-terminal	region	leading	to	its	increased	interaction	with	the	NAC	domain	
rather	than	long-range	contacts	with	the	N-terminus	[302].	These	conformational	
changes	may	underlie	an	increased	propensity	to	become	misfolded	or	a	stabilization	of	
a-syn	oligomeric	intermediates	and	a	concomitant	decreased	energetic	barrier	to	
fibrillization	[303].	While	the	process	of	a-syn	aggregation	is	a	multifactorial	equation,	
factors	such	as	genetic	variants	in	protein	sequence	or	expression,	PTMs	such	as	S129	
phosphorylation,	and	solutions	conditions	represent	some	of	the	most	important	
influences.		
	 Strains.	Just	as	prions	exhibit	the	structural	heterogeneity	to	fold	into	multiple	
self-replicating	strains	that	produce	distinct	disease	phenotypes	[52],	a-syn	has	also	
been	shown	to	adopt	distinct	strain	conformations,	perhaps	underlying	the	phenotypic	
diversity	of	a-synucleinopathies	caused	by	aggregates	of	a	single	protein	[304].	The	
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strain	phenomenon	for	a-syn	was	first	elucidated	by	Ronald	Melki	and	colleagues,	who	
demonstrated	that	two	distinct	conformations	of	a-syn	fulfilled	the	molecular	criteria	to	
be	designated	as	different	strains	by	exhibiting	differences	in	structure,	level	of	toxicity,	
and	in	vitro	and	in	vivo	seeding	and	propagation	properties	[305]	(Figure	4).	
Subsequently,	these	two	strains,	named	a-syn	fibrils	and	ribbons	for	their	different	
conformational	architectures,	were	shown	to	induce	distinct	histopathological	and	
behavioral	phenotypes	when	injected	into	rat	brain	[218].	Both	a-syn	strains	faithfully	
seeded	aggregation	and	templated	their	unique	conformations	onto	expressed	a-syn	to	
amplify	in	vivo,	but	a-syn	fibrils	exhibited	a	higher	level	of	toxicity	with	accompanying	
progressive	motor	impairment	and	cell	death	compared	to	a-syn	ribbons,	which	caused	
a	different	phenotype	with	characteristics	resembling	both	PD	and	MSA	[218].	Multiple	
different	a-syn	strains,	or	polymorphs,	have	been	produced	in	vitro	by	varying	solution	
conditions	during	aggregation,	and	they	have	been	rigorously	characterized	by	solid-
state	nuclear	magnetic	resonance	(NMR)	spectroscopy	and	atomic-force	microscopy	
(AFM)	to	differ	by	morphology	and	physical	properties	[306-310].	The	existence	of	
different	a-syn	strains	was	confirmed	in	other	studies	by	demonstrating	differences	in	
cross-seeding	efficiency	between	different	a-syn	strains	and	tau	protein	[311],	by	
detecting	differences	in	biochemical	properties	between	in	vitro-prepared	a-syn	strains	
and	a-syn	extracted	from	PD	brain	[311],	and	by	transmitting	a	distinct	a-syn	pathology	
from	MSA	brain	samples	to	a-syn	overexpressing	mice	different	from	that	induced	by	
injection	of	PD	brain	samples	or	brain	homogenate	from	diseased	mice	[312-314].	The	
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conditions	under	which	a-syn	aggregates	are	formed	can	therefore	significantly	impact	
the	conformation	of	the	resulting	fibrils	and	the	pathological	phenotype	they	induce.	
Additionally,	the	presence	of	the	bacterial	endotoxin	lipopolysaccharide	(LPS)	during	the	
a-syn	aggregation	process	produces	a	structurally	distinct	fibril	strain	that	causes	a	
unique	pattern	of	a-synucleinopathy,	raising	the	possibility	that	exposure	to	exogenous	
pathogens	may	also	influence	the	aggregation	process	and	contribute	to	the	diversity	of	
disease	phenotype	[315].	Finally,	a-syn	S129	phosphorylation	also	induces	formation	of	
a	distinct	a-syn	strain	with	a	different	structure,	propagation	pattern,	and	higher	
cytotoxicity	compared	to	WT	a-syn,	indicating	that	this	highly	prevalent	PTM	enriched	in	
LB	inclusions	strongly	influences	strain	conformation	and	increases	aggregate	toxicity	
[316].	Overall,	the	concept	that	a-syn	aggregates	can	adopt	unique	strain	conformations	
has	only	recently	become	apparent,	but	it	has	an	incredible	potential	to	explain	the	
wide	variety	of	disease	phenotypes	experienced	with	a-synucleinopathies	and	may	
underlie	unique	aspects	of	a-syn	pathological	behavior.		
Degradation	and	Disease-Induced	Dysfunction.	
	 	Maintaining	homeostasis	in	cells	burdened	by	misfolded	protein	aggregates	is	
the	role	of	degradative	processes	tasked	with	both	the	clearance	of	aberrant	proteins	
and	the	recycling	of	their	individual	amino	acid	constituents.	Both	the	ubiquitin-
proteosome	system	(UPS)	and	the	autophagy-lysosome	pathway	(ALP)	are	involved	in	
the	degradation	of	misfolded	a-syn,	although	the	work	of	degrading	higher-molecular	
weight	aggregates	of	a-syn	is	mainly	performed	by	the	ALP,	the	only	known	mechanism	
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in	eukaryotic	cells	to	degrade	protein	aggregates	or	damaged	organelles	that	cannot	be	
processed	by	the	proteasome	[317].	Autophagy,	which	means	“self-eating”	in	Greek,	
was	originally	viewed	as	only	active	in	response	to	nutrient	deprivation,	but	more	
recently	has	been	appreciated	as	playing	a	key	constitutive	role	in	promoting	neuronal	
survival	through	its	basal	level	of	activity	[318].	Consequently,	dysfunction	in	this	
process	can	also	contribute	to	neurodegeneration	[319,	320].	Since	the	discovery	that	a-
syn	is	contained	within	autophagosomes	[321],	the	double-membrane	structures	that	
engulf	cytoplasmic	contents	and	eventually	fuse	with	lysosomes	to	degrade	the	cargo,	
investigation	of	this	process	has	elucidated	the	circular	mechanisms	of	autophagy-
mediated	a-syn	degradation	and	a-syn-induced	autophagic	dysfunction,	and	focused	on	
promoting	degradation	through	the	ALP	as	a	possible	therapeutic	approach	for	PD.	
	 Within	the	ALP,	there	are	three	autophagic	pathways	through	which	substrates	
destined	for	degradation	can	be	processed.	The	first	type	of	autophagy	is	known	as	
microautophagy,	where	substrates	are	directly	taken	up	into	lysosomes	via	invagination	
of	the	lysosomal	membrane	and	promptly	degraded	by	proteolytic	enzymes,	although	
this	form	of	autophagic	degradation	has	not	been	demonstrated	for	a-syn	[317,	318].	
The	second	form	of	autophagic	degradation,	chaperone-mediated	autophagy	(CMA),	is	
known	to	be	important	for	a-syn	degradation	[322,	323].	CMA	substrates	such	as	a-syn	
are	first	bound	at	the	consensus	KFERQ	motif	by	the	chaperone	heat	shock	cognate	71	
kD	protein	(HSC70)	which	induces	the	unfolding	of	the	target	[317].	Substrates	then	
bind	the	CMA	receptor	lysosomal-associated	membrane	protein	type	2A	(LAMP2A)	at	
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the	lysosomal	membrane	which	induces	membrane	translocation	and	subsequent	
proteolytic	digestion	of	the	target	[324].	Despite	the	importance	of	CMA	for	degradation	
of	misfolded	a-syn	monomers	and	dimers,	it	is	not	capable	of	degrading	a-syn	
oligomers	or	higher	molecular	weight	aggregates	because	of	the	requirement	to	
translocate	across	the	lysosomal	membrane	[324,	325].	Thus,	it	is	the	role	of	the	third	
form	of	autophagic	degradation,	macroautophagy,	to	degrade	larger	a-syn	aggregates	
that	accumulate	in	diseased	neuronal	cells,	and	because	this	process	is	the	most	well-
characterized	of	the	three	forms	of	autophagy	and	most	important	for	bulk	degradation	
of	dysfunctional	organelles	or	misfolded	protein	aggregates,	the	use	of	the	general	term	
“autophagy”	most	often	refers	to	this	process	of	macroautophagy,	a	convention	that	
will	also	be	used	here	in	the	discussion	that	follows.	
	 Autophagy	involves	the	engulfment	of	cytoplasmic	cargo	by	a	double-membrane	
phagophore,	further	expansion	into	an	autophagosome,	and	fusion	with	a	lysosome	to	
become	an	autophagolysosome	where	the	cargo	is	degraded	by	proteolytic	enzymes	
active	in	this	low	pH	compartment	[317].	This	process	plays	an	essential	role	in	
degrading	protein	complexes	like	oligomers	and	aggregates	that	fail	to	pass	through	the	
proteasome	barrel	or	translocate	through	the	lysosomal	membrane	in	CMA	[326].	When	
the	UPS	is	inhibited,	low	pH	compartments	containing	cathepsin	D	(CatD)	are	increased,	
representing	a	compensatory	increase	in	autolysosomes	and	lysosomes	that	degrade	
misfolded	a-syn	[327].	Inhibiting	autophagic	or	lysosomal	degradation	results	in	an	
increase	in	large	cytoplasmic	a-syn	inclusions,	whereas	activation	of	autophagy	causes	
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dissolution	of	these	inclusions	and	increases	the	number	of	smaller	a-syn	aggregates	
[327].	Autophagic	components	are	known	to	be	significantly	increased	in	the	brains	of	
DLB	patients	and	transgenic	mice	overexpressing	mutant	a-syn,	indicating	that	
autophagy	is	induced	to	facilitate	clearance	of	a-syn	aggregates	[328].	Moreover,	
overexpression	of	transcription	factor	EB	(TFEB),	a	master	regulator	of	the	autophagy-
lysosomal	pathway,	or	Ras-related	protein	Rab7	(Rab7),	a	regulator	of	endosomal	and	
autophagosomal	trafficking,	reduced	accumulation	of	aggregated	a-syn	by	inducing	its	
autophagic	clearance,	further	supporting	a	role	for	this	pathway	in	degradation	of	a-syn	
[329,	330].	PLK2	and	PLK3,	kinases	involved	in	phosphorylation	of	a-syn	S129,	enhance	
a-syn	autophagic	degradation	by	forming	a	complex	with	pS129	a-syn	and	acting	as	a	
target	for	polyubiquitination,	allowing	the	selective	recognition	of	the	complex	by	the	
autophagic	machinery	[273,	331].	Additionally,	phosphorylation	of	S129	is	implicated	in	
targeting	a-syn	for	autophagic	degradation	because	cellular	expression	of	the	S129A	
mutant	failed	to	cause	the	induction	of	autophagy	seen	with	expression	of	WT	a-syn	
[271].	Once	the	a-syn	cargo	encounters	the	environment	of	the	lysosome,	the	actions	of	
proteolytic	enzymes	such	as	CatD	have	been	shown	to	be	effective	in	degrading	a-syn	
[332,	333],	although	mature	fibrillar	a-syn	inclusion	bodies	have	been	shown	to	be	
refractory	to	lysosomal	or	autophagic	clearance	[134,	334].	Lysosomal	clearance	of	a-
syn	has	been	demonstrated	in	vivo	by	the	detection	of	a-syn	within	the	lumen	of	
lysosomes	isolated	from	mouse	midbrain,	colocalization	in	nigral	tissue	of	a-syn	with	
LAMP2A	staining,	and	elevation	of	LAMP2A	expression	in	a-syn	overexpressing	mice	
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[335].	These	findings	implicate	the	ALP	as	a	key	mediator	of	a-syn	degradation	and	a	
first-line	strategy	for	maintaining	cellular	homeostasis	in	the	face	of	increased	protein	
aggregation.		
	 Given	the	importance	of	the	ALP	for	degradation	of	a-syn	aggregates,	one	of	the	
most	challenging	aspects	of	PD	pathology	is	the	circular	positive-feedback	effect	of	a-
syn	aggregates	inducing	dysfunction	in	ALP	degradation	processes.	This	a-syn-induced	
dysfunction	occurs	in	both	CMA	and	macroautophagy.	In	the	CMA	pathway,	a-syn	
familial	mutants	A53T	and	A30P	as	well	as	DA-modified	a-syn	are	known	to	bind	the	
LAMP2A	receptor	on	lysosomal	membranes	with	increased	affinity	compared	to	WT	a-
syn	and	act	as	uptake	blockers,	impairing	their	own	degradation	as	well	as	that	of	other	
autophagic	substrates	[322,	325,	336].	CMA	inhibition	by	a-syn	is	known	to	produce	a	
compensatory	increase	in	macroautophagy,	but	this	autophagic	mechanism	is	also	
dysfunctional	because	of	a-syn	aggregation.	Nigral	dopaminergic	neurons	of	PD	patients	
have	been	shown	to	undergo	both	apoptosis	and	autophagic	degeneration,	
characterized	by	an	increased	number	of	autophagic	vacuoles	found	in	diseased	
neurons	[337],	and	the	level	of	LC3	is	known	to	be	elevated	in	insoluble	fractions	from	
brains	of	patients	with	DLB	[132].	This	abnormal	accumulation	of	autophagosomes	and	
increase	in	LC3	is	also	seen	in	cell	culture	models	of	PD	[338,	339],	indicating	a	
combination	of	both	upregulation	due	to	increased	burden	of	misfolded	proteins	and	
persistence	due	to	dysfunctional	clearance.	While	an	increased	abundance	of	
autophagosomes	may	represent	ongoing	cellular	attempts	to	combat	accumulation	of	
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misfolded	proteins,	a	more	detailed	examination	reveals	that	these	accumulating	
autophagosomes	are	abnormal	and	dysfunctional	[131,	339].	In	cell	culture	models	and	
in	brains	of	a-syn	transgenic	mice	and	DLB	patients,	the	accumulating	autophagosomes	
are	significantly	enlarged	compared	to	normal	autophagosomes	and	irregular	in	
appearance,	some	of	which	only	having	a	single	membrane	rather	than	the	
characteristic	double-membrane	structure	[131,	134,	339].		
	 There	are	several	mechanisms	whereby	accumulation	of	a-syn	induces	
dysfunction	in	autophagy.	One	cause	of	compromised	autophagy	is	the	inhibition	by	a-
syn	of	Rab1a,	which	then	causes	mislocalization	of	autophagy-related	protein	(Atg)	9,	a	
key	regulator	of	membrane	transport	to	the	degradation	site,	preventing	proper	
autophagosome	formation	[340].	Another	reason	for	the	accumulation	of	
autophagosomes	unable	to	degrade	their	cargo	is	the	permeabilization	of	lysosomal	
membranes	by	mitochondrial-derived	ROS,	induced	by	parkinsonian	neurotoxin	1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine	(MPTP)	or	a-syn,	and	the	subsequent	
release	of	lysosomal	proteases	into	the	cytosol	[130].	This	lysosomal	depletion	results	in	
defective	clearance	of	autophagosomes	since	fusion	with	lysosomes	for	final	
degradation	is	impaired.	Additionally,	excessive	a-syn	in	nigral	dopaminergic	neurons	is	
associated	with	cytoplasmic	retention	of	TFEB	by	sequestration	into	LBs,	resulting	in	an	
inability	of	this	key	transcriptional	regulator	of	the	ALP	to	translocate	into	the	nuclear	
compartment	[341].	Finally,	a-syn	aggregates	are	known	to	activate	Toll-like	receptor	2	
(TLR2)	[342],	and	TLR2	activation	in	neurons	results	in	inhibition	of	autophagy	through	
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activation	of	AKT	and	mammalian	target	of	rapamycin	(mTOR)	[343].	Thus,	an	additional	
positive-feedback	loop	exists	whereby	activation	of	TLR2	by	a-syn	aggregates	impairs	
autophagy	and	results	in	accumulation	of	additional	a-syn	aggregates.	In	addition	to	
impairing	autophagy,	a-syn	aggregation	induces	dysfunction	in	lysosomal	degradation	
as	well.	In	a	similar	situation	to	that	of	autophagosomes,	lysosomes	are	abundant	in	
cells	exhibiting	a-syn	aggregation	as	a	compensatory	effort	to	degrade	the	burden	of	
misfolded	proteins	[344,	345],	but	these	lysosomes	are	dysfunctional	as	evidenced	by	
decreases	in	lysosome-associated	membrane	protein	1	(LAMP1)	and	CatD	in	human	and	
rat	nigral	neurons	containing	a-syn	inclusions	[346].	These	several	mechanisms	by	which	
a-syn	impairs	the	ALP	illustrate	the	difficulty	in	maintaining	proteostasis	when	the	
buildup	of	protein	aggregates	directly	contributes	to	dysfunction	in	the	autophagic	and	
lysosomal	degradative	machinery.		
	 While	a-syn	aggregation	clearly	induces	ALP	dysfunction,	and	one	result	of	this	
dysfunction	is	a	further	accumulation	of	a-syn	aggregates	[323,	328,	334,	347-349],	
additional	insight	into	functional	and	dysfunctional	a-syn	degradation	can	be	gained	by	
examining	genetic	diseases	that	exhibit	impairments	in	degradative	processes.	
Homozygous	loss-of-function	mutations	in	the	GBA1	gene	encoding	the	lysosomal	
hydrolase	b-glucocerebrosidase	(GCase)	cause	Gaucher’s	disease,	the	most	common	
lysosomal	storage	disorder,	characterized	by	a	toxic	buildup	of	the	GCase	substrate	
glucosylceramide	(GlcCer)	[350,	351].	Interestingly,	mutations	in	GBA1	are	also	
considered	the	most	common	genetic	risk	factor	for	PD,	such	that	PD	patients	are	more	
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than	5	times	more	likely	to	carry	a	GBA1	mutation	than	normal	healthy	controls	[350,	
352].	The	association	between	a-synucleinopathy	and	GBA1	mutation	status	is	even	
more	pronounced	for	DLB,	where	DLB	patients	are	more	than	8	times	more	likely	than	
controls	to	carry	a	GBA1	mutation	[353].	GBA	mutation-associated	PD	and	DLB	patients	
have	an	earlier	age	of	disease	onset	than	non-carriers,	are	more	likely	to	have	affected	
relatives,	and	exhibit	a	more	rapid	progression	of	motor	impairment	and	cognitive	
decline	[352-354].	GCase	enzymatic	activity	was	lower	in	Gaucher’s	patients	with	a	
homozygous	GBA1	mutation	than	in	carriers	with	only	a	heterozygous	mutation,	
although	the	heterozygous	mutant	GBA1	patients	exhibited	a	lower	GCase	activity	than	
non-carriers	[355].	When	all	PD	patients	were	compared	with	controls,	GCase	activity	
was	diminished	in	diseased	patients	even	in	idiopathic	PD,	when	GBA	mutants	were	
excluded,	and	after	adjusting	for	age	and	gender,	suggesting	that	both	GBA	mutation	
carriers	and	PD	patients	without	GBA	mutations	exhibit	loss	of	GCase	function,	and	that	
this	diminished	lysosomal	degradative	activity	may	contribute	to	PD	pathogenesis	[355].	
	 The	molecular	explanation	for	this	unexpected	link	between	PD	and	Gaucher’s	
disease	was	established	when	it	was	discovered	that	loss	of	GCase	function	results	in	
compromised	lysosomal	degradation	and	a	consequential	accumulation	of	a-syn	[356,	
357].	Moreover,	the	GCase	substrate	GlcCer	also	accumulates,	and	can	stabilize	a-syn	
oligomers	to	promote	amyloid	formation	[356].	Finally,	the	accumulating	a-syn	inhibits	
the	activity	of	normal	GCase,	forming	a	positive	feedback	loop	of	compromised	
lysosomal	degradation,	accumulation	of	a-syn	and	GlcCer,	and	further	degradative	
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impairment	which	leads	to	a	progressive	neurotoxicity	in	both	GBA1	mutation	carriers	
and	idiopathic	PD	patients	[356].	Recently,	the	disruptive	influence	of	a-syn	
accumulation	in	sporadic	PD	was	more	completely	understood	with	the	observation	that	
a-syn	disrupts	the	proper	trafficking	of	multiple	lysosomal	hydrolases	by	interfering	with	
the	normal	association	between	GM130	and	Rab1a	and	inhibiting	their	cis-Golgi	
tethering	activity,	critically	impairing	Golgi	structure	and	vesicular	trafficking	[358].	
Consistent	with	the	view	that	a-syn	aggregation	impairs	GCase	and	overall	lysosomal	
degradative	capacity,	reductions	in	GCase	expression	and	activity	are	seen	in	brain	
tissue	of	idiopathic	PD	patients	just	as	in	that	of	GBA1-mutation	carrying	PD	patients	
[359-361],	and	GCase	depletion	often	occurs	in	brain	regions	burdened	by	increased	a-
syn	levels	[360].	Other	regulatory	factors	may	certainly	impinge	on	the	bidirectional	
interplay	between	a-syn	and	GCase,	as	decreases	in	GCase	mRNA	have	been	
documented	in	SN	of	PD	and	DLB	patients	[361]	and	GCase	activity	gradually	diminishes	
with	age	in	the	SN	and	putamen	of	healthy	controls	to	a	level	comparable	with	that	of	
GBA1-mutation	carrier	PD	patients	[362].	Impaired	GCase	results	in	increased	GlcCer	
and	asyn,	perturbations	in	autophagic	degradation,	and	dysfunctional	and	enlarged	
lysosomes	in	affected	neurons	[360,	363-366].	While	additional	factors,	perhaps	
dependent	on	age,	may	influence	GCase	activity	and	alter	the	threshold	for	disease	
initiation,	a-syn	aggregation	has	been	firmly	established	as	a	primary	cause	of	
decreased	GCase	activity,	initiating	a	positive-feedback	cycle	of	degeneration	central	to	
PD	pathogenesis.		
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	 Other	genetic	diseases	that	exhibit	a	relationship	with	a-syn	through	impairment	
of	degradative	processes	include	Kufor-Rakeb	syndrome	(KRS)	and	neuronal	ceroid-
lipofuscinosis	(NCL).	KRS	is	an	autosomal	recessive	form	of	early-onset	familial	
parkinsonism	with	pyramidal	degeneration	and	dementia	caused	by	homozygous	loss-
of-function	mutations	in	a	late-endosomal	and	lysosomal	transmembrane	P-type	ATPase	
known	as	ATP13A2	[367-369].	Even	single	heterozygous	mutations	in	ATP13A2	have	
etiological	relevance	for	young	onset	PD	[368].	Decreased	ATP13A2	function	results	in	
impaired	lysosomal	acidification,	reduced	proteolytic	processing	of	lysosomal	enzymes	
and	degradation	of	substrates,	diminished	clearance	of	autophagosomes,	and	
accumulation	of	abnormal	lysosomes	[369,	370].	ATP13A2	has	also	been	shown	to	be	
decreased	in	dopaminergic	nigral	neurons	from	patients	with	PD,	where	it	instead	
accumulates	within	LBs,	implicating	ATP13A2-mediated	lysosomal	dysfunction	in	
settings	other	than	just	its	genetic	mutation	[370].	In	vitro	studies	have	demonstrated	
that	loss	of	ATP13A2	function	leads	to	accumulation	of	a-syn	and	a-syn-mediated	
neurotoxicity	through	impairment	of	its	degradation	[371],	but	animal	models	with	
deficient	ATP13A2	observed	defects	in	protein	trafficking,	accumulation	of	ubiquitinated	
protein	aggregates,	and	endolysosomal	abnormalities	occurring	in	the	absence	of	a-syn	
pathology,	suggesting	an	additional	contribution	by	a-syn-independent	mechanisms	to	
endolysosomal	dysfunction	and	neurotoxicity	[372].	NCL	is	a	lysosomal	storage	disorder	
characterized	by	early	onset,	progressive	neurodegeneration	with	gliosis	and	
autofluorescent	deposits	of	lipofuscin	known	to	be	caused	by	homozygous	deficiency	of	
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CTSD,	the	gene	encoding	the	lysosomal	protease	CatD	[372,	373].	CatD	is	instrumental	
for	the	degradation	of	a-syn	in	the	lysosome,	and	thus	expectedly	its	pharmacological	
inhibition,	introduction	of	a	catalytically	inactive	mutant	form,	or	loss-of-function	
genetic	mutation	result	in	a-syn	misprocessing	and	accumulation	[333,	373,	374].	
Although	complete	loss	of	CatD	elicits	the	most	profound	inhibition	of	lysosomal	
function,	heterozygous	mutations	that	result	in	a	partial	loss	of	CatD	still	reduce	
lysosomal	activity	and	cause	accumulation	of	intracellular	a-syn	aggregates	[373].	In	
addition	to	highlighting	the	key	role	of	the	ALP	in	degradation	of	a-syn,	these	studies	
demonstrate	that	slight	perturbations	in	lysosomal	acidification	or	a	partial	loss	of	CatD	
activity,	occurring	even	in	the	absence	of	ATP13A2	or	CTSD	mutations,	may	be	sufficient	
to	cause	a	reduction	in	lysosomal	function	and	result	in	a-syn	aggregation	in	PD.	This,	
coupled	with	the	dysfunction	in	degradative	processes	induced	by	a-syn	aggregates,	
results	in	a	vicious	cycle	of	protein	aggregate	accumulation	and	degradative	dysfunction.		
	 Given	the	dysfunction	induced	by	a-syn	in	degradative	processes,	and	the	critical	
role	of	these	processes	in	clearance	of	a-syn	aggregates,	some	therapeutic	approaches	
have	sought	to	augment	autophagic	or	lysosomal	degradation	as	a	strategy	to	
ameliorate	a-syn	induced	dysfunction,	reduce	the	burden	of	misfolded	a-syn,	and	
prevent	neurotoxicity.	Expression	of	the	autophagy	related	protein	beclin	1	was	shown	
to	activate	autophagy	and	lysosomes,	reduce	accumulation	of	a-syn,	and	ameliorate	
neuritic	pathology	caused	by	a-syn	overexpression	[339].	Likewise,	overexpression	of	
the	transcription	factor	TFEB,	known	to	be	aberrantly	retained	in	the	cytosol	of	PD	
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neurons,	reverses	the	PD-linked	decline	in	lysosome	function	and	facilitates	
neuroprotection	via	clearance	of	a-syn	aggregates	[341].	Overexpression	of	LAMP2A	
attenuates	a-syn-induced	dysfunction	in	CMA	by	upregulating	this	degradative	process,	
reducing	both	total	and	misfolded	a-syn	levels,	and	preventing	a-syn-mediated	
neurotoxicity	[375].	Finally,	boosting	expression	or	activity	of	GCase	in	the	lysosomal	
compartment	has	been	shown	to	ameliorate	histopathological	abnormalities	such	as	
accumulation	of	GlcCer,	ubiquitin,	tau,	and	a-syn,	and	to	reverse	perturbations	in	
hydrolase	trafficking	and	lysosomal	dysfunction	caused	by	the	previously	accumulating	
a-syn	[357,	376,	377].	Correcting	the	defects	in	a-syn	degradation	have	the	therapeutic	
potential	to	break	the	cycle	of	protein	aggregation	and	impaired	degradation,	and	allow	
both	reversal	and	prevention	of	dysfunctional	a-syn	proteostasis.		
Cytotoxicity.	
	 Given	all	the	pathologic	events	associated	with	a-syn	aggregation,	there	are	
many	possibilities	for	how	protein	aggregation	contributes	to	neuronal	cell	death	in	PD.	
Aside	from	the	accumulation	of	misfolded	a-syn	into	LB	inclusions,	the	histologic	
hallmark	of	PD	is	dopaminergic	neurodegeneration	in	the	SNpc.	Aggregates	of	a-syn,	or	
even	just	the	NAC	domain,	induce	apoptotic	cell	death	in	cultured	neuronal	cells	[378],	
and	gene	transfer	of	human	a-syn	to	rat	SN	results	in	50%	loss	of	dopaminergic	neurons	
13	weeks	after	infection	with	the	gene-carrying	viral	vector	[379],	although	several	
mechanisms	have	been	proposed	to	explain	this	neuronal	loss.	One	mechanism	for	
induction	of	cytotoxicity	may	relate	to	the	physiologic	role	of	a-syn	in	associating	with	
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pre-synaptic	membranes,	such	that	a-syn	aggregation	both	sequesters	functional	forms	
of	a-syn	into	insoluble	aggregates	and	further	impairs	the	actions	of	other	synaptic	
proteins	involved	in	membrane	fusion	events	at	synaptic	terminals	[176,	380].	While	the	
knockdown	of	a-syn	and	the	resulting	loss	of	its	physiologic	function	has	been	shown	to	
be	toxic	for	nigrostriatal	dopaminergic	neurons	[175],	a-syn	overexpression	and	
aggregation	results	in	decreased	synaptic	proteins	involved	in	exocytosis	and	
endocytosis,	enlarged	synaptic	vesicles,	deficits	in	neurotransmitter	release,	
impairments	in	excitability	and	connectivity,	and	eventual	neurotoxicity	[202,	381].	One	
reason	for	a-syn	aggregates	causing	dysfunctional	excitability	and	neurotransmitter	
release	may	be	due	to	sequestration	of	a	subunit	of	the	Na+/K+-ATPase	within	
membrane	bound	a-syn	clusters,	reducing	local	densities	of	this	subunit	and	decreasing	
efficiency	of	Na+	extrusion	following	stimulus	[382].	Another	mechanism	whereby	a-syn	
aggregation	results	in	neurotoxicity	is	its	impairment	of	its	own	degradation.	Not	only	
has	a-syn	been	causally	linked	to	impairments	in	the	ALP	which	result	in	toxicity	[336,	
356,	383],	Golgi	fragmentation	and	subsequent	toxic	impairments	in	trafficking	are	
known	to	be	a	specific	consequence	of	a-syn	aggregation	as	well	[129,	358].	Finally,	a-
syn	aggregation	may	cause	neuronal	dysfunction	and	toxicity	by	disrupting	normal	
axonal	transport	[384,	385],	a	key	process	for	movement	of	signaling	components	and	
degradative	vesicles	throughout	the	long,	elaborate	axonal	network	of	dopaminergic	
neurons.	Axonal	transport	motor	proteins	such	as	kinesin	and	dynein	are	decreased	in	
brains	of	sporadic	PD	patients	prior	to	the	onset	of	dopaminergic	neurodegeneration,	
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with	significantly	greater	reductions	observed	in	nigral	neurons	containing	a-syn	
inclusions	[386].	Kinesin	motor	proteins	facilitate	anterograde	transport	from	the	soma	
to	the	presynaptic	terminal	while	dynein	motor	proteins	facilitate	retrograde	transport	
in	the	opposite	direction,	from	the	terminals	back	to	the	soma.	Animal	models	of	PD	
that	overexpress	A53T	or	A30P	a-syn	observe	decreased	kinesin	levels	and	increased	
dynein	levels	in	the	striatum,	the	site	where	nigrostriatal	dopaminergic	neurons	
synapse,	and	increased	kinesin	levels	in	the	SNpc	where	the	cell	bodies	of	nigrostriatal	
neurons	reside	[386,	387].	These	findings	suggest	that	a-syn	causes	motor	proteins	to	
be	trapped	at	their	respective	origins,		unable	to	bind	to	microtubule	tracks	to	facilitate	
axonal	transport	[384].	These	effects	may	be	due	to	direct	actions	of	a-syn	on	
microtubules	themselves,	as	a-syn	pathology	is	known	to	begin	in	axons	as	LNs	before	
progressing	to	more	mature	LB	pathology	in	the	soma.	a-syn	is	known	to	act	in	its	
monomeric	state	as	a	microtubule-dynamase,	binding	tubulin	and	promoting	
microtubule	nucleation	and	enhancing	growth	rate	and	catastrophe	frequency	[172],	
although	this	role	may	be	perturbed	when	a-syn	becomes	misfolded	into	aggregates.	
Indeed,	tubulin	levels	are	decreased	in	nigral	neurons	overexpressing	a-syn	[387],	and	
both	a-syn	fibrils	and	protofibrils	inhibit	microtubule	assembly	by	binding	to	tau	and	
promoting	its	aggregation,	depleting	the	tau	available	for	microtubule	polymerization	
and	inhibiting	its	microtubule	stabilizing	function	[388].	The	great	variety	of	neurotoxic	
insults	brought	on	by	a-syn	aggregation	underscores	the	importance	of	understanding	
this	complex	process	more	fully.		
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	 One	of	the	most	highly	debated	questions	regarding	a-syn-induced	cytotoxicity	
is	whether	smaller	forms	of	a-syn	aggregates	represent	the	more	toxic	a-syn	species,	or	
if	instead	the	larger	histopathologic	hallmark	a-syn	inclusions	induce	the	most	cellular	
toxicity.	Although	structured	intermediates	in	the	fibrillization	spectrum	from	single	
monomer	to	elongated	fibril	may	be	known	by	various	names	such	as	protofibrils	or	
oligomers,	there	are	two	key	differences	between	the	multitude	of	oligomeric	forms	
and	larger	a-syn	inclusions;	the	first	difference	seems	to	be	the	overall	size	of	the	
assembly,	with	inclusions	being	many	times	larger	than	individual	a-syn	oligomers,	and	
the	second	difference	is	the	likelihood	of	a-syn	self-association	or	clustering,	which	is	
necessary	to	generate	a	compact	LB	inclusion	from	multiple	elongated	a-syn	fibrils.	
While	the	subject	of	the	most	toxic	a-syn	species	is	still	actively	contested,	smaller	a-
syn	oligomeric	forms	have	emerged	as	likely	candidates	for	pathological	induction	of	cell	
death	[129,	389,	390].	Smaller	a-syn	oligomeric	or	fibrillar	species	have	been	shown	to	
directly	induce	cytotoxicity	in	a	multitude	of	experimental	settings	[391-393].	In	
contrast,	a-syn	forms	that	fibrillize	to	larger	sizes	more	quickly	are	less	toxic	[393,	394],	
consumption	of	excess	soluble	a-syn	into	fibrillar	forms	is	neuroprotective	[204],	and	
promoting	elongation	and	clustering	of	fibrils	may	reduce	fragmentation,	seeding,	and	
the	resulting	toxicity	[395].	These	findings	agree	with	the	protective	role	of	larger	LB	
inclusions	containing	fibrillar	a-syn	and	suggest	that	smaller	oligomeric	or	fibrillar	a-syn	
forms	represent	the	most	toxic	aggregate	species.	While	there	are	many	possibilities	for	
mechanisms	of	neurotoxicity	induced	by	the	various	forms	of	a-syn	aggregates,	and	
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multiple	mechanisms	may	independently	or	cooperatively	contribute	to	PD,	elucidating	
new	therapeutic	targets	within	these	impaired	pathways	will	result	in	disease-modifying	
treatments.		
Cell-to-Cell	Propagation	
a-Synuclein.	
	 Braak	hypothesis.	The	foundation	for	investigating	the	prion-like	cell-to-cell	
transmission	of	a-syn	was	formed	with	the	pioneering	work	of	Heiko	Braak,	who	
elucidated	a	neuroanatomical	staging	system	of	a-syn	pathology	in	PD	demonstrating	
the	topographical	progression	of	pathologic	a-syn	from	early	to	advanced	cases	of	
idiopathic	PD	[396].	Braak	noted	specific	disease	induction	sites,	such	as	the	dorsal	
motor	nucleus	(DMN)	of	the	glossopharyngeal	and	vagal	nerves	and	the	olfactory	bulb	
(OB),	where	LBs	and	LNs	containing	pathologic	a-syn	initially	occur	[397].	From	lower	
brainstem	or	olfactory	regions	initially	affected,	a-syn	lesions	then	progress	in	a	
topographically-predictable	ascending	fashion	through	six	stages,	progressively	involving	
olfactory,	autonomic,	limbic,	and	somatosensory	brain	regions	with	little	variation	
between	affected	individuals	[397-399].	The	early	presence	of	a-syn	inclusions	in	the	
submucosal	Meissner	plexus	of	the	gastrointestinal	(GI)	tract,	whose	axons	reach	within	
the	intestinal	mucosa	near	mucosal	glands,	or	in	olfactory	neurons,	whose	olfactory	
receptors	reside	in	the	nasal	epithelium,	highlights	the	exposure	of	both	neuronal	cell	
types	to	potentially	hostile	environmental	factors,	and	formed	the	basis	for	what	is	now	
known	as	the	“Braak	hypothesis”,	that	a-syn	pathology	in	PD	originates	outside	the	CNS	
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prior	to	its	stereotypic	CNS	expansion	pattern	[400-402].	While	Braak’s	original	theory	
postulated	the	existence	of	a	yet	unidentified	pathogen	capable	of	crossing	the	GI	
mucosal	barrier,	invading	post-	and	pre-ganglionic	enteric	neurons,	and	eventually	
entering	the	CNS	by	way	of	transneuronal	and	retrograde	axonal	transport	through	
visceromotor	projections	of	the	vagus	nerve,	such	a	pathogen	has	not	been	shown	to	
exist	[400].	The	Braak	hypothesis	has	thus	expanded	to	include	the	idea	that	exposure	
to	environmental	factors	may	induce	initial	a-syn	misfolding	in	the	peripheral	enteric	or	
olfactory	neurons,	and	then	set	into	motion	the	prion-like	cell-to-cell	propagation	of	a-
syn	aggregates	through	seeded	templating	of	further	aggregation	in	the	aforementioned	
uninterrupted	series	of	susceptible	neurons	extending	from	the	periphery	to	the	CNS	
[401,	402].	While	controversial,	the	Braak	hypothesis	has	the	potential	to	explain	many	
relevant	aspects	of	PD	pathology.		
	 In	agreement	with	Braak’s	hypothesis	and	pathological	staging	system,	LBs	are	
frequently	observed	in	the	GI	tract,	in	paraspinal	sympathetic	ganglia,	in	the	vagus	
nerve,	and	in	the	spinal	cord	of	PD	and	DLB	patients	[403-405].	GI	tract	immunostaining	
for	a-syn	occurs	prior	to	the	onset	of	first	motor	PD	symptom,	and	was	not	observed	in	
healthy	control	samples	or	in	subjects	with	inflammatory	bowel	disease,	suggesting	that	
a-syn	histopathology	is	not	a	non-specific	consequence	of	inflammation	or	oxidative	
stress	[406,	407].	Constipation	and	anosmia	are	both	frequent	complaints	of	PD	patients	
prior	to	the	onset	of	classic	motor	symptoms	[80,	85,	88],	possibly	reflecting	an	early-
stage	alteration	in	normal	gut	motility	and	olfaction	induced	by	a-syn	accumulation	in	
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enteric	and	olfactory	neurons.	If,	as	the	Braak	hypothesis	postulates,	exposure	of	enteric	
neurons	to	environmental	factors	present	in	the	GI	tract	can	create	conditions	
promoting	the	initial	misfolding	of	a-syn,	the	intestinal	microbiome,	with	its	diverse	
ecosystem	of	trillions	of	microbes,	represents	one	of	the	most	prominent	exposures	and	
has	the	potential	to	influence	a	multitude	of	immunologic	and	metabolic	processes	
relevant	for	the	microenvironment	of	neurons	in	the	GI	tract.	Analysis	of	intestinal	
microbiomes	by	bacterial	genome	sequencing	revealed	that	bacterial	populations	are	
altered	in	PD	patients	compared	to	controls,	with	a	significant	reduction	in	
Prevotellaceae	and	an	association	between	the	abundance	of	Enterobacteriaceae	and	
the	severity	of	postural	instability	and	gait	difficulty	[408].	In	addition	to	alterations	in	
microbiome	bacterial	populations,	the	presence	of	gut	microbiota	is	required	for	motor	
deficits,	microglial	activation,	and	a-syn	pathology	in	mice	overexpressing	a-syn	[409].	
In	this	mouse	model	of	PD,	removal	of	gut	microbes	with	antibiotic	treatment	or	germ-
free	conditions	reduced	microglial	activation,	a-syn	inclusions,	and	motor	deficits,	
whereas	gut	re-colonization	worsens	neurological	disease	[409].	Recolonization	with	
microbiota	derived	from	PD	patients	results	in	exacerbated	motor	symptoms	compared	
to	recolonization	with	healthy	control	microbiota,	indicating	that	microbiome	dysbiosis	
in	the	PD	gut	influences	the	development	of	a-syn	pathology	in	the	brain	[409].	While	
neuroinflammation	has	been	implicated	as	playing	a	key	role	in	gut-brain	signaling	and	
the	prion-like	behavior	of	a-syn	[410],	identifying	the	specific	microbiome	alterations	
that	pose	an	increased	risk	for	PD	as	well	as	elucidating	the	events,	mediators,	and	
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routes	involved	in	signaling	are	tasks	for	future	study.	Despite	the	lack	of	clarity	
regarding	the	factors	that	initiate	a-syn	pathology	in	the	gut	and/or	OB,	the	Braak	
hypothesis	of	peripheral-to-central	transmission	of	disease	is	nevertheless	supported	by	
the	finding	that	full	truncal	vagotomy	is	associated	with	a	decreased	risk	for	subsequent	
PD	[411].	This	study	and	many	others	highlight	the	need	for	a	deeper	understanding	of	
the	mechanisms	underlying	disease	transmission.		
	 Because	of	the	theory	that	environmental	insults	contribute	to	pathological	a-
syn	misfolding	in	peripheral	nervous	tissue	and	trigger	the	prion-like	invasion	of	
pathology	into	and	throughout	the	CNS	[412],	various	animal	models	have	been	
employed	to	demonstrate	the	feasibility	of	a-syn	peripheral-to-central	transmission.	
Injection	of	a-syn-containing	PD	brain	lysate	or	recombinant	a-syn	aggregates	into	the	
intestinal	wall	leads	to	a-syn	transport	via	the	vagal	nerve	to	the	DMN	in	the	brainstem	
in	a	time-dependent	manner	[413].	Retrograde	transport	on	axonal	microtubules	has	
been	implicated	in	this	gut	to	brain	translocation,	both	through	the	vagal	nerve	when	a-
syn	is	injected	into	the	gut	and	through	the	sciatic	nerve	when	a-syn	is	injected	
intramuscularly	(IM)	into	the	hind	limb	[413,	414].	a-syn	aggregates	are	also	capable	of	
invading	the	CNS	via	intraperitoneal	(IP)	injection	or	crossing	the	blood-brain	barrier	
following	intravenous	(IV)	injection,	although	IM	injection	has	been	shown	to	be	more	
efficient	in	inducing	CNS	pathology	compared	to	IP	or	IV	injections	[218,	415,	416].	
Despite	this	experimental	evidence	for	the	feasibility	of	ascending	disease	from	PNS	to	
CNS,	another	proposed	theory,	contrary	to	Braak’s	hypothesis,	instead	postulates	a	
		
68	
lower	functional	threshold	for	emergence	of	non-motor	symptoms	prior	to	classical	
motor	symptoms,	but	that	both	CNS	and	PNS	exhibit	parallel	degeneration	[417].	Finally,	
there	is	also	evidence	that	a-syn	pathology	can	propagate	in	the	reverse	direction	to	
that	proposed	by	Braak,	that	upon	its	midbrain	overexpression	pathological	a-syn	can	
reach	the	medulla,	then	the	DMN	of	the	vagus	nerve,	and	finally	utilize	vagal	projections	
as	a	conduit	for	transmission	to	the	GI	tract	[418].	Despite	conflicting	theories	regarding	
the	origins	of	a-syn	pathology,	these	studies	illustrate	the	centrality	of	a-syn	cell-to-cell	
propagation	in	PD	progression	and	underscore	the	importance	of	continued	work	to	
understand	this	process	more	completely.		
	 Clinical	evidence	of	propagation.	The	first	studies	to	uncover	cell-to-cell	
propagation	of	a-syn	in	the	PD	brain	involved	pathological	examination	of	brain	tissue	
from	PD	patients	who	had	received	grafts	of	fetal	dopaminergic	neurons	into	the	
striatum	many	years	prior	to	death.	Although	grafted	dopaminergic	neurons	remained	
viable	and	exhibited	extensive	innervation	of	the	host	striatum	more	than	a	decade	
following	transplantation,	long-term	clinical	benefit	was	not	observed	from	this	therapy	
and	grafted	nigral	neurons	developed	pathological	LB	inclusions	containing	a-syn	and	
ubiquitin	(Figure	5C-E)	identical	to	those	observed	in	host	brain	(Figure	5A-B)	[419,	420].	
These	matching	findings	from	both	the	Kordower	and	Brundin	groups	were	the	first	to	
demonstrate	that	ongoing	a-syn	pathology	can	propagate	from	affected	to	naïve	
neurons	in	PD	brain	[419,	420],	although	another	report	observing	long-term	
dopaminergic	graft	survival	in	the	absence	of	infiltrative	a-syn	pathology	suggests	that		
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Figure	5.	Parkinson’s	disease–like	pathology	in	long-term	nigral	grafts.In	the	
nongrafted	host’s	nigra,	typical	a-synuclein	(a)	and	ubiquitin	(b)	neuropathology	was	
observed	(arrows).	(c)	Extensive	a-synuclein	pathology	was	seen	in	grafted	neurons,	
including	cytoplasmic	and	aggregated	a-synuclein	(arrows)	as	well	as	a-synuclein	
neurites.	(d,e)	Pathological	aggregates	of	ubiquitin	were	also	seen	in	grafted	neurons	
(arrows)	and	fibers	(arrowheads).	Scale	bar,	40	mm.	Reprinted	by	permission	from	
Macmillan	Publishers	Ltd:	Nature	Publishing	Group,	Nature	Medicine,	Volume	14,	Issue	
5,	Jeffrey	H	Kordower,	Yaping	Chu,	Robert	A	Hauser,	Thomas	B	Freeman,	C	Warren	
Olanow,	Lewy	body–like	pathology	in	long-term	embryonic	nigral	transplants	in	
Parkinson's	disease	(Reference	419),	Copyright	2008.	(License	Number	4057251374706).	
http://www.nature.com/nm/index.html.			
	
a-syn	transmission	may	not	occur	equally	in	all	patients	[421].	While	most	grafted	
dopaminergic	neurons	remain	unaffected	by	a-syn	pathology,	various	studies	have	
reported	the	presence	of	a-syn-containing	LBs	in	2%-27%	of	grafted	neurons,	illustrating	
varying	degrees	of	propagation	from	host	to	graft	[422-426].	LBs	that	form	within	
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grafted	neurons	are	indistinguishable	from	LBs	in	host	brain,	as	both	are	composed	of	
fibrillar	pS129-a-syn	and	ubiquitin	and	exhibit	positive	staining	for	thioflavin-S	[422,	
423].	Furthermore,	the	distinct	stages	of	LB	development	observed	in	host	brain	are	also	
present	in	grafted	tissue,	which	contains	both	loose	meshwork	aggregates	and	classical	
compact	LBs	[423].	When	dopaminergic	neurons	are	implanted	into	the	striatum	in	a	rat	
model	of	PD,	about	6%	of	grafted	cells	contain	a-syn	5	weeks	following	a-syn	
overexpression	in	a	neighboring	host	brain	region,	indicating	that	a-syn	host-to-graft	
propagation	is	a	possible	mechanism	to	explain	graft	a-syn	pathology	and	the	observed	
results	in	human	grafts	are	not	due	solely	to	non-specific	responses	to	possible	
inflammation	in	the	graft	area	[424].	Despite	the	positive	observations	that	graft	cells	
exhibit	long-term	viability,	provide	DA	re-innervation	to	a	widespread	area	of	the	
striatum,	and	in	some	cases	result	in	albeit	temporary	major	motor	improvement,	the	
lack	of	sustained	clinical	improvement	following	transplantation	could	reflect	
progression	of	degenerative	changes	into	grafted	cells	induced	by	infiltrating	a-syn	
pathology	[425,	426].		
	 Another	set	of	clinical	observations	that	support	a-syn	cell-to-cell	propagation	
are	those	that	have	identified	a-syn	within	the	cerebrospinal	fluid	(CSF)	of	PD	patients.	
The	presence	of	a-syn	in	the	CSF	reflects	a	process	of	neuronal	release	that	would	be	
relevant	for	cell-to-cell	propagation	if	taken	up	by	neighboring	naïve	cells.	Following	the	
identification	of	a-syn	in	human	CSF	and	blood	plasma	[427],	further	investigation	
revealed	that	a-synucleinopathy	patient	CSF	exhibited	lower	total	a-syn	but	elevated	
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levels	of	oligomeric	or	aggregated	a-syn	compared	to	healthy	control	CSF	[428-432].	
Even	pS129	a-syn	has	been	identified	in	CSF	of	PD	patients	[432,	433],	and	despite	high	
levels	of	a-syn	expression	in	blood,	the	principal	source	of	a-syn	in	CSF	is	known	to	be	
neurons	of	the	brain	and	spinal	cord	[434].	Additionally,	a-syn	was	detected	in	the	CSF	
of	patients	with	traumatic	brain	injury	and	with	CJD,	implicating	cell	death	processes	as	
an	additional	mechanism	for	neuronal	release	of	a-syn	[429,	435].	Methods	such	as	
enzyme-linked	immunosorbent	assay	(ELISA)	and	mass	spectrometry	(MS)	have	been	
employed	for	detection	of	a-syn	in	CSF	samples	[427-430,	433,	435],	although	one	
recent	study	utilized	PMCA	to	successfully	identify	PD	patients	with	a	sensitivity	of	
88.5%	and	specificity	of	96.9%	by	detecting	as	little	as	0.1	pg/mL	of	a-syn	oligomers	in	
CSF	[436].	Critically,	despite	a-syn	detection	in	the	extracellular	environment	of	the	CNS	
and	in	blood,	a	large-scale	retrospective	cohort	study	of	nearly	1.5	million	blood	
transfusion	patients	over	more	than	50	years	did	not	observe	any	evidence	of	PD	
transmission,	nor	transmission	of	any	neurodegenerative	disease	investigated,	despite	
2.9%	of	included	patients	receiving	a	transfusion	from	a	donor	diagnosed	with	one	of	
the	studied	neurodegenerative	diseases	[437].	While	the	presence	of	a-syn	in	biological	
fluids	does	not	result	in	disease	transmission	between	hosts	in	the	manner	of	prion	
infection,	and	thus	is	the	reason	its	propagation	is	referred	to	as	“prion-like”,	a-syn	
aggregates	released	from	diseased	cells	into	CSF	certainly	impact	neighboring	
susceptible	cell	populations.	Although	the	presence	of	a-syn	in	grafted	dopaminergic	
neurons	and	in	the	extracellular	environment	of	the	CSF	implies	a	process	for	its	release,	
		
72	
intercellular	trafficking,	and	uptake,	the	specific	mechanisms	involved	in	this	life	cycle	
remain	unclear	(Figure	6).	
	 Axonal	transport.	Just	as	in	Braak’s	hypothesis	for	transfer	of	pathological	a-syn	
from	peripheral	neurons	to	the	CNS,	axonal	transport	has	been	a	central	focus	for	the	
movement	of	a-syn	within	cells	and	between	interconnected	brain	regions	[385,	438].	
The	propagation	of	a-syn	to	distant	brain	regions	through	axonal	connections	was	first	
demonstrated	in	young	asymptomatic	a-syn	transgenic	mice	following	intracerebral	
injections	of	brain	homogenates	from	older	a-syn	transgenic	mice	which	had	developed	
a-syn	pathology	[212].	Coincident	with	the	propagation	of	pathological	a-syn	through	
axonal	transport	to	interconnected	brain	regions	is	an	acceleration	of	LB	inclusion	
formation,	consistent	with	seeded	templating	of	endogenous	a-syn	by	exogenous	
aggregates,	as	well	as	a	quicker	onset	of	neurological	symptoms	and	reduced	survival	in	
animals	receiving	a-syn	injections	[212].	Crucially,	an	identical	phenotype	of	PD-like	LB	
formation,	a-syn	propagation	to	interconnected	brain	regions,	neuronal	loss,	and	
eventual	neurological	symptoms	is	observed	following	intracerebral	or	intrastriatal	
inoculation	of	both	a-syn	transgenic	and	WT	nontransgenic	mice	with	synthetic	a-syn	
fibrils	assembled	from	recombinant	a-syn	[212,	213].	Because	synthetic	a-syn	fibrils	are	
sufficient	to	initiate	and	propagate	disease,	these	findings	implicate	the	prion-like	cell-
to-cell	transmission	of	a-syn	aggregates	as	underlying	neuronal	degeneration	and	
clinical	progression	of	PD.		
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Figure	6.	Potential	mechanisms	mediating	cell-to-cell	transmission	of	cytosolic	protein	
aggregates.	(a,b)	Misfolded	protein	seeds	(for	example,	oligomers	and	protofibrils)	first	
form	in	the	cytoplasm	of	the	releasing	neuron	(left),	where	soluble	native	monomers	are	
recruited	into	large	intracellular	aggregates	and	a	positive	feedback	loop	can	be	initiated	
by	generation	of	more	seeds	through	fragmentation	or	secondary	nucleation.	A	small	
amount	of	protein	aggregates	can	be	released	into	the	extracellular	space	in	the	‘naked’	
form	(a)	or	via	membrane-bound	vesicles	such	as	exosomes	(b).	Free-floating	seeds	may	
directly	penetrate	the	plasma	membrane	of	the	recipient	neuron	(1)	or	enter	by	fluid-
phase	endocytosis	(2)	or	receptor-mediated	endocytosis	(3),	whereas	exosomes	
containing	seeds	may	fuse	with	the	membrane	of	the	recipient	neuron	(4).	Intercellular	
transfer	of	seeds	may	also	occur	by	nanotubes	that	directly	connect	the	cytoplasm	of	
two	cells	(5).	Internalized	seeds	then	nucleate	the	fibrillization	of	native	monomers	in	
the	cytoplasm	of	the	recipient	neuron.	Reprinted	by	permission	from	Macmillan	
Publishers	Ltd:	Nature	Publishing	Group,	Nature	Medicine,	Volume	20,	Issue	2,	Jing	L	
Guo,	Virginia	M	Y	Lee,	Cell-to-cell	transmission	of	pathogenic	proteins	in	
neurodegenerative	diseases	(Reference	465),	Copyright	2014.	(License	Number	
4057270285760).	http://www.nature.com/nm/index.html.	
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	 These	initial	observations	of	a-syn	transmission	through	axonal	contact	have	
been	substantiated	using	several	other	model	systems.	When	pathological	a-syn	
contained	within	LB-enriched	isolates	from	the	SN	of	postmortem	PD	brain	were	
injected	into	the	SN	or	striatum	of	mice	or	monkeys,	the	exogenous	human	a-syn	was	
quickly	taken	up	by	host	neurons	where	seeding	of	expressed	a-syn	then	occurred	
[216].	This	was	followed	by	both	anterograde	and	retrograde	axonal	transport	to	
interconnected	brain	regions	and	eventual	nigrostriatal	degeneration	that	required	the	
presence	of	a-syn	in	both	PD	brain	extracts	and	host	cells,	implying	that	both	exogenous	
and	expressed	a-syn	play	a	role	in	transmission	and	toxicity	[216].	Although	fibrillar	
forms	of	injected	a-syn	induce	a	greater	accumulation	of	pS129	a-syn	LB	pathology	in	
rat	striatum,	injection	of	non-aggregated	a-syn	can	also	produce	this	effect,	and	both	
injection	forms	produce	LBs	in	brain	regions	that	supply	innervation	to	the	striatum	
injection	site	[217].	Another	study	revealed	pS129	LB	inclusions	are	found	at	first-order	
afferent	sites	in	the	piriform	and	entorhinal	cortices,	amygdala,	and	hippocampus	three	
months	following	infusion	of	a-syn	fibrils	into	the	OB	of	mice,	whereas	areas	nearby	but	
without	axonal	connections	to	the	injection	site	lacked	LB	inclusions,	supporting	
movement	of	a-syn	through	axonal	routes	rather	than	simple	diffusion	[439].	Finally,	
targeted	overexpression	of	a-syn	using	unilateral	intracerebral	injection	of	an	a-syn	
lentiviral	vector	caused	axonal	propagation	of	expressed	a-syn	to	the	contralateral	side	
along	with	axonal	degeneration	and	behavioral	deficits	in	mice	[440].	These	findings	
implicate	trafficking	of	a-syn	aggregates	through	axonal	networks	as	a	key	mediator	of	
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pathological	propagation,	and	indicate	the	importance	of	elucidating	both	the	species	of	
a-syn	involved	as	well	as	mechanisms	facilitating	intercellular	spreading.		
It	is	of	utmost	importance	to	elucidate	the	molecular	form	of	a-syn	most	capable	
of	cell-to-cell	transmission	so	that	therapeutic	efforts	targeting	these	propagating	forms,	
such	as	immunotherapy,	will	have	maximum	success	in	halting	disease	progression	
[440].	Just	as	smaller	forms	of	a-syn	aggregates	have	emerged	as	the	molecular	species	
most	capable	of	seeding	further	aggregation	and	inducing	the	most	cytotoxicity,	smaller	
a-syn	aggregates	also	appear	to	propagate	from	one	cell	to	another	with	much	greater	
efficiency.	Most	PD	models	utilizing	exposure	to	exogenous	a-syn	aggregates	generated	
in	vitro	from	purified	recombinant	a-syn	will	perform	sonication	to	fragment	larger	a-
syn	fibrils	into	multiple	smaller	components	that	retain	their	original	structure	although	
with	a	much-decreased	population	size	distribution	[200,	202,	203,	212,	213,	219,	439].	
These	smaller	fragments	of	previously	elongated	a-syn	fibrils	are	known	as	“pre-formed	
fibrils”	(PFFs)	and	are	widely	utilized	to	examine	the	impact	of	exogenous	a-syn	on	
seeding	aggregation,	intracellular	toxicity,	and	intercellular	transmission	precisely	
because	their	smaller	size	distribution	allows	them	to	be	readily	taken	up	by	recipient	
cells	[202,	203].	The	increased	propagation	efficiency	of	smaller	a-syn	aggregates	is	
illustrated	in	recent	work	examining	transmission	of	a-syn	from	OB	to	other	brain	
structures.	When	monomeric,	oligomeric,	and	elongated	fibrillar	preparations	of	a-syn	
aggregates	were	injected	into	the	mouse	OB,	monomeric	and	oligomeric	a-syn,	but	not	
the	larger	fibrillar	forms,	were	readily	taken	up	by	OB	neurons	and	transferred	to	
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axonally	interconnected	brain	regions	within	minutes	to	hours,	although	these	non-
fibrillar	preparations	are	cleared	from	the	brain	within	a	few	days	following	injection	
[441].	In	contrast,	when	elongated	a-syn	fibrils	were	fragmented	to	smaller	sizes	by	
vigorous	sonication	to	create	PFFs	prior	to	injection	into	mouse	OB,	they	efficiently	seed	
the	aggregation	of	endogenous	a-syn	into	pS129	LB	inclusions	and	spread	over	several	
months	via	axonal	connections	first	within	the	olfactory	network	and	later	in	distant	
connected	brain	regions	[219].	Another	study	found	that	waterbath	sonication	of	fibrils	
for	1	hour	significantly	reduced	fibril	size	by	EM	compared	to	1	minute	probe	sonication,	
and	this	results	in	improved	a-syn	cell-to-cell	transmission	[439].	Finally,	viral	vector-
based	overexpression	of	a-syn	in	the	medulla	results	in	monomeric,	oligomeric,	and	
fibrillar	immunoreactivity	in	donor	neurons	at	this	site,	but	only	the	non-fibrillar	forms	
of	a-syn	were	similarly	detected	in	pontine	recipient	neurons,	indicating	that	larger	a-
syn	fibrils	have	significant	barriers	to	propagation	because	of	their	larger	size	[442].	
These	studies	demonstrate	that	smaller	a-syn	fibrils,	because	of	their	decreased	size,	
are	readily	taken	up	by	recipient	neurons,	efficiently	seed	aggregation	of	expressed	a-
syn,	and	are	quickly	spread	along	axonal	connections	to	naïve	brain	regions,	facilitating	
further	aggregation	and	disease	propagation.		
Investigation	into	the	mechanisms	of	a-syn	axonal	propagation	have	been	
ongoing,	but	studies	utilizing	microfluidic	devices	where	axons	project	through	small	
channels	to	terminate	in	a	microenvironment	isolated	from	that	of	their	respective	cell	
bodies	have	brought	new	insights	regarding	the	steps	in	the	process.	a-syn	fibrils	have	
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been	shown	to	be	transferred	from	axons	to	second-order	neurons	following	axonal	
transport	through	a	process	that	did	not	require	direct	cell-to-cell	contacts,	implying	the	
existence	of	an	extracellular	phase	between	donor	and	recipient	cell	[443]	(Figure	6).	In	
addition,	this	release	of	a-syn	following	axonal	transport	was	not	due	to	axonal	lysis,	but	
occurred	in	healthy,	intact	neurons	[444].	Contrary	to	these	findings,	however,	a-syn	
has	also	been	shown	to	transit	from	donor	to	acceptor	cells	through	TNTs	inside	
lysosomal	vesicles,	and	even	to	increase	cellular	formation	of	TNTs,	eventually	resulting	
in	seeding	of	further	a-syn	aggregation	in	the	cytoplasm	of	acceptor	cells	[445].	Since	
TNTs	are	F-actin	containing	membranous	bridges	that	connect	the	cytoplasm	of	remote	
cells,	this	direct	transfer	of	lysosomal	vesicles	and	their	a-syn	cargo	would	avoid	an	
extracellular	phase	in	the	intercellular	journey	[445]	(Figure	6).	While	multiple	
mechanisms	of	transmission	may	play	a	role	in	a-syn	cell-to-cell	spreading,	the	specific	
form	of	propagating	a-syn	as	well	as	its	accessibility	to	therapeutic	targeting	during	this	
transit	are	crucial	factors	for	the	success	of	immunotherapy	treatment	approaches	
[440].		
Despite	the	highly	reproducible	nature	of	the	findings	detailing	a-syn	cell-to-cell	
propagation	via	axonal	transport	by	multiple	independent	groups,	this	phenomenon	has	
not	been	without	contradiction.	One	study	found	that	injected	a-syn	PFFs	induced	
widespread	LB	inclusion	formation	only	in	transgenic	mice	expressing	A53T	a-syn	but	
not	in	non-transgenic	mice	or	transgenic	mice	expressing	E46K	a-syn,	which	instead	
exhibited	inclusion	pathology	restricted	to	the	site	of	injection	and	had	no	evidence	of	
		
78	
spreading	[446].	This	observation	suggests	that	alternative	processes	may	also	
contribute	to	a-syn	inclusion	formation	and	neurotoxicity	in	addition	to	or	instead	of	a-
syn	prion-like	spreading.	Also,	seeding	and	propagation	processes	may	operate	
independently	of	one	another,	as	evidenced	by	the	observation	that	a	lack	of	
endogenous	a-syn	expression	does	not	counteract	axonal	transport	and	intercellular	
transmission	of	exogenous	asyn,	but	instead	results	in	its	more	pronounced	intercellular	
movement	[442].	Although	the	seeding	process	induces	neurotoxicity	and	explains	the	
amplifying	nature	of	a-syn	aggregation	throughout	the	brain,	this	finding	indicates	that	
seeding	endogenous	aggregation	may	also	consume	exogenous	propagating	seeds	into	
larger	aggregates	that	propagate	less	efficiently.	Thus,	intercellular	transmission	of	a-
syn	may	also	occur	in	the	absence	of	seeding,	suggesting	two	separate	but	intertwined	
processes.	Axonal	transport	has	been	extensively	implicated	in	the	cell-to-cell	
propagation	of	pathological	a-syn,	and	forms	the	rationale	for	further	investigation	into	
the	mechanistic	steps	of	its	intercellular	life	cycle.		
Endocytosis.	The	process	of	endocytosis,	where	cells	sample	their	extracellular	
environment	through	plasma	membrane	invaginations	and	inward	budding	of	vesicles	
containing	extracellular	components	[447],	has	been	repeatedly	implicated	as	a	central	
mechanism	for	the	cellular	uptake	of	a-syn	aggregates	(Figure	6).	The	endocytic	route	of	
uptake	features	prominently	in	the	cellular	life	cycle	of	a-syn	aggregate	propagation	as	
a	mechanism	of	entry	into	recipient	cells	[448].	The	first	evidence	for	the	importance	of	
the	endocytic	process	in	the	cellular	uptake	of	a-syn	aggregates	was	the	correlation	
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between	neuronal	cell	death	induced	by	the	addition	of	exogenous	a-syn	and	Rab5A-
specific	endocytosis	[449].	Expression	of	a	GTPase-deficient	Rab5A	resulted	in	a	
decrease	of	a-syn-induced	cytotoxicity	due	to	its	incomplete	endocytosis	[449].	
Additionally,	internalization	of	oligomeric	and	fibrillar	forms	of	a-syn	aggregates	could	
be	inhibited	by	low	temperature	or	expression	of	a	dominant-negative	mutant	of	
dynamin,	a	component	of	the	endocytic	machinery	essential	for	scission	of	endocytic	
intermediates	to	form	vesicles	[450].	These	observations	implicate	endocytosis	as	the	
mechanism	of	internalization	for	a-syn	aggregates,	although	since	the	cellular	entry	of	
monomeric	a-syn	was	unaffected	by	these	manipulations,	single	a-syn	monomers	are	
likely	capable	of	entering	cells	via	direct	membrane	translocation	[450]	(Figure	6).	
Several	other	studies	have	used	similar	methodologies	in	various	model	systems	to	
verify	the	involvement	of	endocytosis	in	a-syn	aggregate	uptake	by	many	different	
recipient	cell	types.	Neurons,	astrocytes,	oligodendrocytes,	and	microglia	all	internalize	
a-syn	aggregates	through	endocytosis,	and	inhibition	of	endocytic	uptake	results	in	
impaired	intercellular	a-syn	propagation,	underscoring	the	importance	of	this	method	
of	cellular	entry	for	the	a-syn	transmission	life	cycle	[450-457].		
Once	a-syn	fibrillar	aggregates	bind	to	the	cellular	membrane,	a	process	that	
occurs	through	lateral	binding	of	the	fibrillar	aggregate	[458],	endocytic	vesicle-
mediated	internalization	matches	the	efficacy	of	membrane	binding	[280].	a-syn	
aggregates	gain	entry	to	recipient	cells	through	either	fluid-phase	endocytosis,	where	
membrane	binding	stimulates	membrane	ruffling	and	endocytic	uptake	[459],	or	
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receptor-mediated	endocytosis,	where	specific	interactions	between	a-syn	aggregates	
and	membrane	components	or	receptors	such	as	heparan	sulfate	proteoglycans	(HSPGs)	
or	lymphocyte-activation	gene	3	(LAG3)	initiate	endocytosis	[460,	461]	(Figure	6).	Once	
inside	the	cell,	a-syn	aggregates	are	first	contained	within	endosomes	that	transition	
into	lysosomes	for	degradation	of	the	a-syn	cargo	[450,	462,	463].	However,	a-syn	
aggregates	taken	up	by	endocytosis	are	well	known	to	serve	as	seeds	for	the	templated	
misfolding	of	monomeric	a-syn	expressed	in	the	cytosol	of	the	recipient	cell,	triggering	
the	formation	of	LB	inclusions	[202,	347,	454,	464].	The	mechanism	by	which	a-syn	
aggregates	escape	the	endocytic	vesicle	compartment	to	access	the	cytosol	and	proceed	
with	seeded	templating	of	further	a-syn	misfolding	was	until	recently	an	open	question	
[448,	465]	(Figure	6),	but	the	demonstration	that	a-syn	aggregates	induce	lysosomal	
rupture	following	endocytosis	provided	an	explanation	[4].	The	identification	of	a-syn-
induced	lysosomal	rupture	following	endocytosis	illuminates	the	connection	between	
exogenous	and	expressed	a-syn	necessary	for	seeding	to	occur	and,	moreover,	
implicates	a-syn	propagation	as	contributing	to	degradative	dysfunction	through	
inducing	lysosomal	damage.	Cellular	entry	of	a-syn	aggregates	through	endocytosis	is	an	
essential	step	in	the	propagation	pathway,	and	contributes	to	many	other	aspects	of	
prion-like	neurodegeneration.	
Exocytosis.	Given	the	presence	of	a-syn	in	the	CSF	and	multiple	synapses	
separating	neurons	along	the	a-syn	cell-to-cell	propagation	pathway,	the	cellular	
release	of	a-syn	from	cells	burdened	by	its	misfolding	and	accumulation	is	necessary	for	
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cell-to-cell	propagation	to	occur	[448,	466,	467]	(Figure	6).	Several	mechanisms	have	
been	proposed	to	account	for	the	jettison	of	a-syn	from	affected	cells	into	the	
extracellular	environment,	each	a	variation	on	the	theme	of	exocytosis.	a-syn,	because	
its	lacks	a	secretory	signal	peptide	sequence,	has	been	shown	to	be	secreted	from	cells	
via	non-classical	endoplasmic	reticulum	(ER)/Golgi-independent	exocytosis	[468].	
Intracellular	a-syn	can	be	contained	within	the	lumen	of	vesicles,	often	in	an	oxidized	
and	aggregation-prone	state,	and	the	fusion	of	these	vesicles	with	the	plasma	
membrane	results	in	the	release	of	the	intralumenal	abnormal	a-syn	contents	into	the	
extracellular	environment	[468,	469].	Unconventional	ER/Golgi-independent	exocytosis	
of	a-syn	can	also	be	caused	by	exophagy,	the	exocytosis	of	autophagosomes	or	their	
contents	upon	fusion	with	the	plasma	membrane	[470,	471].	Late	endosomes	or	
recycling	endosomes	may	also	play	a	role	in	the	release	of	a-syn	cargo	through	
exocytosis	to	the	extracellular	environment,	as	evidenced	by	inhibition	of	a-syn	release	
upon	disruption	of	Rab27a	or	Rab11a	which	are	involved	in	endosomal	regulation	[470,	
472,	473].	Regardless	of	the	identity	of	the	intracellular	vesicle	compartment	fusing	with	
the	plasma	membrane	to	release	a-syn,	these	various	forms	of	exocytosis	discharge	a-
syn	in	a	free	state,	no	longer	associated	with	lipid	membranes,	given	that	the	vesicular	
membrane	remains	associated	to	the	plasma	membrane	upon	fusion	(Figure	6).	Free	a-
syn	outside	the	cell	would	be	susceptible	to	cleavage	by	matrix	metalloproteinases	
(MMPs)	operating	in	the	extracellular	environment	[474],	but	would	also	be	available	
for	uptake	into	neighboring	cells	by	endocytosis	to	further	the	propagation	life	cycle.	
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Additionally,	a-syn	has	also	been	shown	to	be	released	from	affected	cells	
contained	within	exosomes,	a	type	of	extracellular	vesicle	originating	from	the	plasma	
membrane	fusion	of	multivesicular	bodies	(MVBs)	which	are	endosomal	compartments	
containing	multiple	internal	vesicles	generated	from	inward	budding	[475-477]	(Figure	
6).	Exosomes	have	been	found	to	contain	both	monomeric	and	oligomeric	a-syn,	and	
exosome-associated	a-syn	is	more	likely	to	be	taken	up	by	recipient	neurons	where	it	
causes	more	toxicity	than	free	a-syn	released	by	exocytosis	in	a	non-membrane	bound	
form	[478,	479].	a-syn	within	exosomes,	as	well	as	a-syn	within	extracellular	vesicles	
derived	from	plasma	membrane	blebbing	and	shedding	[473],	are	immune	to	the	hostile	
extracellular	environment	because	of	their	protected	membrane-bound	state.	Sorting	of	
a-syn	into	exosomes	may	be	regulated	by	post-translational	addition	of	small	ubiquitin-
like	modifier	(SUMO)	which	facilitates	a-syn	interaction	with	the	endosomal	sorting	
complex	required	for	transport	(ESCRT)	machinery	and	eventual	extracellular	release	
[480].	Interestingly,	the	ESCRT	pathway	is	also	important	for	a-syn	transport	through	
MVBs	for	degradation,	but	a-syn	is	known	to	promote	degradation	of	the	ESCRT	protein	
charged	multivesicular	body	protein	(CHMP2B),	resulting	in	impaired	ESCRT	activity,	
accumulation	of	a-syn	unable	to	be	degraded,	and	increased	exocytosis	of	a-syn	[481].	
Exosomes	represent	another	mechanism	for	the	cellular	release	of	a-syn	via	exocytosis,	
and	given	their	utility	for	intercellular	delivery	of	biochemical	information	to	directly	
modify	signaling	pathways	or	proteostasis	in	receiving	cells	[475],	elucidating	the	
underlying	mechanisms	prompting	their	release	is	of	utmost	importance.		
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Stress-induced	propagation.	Despite	the	detrimental	consequences	of	a-syn	
release	for	the	propagation	of	protein	misfolding	and	its	associated	neurotoxicity	
throughout	the	brain,	paradoxically,	the	release	of	a-syn	aggregates	is	also	a	protective,	
last-resort	response	of	stressed	cells	overwhelmed	by	a-syn	accumulation	and	their	
ineffective	or	dysfunctional	degradative	clearance	mechanisms	[318,	482,	483].	When	
cellular	degradative	mechanisms	are	insufficient	to	cope	with	the	continued	
accumulation	of	misfolded	a-syn	aggregates,	or	increasing	mitochondrial	stress	perturbs	
cellular	homeostasis,	this	prompts	a-syn	clearance	through	cellular	release	instead.	
Pharmacological	inhibition	of	the	proteasome	or	of	mitochondrial	complex	I	increases	
the	release	of	both	monomeric	and	aggregated	a-syn,	although	more	aggregated	forms	
are	present	in	the	released	proteins	[468,	469].	Furthermore,	elevated	ROS	occurring	as	
a	byproduct	of	DA	synthesis	results	in	mitochondrial	dysfunction	and	increased	
secretion	of	a-syn	oligomers,	but	not	monomers,	into	the	extracellular	space	[294].		
Perhaps	the	most	significant	stressor	contributing	to	a-syn	release	and	
propagation	in	PD	is	dysfunction	in	the	ALP,	as	this	pathway	is	the	main	mechanism	for	
degradation	of	a-syn	aggregates.	Failure	of	autophagic	processes,	modeled	by	
pharmacological	or	genetic	inhibition,	increases	the	exocytosis	of	a-syn	[484],	as	does	
the	lowering	of	autophagosomal	mobility	and	the	prevention	of	fusion	with	lysosomes	
[470,	471].	Lysosomal	failure	has	even	more	far-reaching	consequences,	as	lysosomal	
degradation	is	responsible	for	ultimate	clearance	of	both	autophagic	and	endocytic	
compartments.	Dysfunctional	lysosomal	degradation,	which	has	been	extensively	
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modeled	by	treatment	with	bafilomycin	A1	(Baf)	to	inhibit	the	acidifying	action	of	the	
lysosomal	H+-ATPase,	also	results	in	increased	a-syn	release	from	affected	cells	[469-
471,	473,	479,	485].	Deficiency	of	lysosomal	enzymes	CatD	or	GCase,	occurring	
profoundly	when	mutated	in	genetic	forms	of	PD	but	still	contributing	to	lysosomal	
dysfunction	even	in	sporadic	PD,	also	results	in	increased	a-syn	secretion	to	the	
extracellular	environment	[364,	366,	373,	486].	Lysosomal	degradation	is	also	known	to	
be	impaired	during	normal	aging,	and	as	a	result,	the	rate	of	cell-to-cell	transmission	of	
a-syn	aggregates	was	also	increased	in	an	aging	model	[487].	These	findings	highlight	
the	essential	nature	of	the	ALP	in	the	degradation	of	a-syn	aggregates,	and	illustrate	
how	its	dysfunction	can	result	in	the	pathological	release	of	a-syn	from	affected	cells	as	
a	last-resort	mechanism	of	clearance.	
Tau.	
The	microtubule-associated	protein	tau	(MAPT),	pathologically	aggregated	in	
diverse	tauopathies	including	AD,	chronic	traumatic	encephalopathy	(CTE),	tangle-only	
dementia	(TD),	Pick’s	disease	(PiD),	progressive	supranuclear	palsy	(PSP),	corticobasal	
degeneration	(CBD),	agyrophilic	grain	disease	(AGD),	and	frontotemporal	dementia	and	
parkinsonism	linked	to	chromosome	17	(FTDP-17T),	exhibits	many	similarities	to	a-syn	
as	a	prion-like	amyloid	protein	[488].	Just	as	for	a-syn,	tau	aggregation	from	a	soluble,	
unfolded,	phosphorylated	monomer	to	an	insoluble,	hyperphosphorylated	neuropil	
thread	(NT)	or	neurofibrillary	tangle	(NFT)	results	in	unique	strain	conformations,	arising	
due	to	seeded	templating	of	aggregation,	which	impart	tropism	for	different	cell	types	
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and	brain	regions	and	result	in	distinct	patterns	of	pathology	for	human	tauopathies	
[314,	488-492].	Although	alternative	mRNA	splicing	results	in	tau	expression	as	six	
different	isoforms,	composed	of	0,	1,	or	2	N-terminal	inserts	(0N,	1N,	2N)	and	either	3	or	
4	C-terminal	repeats	(3R,	4R),	the	various	compositions	of	tau	isoforms	(1N3R	vs.	1N4R,	
for	example)	allow	higher-order	aggregates	to	adopt	different	shapes	or	conformations	
that	behave	as	distinct	strains	[488].		
Tau	strains	propagate	their	conformation	through	seeding	aggregation	of	
additional	monomeric	tau,	and	a	specific	strain	conformation	and	its	associated	
pathological	phenotype	of	affected	cell	types	and	brain	regions	can	be	faithfully	
reproduced	when	tau	strains	are	re-introduced	into	naïve	cells	or	successively	
inoculated	into	mice	[490,	492,	493].	Distinct	tau	strains	may	also	exhibit	varying	levels	
of	potency	in	their	seeding	of	further	aggregation	because	of	their	unique	
conformations,	as	strains	purified	from	AD	brain	exhibited	increased	seeding	potency	
compared	with	synthetic	tau	fibrils	[491].	Seeding	occurs	between	like	isoforms,	as	
aggregation	of	expressed	4R	tau	will	occur	following	cellular	uptake	of	4R	fibrils	but	not	
3R	fibrils,	and	vice	versa	when	3R	tau	is	expressed	in	target	cells	[201].	This	nucleation-
dependent,	composition-specific	aggregation	of	tau	recapitulates	Prusiner’s	protein-
only	hypothesis	by	the	induction	of	NFT	insoluble	aggregates	following	cellular	uptake	of	
tau	fibrils	[494].	If	seeding	of	further	aggregation	is	inhibited	by	suppressing	the	
expression	of	soluble	tau,	cellular	degradative	mechanisms	are	no	longer	overwhelmed	
by	amyloid	accumulation	and	tau	aggregates	can	be	cleared	by	the	ALP,	just	as	a-syn	
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aggregates	are	cleared,	although	both	the	UPS	and	ALP	have	difficulty	clearing	large	
aggregates	[495].	Tau	inclusions	formed	within	affected	cells	are	highly	dynamic	
structures,	undergoing	fission	and	fusion	events	that	facilitate	pathological	propagation	
by	additional	seeding	events	[495].	The	observation	that	different	tauopathies	are	
associated	with	different	sets	of	strains	[490]	raises	the	possibility,	just	as	for	a-
synucleinopathies	or	prion	diseases,	that	conformational	diversity	of	tau	aggregation	
dictates	the	phenotype	of	clinical	disease	[492].	
Another	feature	of	tau	pathology	that	is	analogous	to	a-syn	is	in	the	prion-like	
cell-to-cell	propagation	of	tau	aggregates.	Heiko	Braak	and	colleagues	also	described	a	
staging	system	for	tau	pathology	in	AD	just	as	for	a-syn	in	PD,	detailing	six	distinct	
stages	of	an	evolving	characteristic	distribution	pattern	for	NT	and	NFT	pathology	[496].	
An	ordered	and	predictable	progression	of	hyperphosphorylated	tau	pathology	was	also	
seen	in	CTE	co-occurring	with	axonal	disruption	and	death,	leading	to	the	progressive	
staging	of	pathology	through	4	stages	[497].	These	findings	suggest,	through	the	
predictable,	conserved	expansion	pattern	of	tau	pathology	in	different	tauopathies,	that	
cell-to-cell	propagation	of	tau	aggregates	may	also	contribute	to	unique	clinical	
phenotypes	and	may	be	an	etiological	factor	for	disease	progression	and	increasing	
severity.	Cell-to-cell	spreading	of	aggregated	tau	has	been	observed	in	numerous	
experimental	models,	where	expressed	tau	adopts	characteristics	of	the	pathological	
tau	seeds	and	spreads	to	neighboring	cultured	cells	or	interconnected	brain	regions.	
Extracellular	tau	aggregates,	but	not	monomer,	become	internalized	into	recipient	cells	
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where	they	induce	formation	of	expressed	tau	aggregates	which	then	transfer	between	
co-cultured	cells	[498].	When	brain	extracts	are	prepared	from	mice	expressing	human	
P301S	mutant	tau,	the	tau	mutation	that	causes	FTDP-17T	in	humans	and	results	in	
widespread	hyperphosphorylated	tau	and	neurodegeneration	in	transgenic	mice,	
extract	injection	into	the	brains	of	transgenic	WT	human	tau-expressing	mice	which	do	
not	normally	develop	tau	filaments	or	neurodegeneration	induces	aggregation	of	WT	
tau	and	the	spreading	of	these	aggregates	to	neighboring	brain	regions	[499].	Similar	
results	were	observed	when	brain	extracts	from	humans	with	AD,	AGD,	PSP,	and	CBD	
were	injected	into	the	brain	of	WT	mice	and	caused	the	seeding	and	cell-to-cell	
propagation	of	endogenous	tau	with	a	phenotype	that	recapitulated	the	hallmark	
disease	lesions	of	the	extract	source	[500,	501].	Even	intracerebral	injection	of	synthetic	
tau	PFFs	into	mice	overexpressing	P301S	mutant	tau	induces	NFT	inclusions	and	
propagation	of	tau	pathology	to	connected	brain	regions	over	time	[502].	In	the	process	
of	spreading	between	interconnected	brain	regions	[491,	502],	synaptic	connections	
appear	to	enhance	tau	propagation	[503],	although	transmission	can	also	occur	via	non-
synaptic	mechanisms	such	as	along	glymphatic	or	CSF	pathways	[504,	505].	The	prion-
like	cell-to-cell	propagation	of	tau	aggregates	represents	a	mechanism	for	the	
amplification	and	dissemination	of	tau	pathology	throughout	the	brain	of	affected	
patients,	and	thus	understanding	the	mechanisms	underlying	cellular	uptake	and	
release	of	tau	aggregates	are	of	utmost	importance.		
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Examination	of	potential	mechanisms	of	tau	cellular	entry	and	egress	again	
reveals	numerous	similarities	with	a-syn	and	prions.	Endocytosis	is	again	the	
predominant	mechanism	for	cellular	uptake	of	tau	aggregates	as	for	a-syn	aggregates	
[498,	506-508],	perhaps	occurring	after	interaction	at	the	plasma	membrane	between	
tau	aggregates	and	HSPGs	[460].	Tau	uptake	depends	on	both	the	conformation	and	the	
size	of	the	aggregates,	as	low-molecular	weight	aggregates	or	short	fibrils,	but	not	
monomers,	long	fibrils,	or	long	filaments,	were	capable	of	cellular	entry	via	endocytosis	
[509].	This	endocytic	uptake	process	is	regulated	in	part	by	the	neuronal	isoform	of	the	
BIN1	protein	which	serves	as	a	negative	regulator	of	endocytic	flux,	preventing	tau	
propagation	through	endocytosis	when	functional	but	promoting	tau	propagation	when	
downregulated	in	AD	brain	[507].	The	conserved	role	of	endocytosis	in	the	uptake	of	tau	
and	a-syn	aggregates	underscores	the	importance	of	this	pathway	in	the	cellular	life	
cycle	of	these	amyloid	proteins,	allowing	for	the	propagation	of	misfolded	structure	
from	affected	to	naïve	cells.	Endocytosis	allows	for	the	induction	of	expressed	tau	
aggregation	by	exogenous	tau	seeds,	as	extracellular	seeds	come	into	direct	contact	
with	intracellular	tau	as	seen	by	Förster	resonance	energy	transfer	(FRET)	following	
endocytosis	[498,	510].	Just	as	for	a-syn	aggregates	taken	up	via	endocytosis,	the	
process	by	which	endocytosed	tau	aggregates	escape	the	endocytic	vesicle	and	thus	
become	competent	to	seed	the	aggregation	of	expressed	tau	in	the	cytosol	remains	
unanswered	[465].		
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As	for	the	process	of	tau	cellular	release,	monomeric	tau	is	constitutively	
released,	even	from	normal	healthy	cells,	into	the	interstitial	fluid	(ISF)	and	CSF	for	
unknown	reasons	[511-513],	although	this	release	process	can	be	stimulated	by	
neuronal	activity	and	calcium-influx	and	blocked	by	inhibiting	pre-synaptic	vesicle	
release	[512].	Although	the	CSF	level	of	tau	correlates	with	the	burden	of	
hyperphosphorylated	tau	and	NFT	pathology	[514],	levels	of	tau	in	ISF	are	significantly	
higher	than	in	CSF,	and	following	spontaneous	or	seed-induced	tau	aggregation,	levels	
of	monomeric	ISF	tau	decrease	significantly	as	monomers	are	consumed	into	insoluble	
aggregates	[513].	This	finding	is	additional	evidence	for	the	seeding-dependent	
equilibrium	between	monomeric	and	aggregated	tau	occurring	in	both	the	extracellular	
and	intracellular	environments.	Tau	secretion	can	occur	through	a	non-classical	pathway	
that	is	prevented	by	low	temperature	but	not	blocked	by	inhibitors	of	the	conventional	
secretory	pathway	[511].	This	form	of	tau	secretion	results	in	extracellular	tau	that	is	not	
associated	with	membranes,	and	thus	illustrates	the	mechanism	of	therapeutic	efficacy	
underlying	antibody-mediated	reduction	in	insoluble	tau	aggregates	and	inhibition	of	
tau	seeding	and	propagation	[510,	515].	Tau	can	also	be	released	from	affected	cells	in	a	
membrane-bound	form,	either	in	ectosomes	formed	from	outward	budding	of	the	
plasma	membrane	or	in	exosomes	released	upon	plasma	membrane	fusion	of	MVBs	
containing	internal	vesicles	[516-519].	Similar	to	a-syn	release,	tau	secretion	is	
increased	under	conditions	of	cellular	stress	[518].	Finally,	just	as	for	a-syn	and	prions,	
TNTs	have	been	implicated	in	the	intercellular	transmission	of	tau	aggregates,	and	tau,	
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like	a-syn,	promotes	the	formation	of	TNT	connections	that	facilitate	its	transmission	
[520,	521].	There	are	many	similarities	in	the	aggregation	and	propagation	processes	of	
tau	and	a-syn	as	prion-like	amyloid	proteins,	and	there	may	also	be	similar	therapeutic	
approaches	to	arrest	progression	of	the	diverse	diseases	caused	by	these	different	
proteins	with	similar	pathological	activities.		
Huntingtin.	
	 HD	is	among	a	group	of	neurodegenerative	disorders	exclusively	caused	by	
dominantly-inherited	genetic	mutations	that	expand	a	CAG	repeat	sequence	in	the	
coding	region	of	the	affected	gene	and	result	in	expression	of	proteins	with	expanded	
tracts	of	uninterrupted	polyglutamine	(polyQ)	residues	that	are	longer	than	in	the	WT	
protein	[522].	In	the	case	of	HD,	this	trinucleotide	repeat	expansion	occurs	in	the	gene	
encoding	the	huntingtin	protein,	HTTExon1,	and	a	polyQ	tract	greater	than	37Q	causes	
HD	[523].	When	the	polyglutamine	expansion	is	in	the	pathogenic	range,	for	HTTExon1-
Q³37,	this	alteration	induces	the	formation	of	insoluble,	high-molecular	weight	
aggregates	that	adopt	a	fibrillar	morphology	like	that	of	prions,	a-syn,	and	tau	[524].	
Since	this	discovery	of	the	effect	of	polyQ	expansion	on	the	structure	of	the	huntingtin	
protein,	several	commonalities	have	been	revealed	between	HTTExon1	aggregates	and	
other	prion-like	amyloid	aggregates	such	as	those	of	a-syn	and	tau	[522].		
Just	as	for	a-syn	and	tau,	the	aggregation	process	of	HTTExon1-Q³37	exhibits	
prion-like	properties.	PolyQ	repeat	lengths	of	greater	than	37	increase	the	kinetics	and	
thermodynamic	favorability	of	the	spontaneous	misfolding	reaction	into	amyloid	
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aggregates,	and	although	shorter	repeats	do	not	undergo	spontaneous	aggregation,	
they	are	capable	of	adding	to	an	already	formed	aggregate	and	will	be	recruited	into	
insoluble	aggregates	when	exposed	to	extended	polyQ	tracts	[525,	526].	Indeed,	in	
addition	to	the	length-	and	concentration-dependence	of	aggregation,	exposure	to	pre-
formed	seeds	significantly	abbreviates	the	normal	lag	phase	associated	with	
spontaneous	misfolding	just	as	for	other	prion-like	amyloid	proteins	[527].	This	seeded	
recruitment	and	templating	of	further	misfolding	continues	the	prion-like	aggregation	
theme	of	a-syn,	tau,	and	others,	and	just	as	for	these	other	amyloid	proteins	that	adopt	
b-sheet	ThT-positive	filamentous	structures,	the	smaller,	more	finely-divided	aggregates	
of	HTTExon1	are	much	more	efficient	at	recruiting	additional	polyQ	peptides	than	larger	
aggregates	[525,	527].		
Again	like	a-syn	and	tau,	prion-like	mechanisms	of	cell-to-cell	propagation	have	
been	implicated	in	the	progression	of	HD	pathology	[522].	In	the	cell-to-cell	propagation	
pathway,	the	membrane	association	mechanisms	of	monomeric	and	assembled	
HTTExon1	are	of	significant	interest.	The	N-terminus	of	monomeric	HTTExon1	binds	to	
membranes	through	a	charge-based	mechanism	where	it	forms	an	amphipathic	a-helix	
that	inserts	into	the	lipid	bilayer	[528].	PolyQ	expansion	allows	for	a	greater	depth	of	a-
helix	membrane	insertion	that	may	perturb	the	function	of	cellular	membranes	and	
alter	the	normal	membrane-bound	cellular	localization	of	HTTExon1	[528,	529].	Once	in	
an	aggregated	form,	HTTExon1	aggregates	will	become	internalized	into	recipient	cells	
following	binding	of	cell	surface	membrane	proteins	that	uniquely	recognize	its	fibrillar	
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amyloid	structure	[530].	This	membrane	binding	occurs,	as	for	a-syn	aggregates,	
through	lateral	association	between	the	fibrillar	aggregate	and	the	cell	membrane	[458],	
although	HSPGs	do	not	seem	to	be	involved	for	binding	and	internalization	of	HTTExon1	
aggregates	as	they	were	for	aggregates	of	a-syn	and	tau	[460].	Once	bound	to	the	
membrane,	HTTExon1	aggregates	are	internalized	via	endocytosis	and	directed	to	the	
lysosome	[531],	although	the	process	of	escaping	the	vesicle	to	gain	access	to	the	
cytosol	following	endocytic	uptake	remains	unclear	[522,	531].	Despite	the	question	of	
the	specific	vesicle	escape	mechanism	remaining	open	just	as	for	a-syn	and	tau,	
exogenous	HTTExon1	aggregates	do	gain	entry	to	the	cytoplasm	following	
internalization	where	they	become	sequestered	into	aggresomes	and	recruit	additional	
soluble	homologous	counterparts	through	seeded	templating	[531-533].	The	technique	
of	bimolecular	fluorescence	complementation	(BiFC)	illustrates	that	exogenous	
HTTExon1	aggregate	seeds	contact	cytosolic	HTTExon1	and	induce	its	misfolding	in	the	
cell-to-cell	transmission	pathway	[534].	Cell-to-cell	propagation	of	HTTExon1	aggregates	
can	occur	through	direct	cell-to-cell	contact,	where	TNT-mediated	transmission	is	
implicated	and	expression	of	mutant	HTT	can,	like	a-syn	and	tau,	increase	formation	of	
TNTs	to	facilitate	transmission	[535].	HTTExon1	aggregates	can	be	transported	within	
the	cell	in	both	anterograde	and	retrograde	directions,	and	can	also	be	secreted	from	
axons	of	affected	cells	following	anterograde	transport	to	spread	trans-neuronally	in	the	
absence	of	axonal	lysis	[444].	These	various	prion-like	characteristics	of	HTTExon1	
aggregates	illustrate	similarities	with	aggregates	of	a-syn	and	tau,	and	highlight	the	
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importance	of	more	clearly	understanding	steps	in	the	intercellular	propagation	
pathway	so	that	new	effective	therapeutic	strategies	can	be	developed.		
Vesicle	Rupture	
Membrane	Pores.	
	 In	considering	the	means	through	which	prion-like	amyloid	aggregates	of	a-syn	
escape	the	vesicular	compartment	following	their	endocytosis	to	proceed	with	
propagating	protein	misfolding,	investigation	of	their	effects	on	vesicle	membranes	
begins	with	the	proposed	physiological	role	of	monomeric	a-syn,	involving	interaction	
through	its	amphipathic	N-terminal	domain	with	phospholipid	membranes	in	synaptic	
vesicles	[143].	a-Syn	has	been	shown	to	induce	membrane	thinning	and	curvature	by	
inserting	its	N-terminal	amphipathic	domain	as	a	wedge	into	the	membrane,	resulting	in	
the	conversion	of	large	low-curvature	vesicles	into	highly	curved	membrane	tubules	and	
vesicles	[536-540].	This	curvature	and	membrane	tubulation	is	caused	only	by	
monomeric	a-syn	[538],	and	can	result	in	the	disruption	of	membrane	integrity	[536,	
540].	While	it	is	tempting	to	speculate	that	these	same	membrane	curvature	
mechanisms	underlie	cellular	invasion	by	a-syn	amyloid	fibrils	at	the	plasma	or	
endocytic	membrane,	the	actions	of	an	unfolded	or	a-helical	a-syn	monomer	on	
biological	membranes	are	not	likely	to	translate	to	higher-order	b-sheet	amyloid	
assemblies	of	a-syn,	as	assembly	of	a-syn	monomers	into	an	insoluble	fibrillar	
conformation	involves	both	multimerization	and	a	conformational	change.		
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	 Once	aggregation	of	a-syn	begins,	however,	aggregates	do	not	lose	their	affinity	
for	membranes.	Specific	pre-fibrillar	intermediates	called	protofibrils	are	b-sheet-rich	
annular	ring-like	or	wreath-like	assemblies	resembling	a	pore-forming	bacterial	toxin,	
and	these	a-syn	protofibrillar	assemblies	have	been	shown	to	permeabilize	vesicle	
membranes	via	a	pore-forming	mechanism	that	allows	passage	of	ions	or	low-molecular	
mass	structures	[541-545].	The	pore-like	structure	of	a-syn	protofibrils	containing	a	
central	channel	illustrates	how	membrane	penetration	of	the	annular	protofibrils	results	
in	perforation	of	the	lipid	bilayer	[546,	547].	Protofibril	membrane	insertion	and	
subsequent	membrane	pore	formation	results	in	an	increase	in	the	conductance	of	the	
lipid	bilayer,	eliciting	ion-channel	currents	as	a	result	of	the	non-selective	passage	of	
ions	[548,	549].	Especially	critical	for	the	survival	of	neurons,	a	dysregulated	influx	of	
Ca2+	ions	through	a-syn	membrane	pores	results	in	cell	death	[550-552].	Alternatively,	
other	studies	have	found	an	a-syn	oligomer-mediated	increase	in	plasma	membrane	ion	
conductance	in	the	absence	of	pore	formation	[553],	possibly	occurring	through	a	
thinning	of	the	plasma	membrane	hydrophobic	core	resulting	from	oligomer	insertion	
between	tightly	packed	lipids	[554].	In	any	case,	these	studies	examine	the	actions	of	a-
syn	monomers	or	oligomers	on	lipid	membranes,	and	while	related,	they	do	not	
necessarily	apply	to	the	actions	of	a-syn	amyloid	fibrils	on	biological	membranes.	While	
some	characteristics	of	a-syn	monomers	or	oligomers	may	remain	upon	fibril	formation,	
it	is	doubtful	that	the	same	membrane	association	properties	of	a-syn	monomers	or	
oligomers	will	be	maintained	following	fibril	assembly.	Thus,	membrane	perturbations	
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induced	by	a-syn	monomers,	oligomers,	protofibrils,	and	fibrils	are	likely	distinct	
processes.	Whereas	monomers	can	induce	membrane	curvature	possibly	due	to	their	
physiological	role	and	oligomers	can	form	membrane	pores,	the	vesicular	escape	of	a-
syn	fibrillar	assemblies	likely	occurs	via	a	different	mechanism	due	to	their	larger	size.		
Amyloid-Induced	Vesicle	Rupture.	
Investigation	into	the	effects	on	biological	membranes	of	amyloid	proteins	in	the	
fibrillar	assembly	conformation	is	most	relevant	for	aggregate	cell-to-cell	propagation	
and	has	yielded	some	new	insight,	but	the	understanding	of	how	these	membrane	
interactions	relate	to	disease	pathogenesis	remains	largely	incomplete.	To	determine	
the	specific	effect	of	fibrillar	amyloid	forms	on	membrane	structure	and	integrity,	
amyloid	fibrils	generated	in	vitro	are	often	incubated	with	artificial	liposome	
suspensions.	Fibrillar	forms	of	amyloid	proteins,	just	like	monomeric	and	oligomeric	
forms,	are	known	to	associate	with	lipid	membranes,	and	in	vitro	association	of	a-syn	or	
HTTExon1	fibrils	with	artificial	liposomes	is	known	to	induce	permeabilization	or	
destruction	of	the	liposomal	membrane	[555,	556].	Membrane	disruption	or	
permeabilization	of	artificial	liposomes	and	natively	derived	membranes	was	enhanced	
when	fragmentation	of	fibrils	was	performed,	suggesting	an	increased	toxic	action	on	
membrane	integrity	by	smaller	fibrillar	amyloid	forms	rather	than	larger	entangled	
amyloid	inclusions	[557].	In	addition,	the	binding	of	amyloid	fibrils	to	the	plasma	
membrane	is	known	to	induce	cellular	Ca2+	influx	through	a	mechanism	that	has	yet	to	
be	defined,	but	may	be	similar	to	its	lipid	permeabilization	of	artificial	liposomes	that	
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allows	the	release	of	intravesicular	indicator	dyes	[210,	556].	While	these	models	of	a-
syn	fibril	association	with	lipids	are	certainly	relevant	for	membrane	interactions	that	
may	occur	within	the	endocytic	compartment	during	pathological	cell-to-cell	
propagation,	the	mechanisms	of	membrane	perturbation	by	a-syn	fibrils	on	the	external	
face	of	artificial	liposomes	or	at	the	plasma	membrane	may	not	directly	relate	to	the	
process	of	intravesicular	escape	and	cellular	invasion.		
The	most	authentic	representation	of	endocytic	vesicle	integrity	relies	on	the	
identification	of	specific	factors	enriched	within	intact	endocytic	vesicles	or	that	become	
enriched	in	the	endocytic	compartment	upon	loss	of	membrane	integrity.	Our	group	
was	the	first	to	apply	one	such	approach	to	the	study	of	cellular	invasion	by	a-syn	
aggregates.	By	exploiting	the	ability	of	cytosolic	galectin	3	(Gal3)	to	become	enriched	at	
the	site	of	intracellular	vesicle	damage	due	to	its	binding	of	target	b-galactoside	residues	
exposed	as	a	result	of	damage,	we	determined	that	aggregates	of	a-syn	are	capable	of	
inducing	membrane	rupture	of	lysosomes	following	their	endocytic	uptake	[4,	280].	
Utilizing	both	the	cellular	uptake	of	exogenous	a-syn	aggregates	prepared	in	vitro	from	
recombinant	purified	protein	as	well	as	the	cell-to-cell	transmission	of	a-syn	aggregates	
from	over-expressing	donor	cells	to	naïve	recipient	cells,	this	study	demonstrated	
induction	of	vesicle	rupture	through	the	colocalization	between	a-syn	aggregates	and	
distinct	Gal3	puncta	formed	at	the	site	of	vesicle	rupture	(Figure	7).	These	findings	
illuminated	a	potential	mechanism	for	exogenous	a-syn	fibrillar	amyloid	assemblies	to	
escape	the	endocytic	compartment	to	access	the	cytosol,	and	did	so	in	a	model	that		
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Figure	7.	Vesicle	rupture	following	the	cell	to	cell	transfer	of	a-synuclein.	N27	cells	
stably	expressing	a-synuclein	and	treated	with	MPP+	for	24	hours.	N27chGal3	cells	were	
then	added	to	the	culture	and	co-cultured	for	48	hours.	Cells	were	then	fixed	and	
stained	for	a-synuclein	(green).	The	boxed	areas	in	the	left	panel	are	enlarged	to	allow	
visualization	of	a-synuclein	and	chGal3	colocalization.	Reprinted	from	PLoS	One,	
Volume	8,	Issue	4,	David	Freeman,	Rudy	Cedillos,	Samantha	Choyke,	Zana	Lukic,	
Kathleen	McGuire,	Shauna	Marvin,	Andrew	M.	Burrage,	Stacey	Sudholt,	Ajay	Rana,	
Christopher	O’Connor,	Christopher	M.	Wiethoff,	Edward	M.	Campbell,	Alpha-Synuclein	
Induces	Lysosomal	Rupture	and	Cathepsin	Dependent	Reactive	Oxygen	Species	
Following	Endocytosis,	e62143,	doi:10.1371/journal.pone.0062143	(Reference	4),	
Copyright	2013,	reproduced	under	the	terms	of	the	Creative	Commons	Attribution	
License.		
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recapitulates	both	the	neuronal	endocytic	membrane	components	and	the	proper	
orientation	of	escape,	from	intravesicular	to	cytosolic,	that	are	involved	in	pathologic	a-
syn	amyloid	cell-to-cell	propagation.	
a-Syn-induced	lysosomal	rupture	not	only	allowed	cellular	invasion	of	misfolded	
amyloid	fibrils,	but	also	resulted	in	a	CatB-dependent	increase	in	ROS	in	target	cells	
following	proteolytic	enzyme	leakage	from	damaged	lysosomes.	A	later	study	found	that	
the	induction	of	cytosolic	a-syn	misfolding	by	exogenous	a-syn	seeds	was	enhanced	by	
the	actions	of	CatB,	proposed	to	increase	the	amount	of	smaller	a-syn	seeds	in	the	
lysosome	through	partial	digestion	that	could	then	trigger	intravesicular	aggregation	by	
recruiting	additional	membrane-bound	monomers	and,	through	further	growth	within	
the	vesicular	compartment,	result	in	vesicle	rupture	and	escape	[296].	While	CatB	may	
perform	this	facilitative	role	for	a-syn	aggregation	in	the	lumen	of	the	lysosome	prior	to	
rupture,	its	leakage	from	the	lysosome	following	rupture	may	also	result	in	its	action	on	
expressed	monomeric	a-syn	in	the	cytosol,	perhaps	accounting	for	its	enhancement	of	
cytosolic	aggregate	formation.	This	process	of	intravesicular	aggregation	and	eventual	
vesicle	rupture	due	to	the	large	size	of	the	resulting	aggregate	is	one	mechanism	
proposed	for	the	induction	of	a-syn	amyloid-mediated	vesicle	rupture.	Additionally,	
recruitment	of	a-syn	monomers	away	from	the	vesicular	membrane	and	into	a	growing	
intravesicular	aggregate	may	result	in	membrane	destabilization	through	lipid	
extraction,	another	possible	mechanistic	explanation	for	a-syn	fibril-mediated	rupture	
[558].	Finally,	uptake	of	rigid	a-syn	amyloid	fibrils	into	endocytic	vesicles	could	result	in	
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physical-mechanical	perturbations	of	the	vesicle	membrane	as	another	mechanistic	
possibility,	due	to	trafficking	of	intracellular	vesicles	through	the	dense	cytoplasmic	
environment	carrying	their	rigid	fibrillar	cargo	[559].			
	 Endocytic	vesicle	rupture	has	also	been	suggested	as	a	mechanism	of	cellular	
invasion	for	fibrillar	assemblies	of	other	amyloid	proteins.	Tau	aggregates	have	been	
proposed	to	rupture	the	endocytic	membrane	during	cellular	uptake,	although	the	
evidence	supporting	this	conclusion	is	limited	by	a	lack	of	specificity	in	defining	tau	
aggregates	that	cause	this	damage	[507,	560].	Exposure	of	artificial	liposomes	to	fibrillar	
assemblies	of	Ab	has	been	shown	to	result	in	vesicle	permeabilization	[561],	and	
endocytic	uptake	of	degradation-resistant	Ab1-42	into	target	cells	results	in	lysosomal	
permeabilization	indicated	by	cytosolic	release	of	the	endocytic	tracer	Lucifer	Yellow	as	
well	as	the	lysosomal	enzymes	CatD	and	b-hexosaminidase	[562].	Finally,	amyloid	fibrils	
composed	of	b2-microglobulin,	associated	with	dialysis-related	amyloidosis,	have	also	
been	shown	to	disrupt	lipid	bilayers	in	vitro	resulting	in	membrane	leakage,	and	this	
effect	was	enhanced	by	low	pH	conditions	such	as	those	in	the	endocytic	pathway	[563,	
564].	While	less	is	known	about	the	actions	of	amyloid	fibrils	on	biological	membranes	
compared	to	monomers	or	oligomers	of	these	proteins,	insights	into	membrane	
association	in	vitro	or	upon	cellular	uptake	have	postulated	a	vesicle	rupture	mechanism	
for	the	cellular	invasion	of	amyloid	fibrils	through	the	endocytic	compartment.		
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Utility	and	Role	of	Galectin	Proteins.	
	 Galectin	family	proteins	derive	their	name	from	their	function	as	galactoside-
binding	lectins,	and	b-galactoside	recognition	by	the	galectin	carbohydrate	recognition	
domain	(CRD)	mediates	their	diverse	functions	in	cell	communication,	inflammation,	
development,	and	differentiation	[565-569].	One	such	function,	critical	for	innate	
immunity,	is	the	action	of	cytosolic	galectins	as	membrane	sensing	pattern	recognition	
receptors	(PRRs)	or	danger	receptors	that	continually	ensure	intracellular	endosomal	
and	lysosomal	membrane	integrity	through	their	lack	of	binding	to	carbohydrate	targets	
that	are	sequestered	within	intact	intracellular	vesicles	and	thus	absent	from	the	cytosol	
[570,	571].	The	ability	of	cytosolic	galectins	to	recognize	exposed	b-galactoside	targets	
upon	vesicular	membrane	permeabilization	highlights	their	utility	for	studying	the	
vesicle	membrane	rupture	ability	of	fibrillar	amyloid	aggregates	following	endocytosis.	
Galectins	detect	vesicle	rupture	induced	by	the	cellular	invasion	of	numerous	
pathogens,	such	as	Salmonella	enterica	serovar	Typhimurium,	Shigella	flexneri,	Listeria	
monocytogenes,	Mycobacterium	tuberculosis,	Burkholderia	cenocepacia,	Ureaplasma	
parvum,	and	non-enveloped	viruses	such	as	adenovirus	[572-575],	that	each	damage	
the	endocytic	compartment	to	gain	entry	to	the	cytoplasm	as	part	of	their	infectious	life	
cycle.	Following	the	rupture	of	the	endocytic	compartment	that	formed	around	the	
pathogen	during	host	cell	uptake,	galectins	become	selectively,	specifically,	and	
instantly	recruited	to	the	site	of	vesicle	damage,	serving	as	a	novel	tool	to	spot	vesicle	
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rupture	and	to	identify	the	molecular	and	cellular	mechanisms	of	rupture	during	
pathogenic	invasion	[570,	576-580].		
	 In	addition	to	this	utility	for	the	study	of	vesicle	rupture	mechanisms,	the	
recruitment	of	cytosolic	galectins	to	the	site	of	intracellular	vesicle	damage	also	plays	a	
physiologic	role	in	innate	immune	signaling	and	inflammation	[581-586],	initiated	as	a	
response	to	vesicle	rupture	by	any	cause;	bacteria,	virus,	or	amyloid	fibril	alike.	Within	
affected	cells	stimulated	by	ischemia	or	a-syn	aggregate	exposure,	a	resulting	increase	
in	Gal3	expression	and/or	activity	prompts	a	signaling	cascade	that	is	required	for	
proper	microglial	activation	and	proliferation	[587-589].	Additionally,	Gal3	expression	is	
markedly	increased	in	prion-infected	brain	tissue	after	central	or	peripheral	inoculation,	
where	it	plays	a	detrimental	role	for	survival	as	evidenced	by	Gal3	KO	mice	exhibiting	
prolonged	survival	times	[590].	Gal3	KO	mice	also	had	decreased	LAMP2	protein	levels,	
suggesting	that	a	regulation	of	lysosomal	function	may	underlie	the	detrimental	role	of	
Gal3	in	prion	infections	[590].	In	additions	to	its	actions	within	affected	cells,	Gal3	can	
also	be	secreted	from	cells	through	a	non-classical	leaderless	secretory	pathway	where	
now	in	the	extracellular	environment	it	acts	as	an	endogenous	danger	signaling	
molecule	producing	proinflammatory	responses	from	nearby	cells	[591-593].	
Extracellular	Gal3,	released	in	a	paracrine	fashion	in	response	to	diverse	stimuli	such	as	
ischemia,	LPS	exposure,	or	traumatic	brain	injury	(TBI),	has	been	proposed	to	act	as	an	
alarmin,	promoting	inflammation	and	neuronal	loss	through	its	binding	to	Toll-Like	
Receptor	4	(TLR4)	[594-596].	Gal3-mediated	TLR4	activation	could	result	in	excessive	
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and	prolonged	microglial	activation	with	resulting	inflammation	becoming	detrimental	
[594],	a	view	supported	by	the	neuroprotective	phenotype	in	Gal3	KO	or	Gal3	
neutralizing	antibody-treated	animals	despite	TBI	insult	[596].	These	actions	not	only	
highlight	the	potential	application	of	galectin	proteins	to	the	study	of	endocytic	vesicle	
rupture	by	invading	fibrillar	amyloid	protein	assemblies,	but	also	portend	the	
consequences	of	such	vesicle	damage	in	the	resulting	intracellular	and	extracellular	
galectin-mediated	inflammatory	responses	that	could	contribute	as	one	of	many	causes	
for	neurotoxicity.		
Infectious	Pathogens	and	Sterile	Damage.	
	 Insight	into	the	mechanisms	and	consequences	of	amyloid	protein-mediated	
vesicle	rupture	can	be	gained	from	examining	other	paradigms	of	cellular	infection	by	
pathogens	that	are	also	confronted	with	this	vesicular	escape	hurdle	en	route	to	cellular	
invasion	and	continuation	of	their	infectious	life	cycle.	While	physical	damage	to	the	
endocytic	vesicle	membrane	allows	invading	pathogens	to	subvert	lysosomal	
degradation	and	escape	into	the	cytosol	where	replication	proceeds,	this	mechanism	of	
cellular	invasion	is	particularly	damaging	to	intracellular	vesicles	and	induces	their	
autophagic	degradation.	Once	a	pathogen	breaks	the	vacuolar	membrane	to	gain	access	
to	the	cytosol,	a	diverse	set	of	cellular	responses	ensues.	PRRs,	with	cytosolic	galectins	
being	some	of	many,	respond	to	danger	by	identifying	both	pathogen-associated	
molecular	patterns	(PAMPs)	associated	with	the	invading	bacterium	or	virus	as	well	as	
damage-associated	molecular	patterns	(DAMPs)	associated	with	the	damaged	vesicles	
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[592].	The	vesicular	membrane	remnants	act	as	a	signaling	node	for	PRR	activity,	
triggering	both	galectin-	and	polyubiquitination-mediated	autophagic	degradation	[570,	
576,	579,	597-600].	This	upregulation	of	autophagic	degradation	mechanisms	not	only	
helps	to	remove	and	recycle	vesicular	debris,	but	can	also	serve	an	antibacterial	function	
to	restrict	intracellular	proliferation	of	invading	pathogens	through	their	degradation	
[570,	579,	601,	602].	Even	in	the	absence	of	pathogen	invasion,	sterile	vesicle	
membrane	damage	caused	by	transfection	reagents	such	as	calcium	phosphate	
precipitates	(CPPs)	or	latex	beads	coated	with	Effectene	also	result	in	ubiquitination	and	
subsequent	autophagic	degradation	of	the	damaged	vesicles	[597,	603].		In	addition	to	
binding	exposed	b-galactosides,	galectins	3	and	8	are	an	essential	component	of	the	
pathway	facilitating	recruitment	of	the	autophagic	machinery	to	the	site	of	vesicle	
damage	[570,	579,	602,	603].	Autophagy-mediated	degradation	of	invading	pathogens	
and	ruptured	vesicular	debris	is	one	adaptive	mechanism	for	cells	to	survive	these	forms	
of	stress.		
	 One	specific	example	of	a	pathogen	infection	that	closely	resembles	the	
mechanism	of	a-syn	cellular	invasion	is	that	of	adenovirus,	where	both	the	process	of	
vesicular	escape	and	the	consequences	of	lysosomal	rupture	are	shared.	As	a	non-
enveloped	virus,	adenovirus	enters	cells	via	endocytosis	where	it	must	then	escape	from	
the	endocytic	compartment	[575].	Upon	exposure	to	the	low	pH	of	the	late	endosome	
or	early	lysosome,	the	viral	capsid	undergoes	a	conformational	change	that	allows	a	
membrane-perturbing	protein	known	as	protein	VI	to	associate	with	the	lipid	membrane	
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and	generate	a	positive	membrane	curvature,	resulting	in	the	physical	rupture	of	the	
endosome	[604,	605].	This	vesicular	membrane	fragmentation	ability	of	adenoviral	
protein	VI	closely	resembles	that	of	a-syn	monomers,	perhaps	mediated	by	their	shared	
amphipathic	nature.	Endocytic	vesicle	rupture	induced	by	adenovirus	also	results	in	Gal3	
recruitment	to	the	site	of	rupture,	occurring	for	adenovirus	most	often	in	the	early	
stages	of	the	endosomal	pathway	for	the	evolutionary	reason	that	adenovirus	thus	
avoids	enzymatic	digestion	in	the	lysosome	[606,	607].	Adenovirus,	like	a-syn,	has	also	
been	shown	to	induce	small	plasma	membrane	lesions	through	the	actions	of	protein	VI,	
resulting	in	Ca2+	influx	and	lysosomal	exocytosis	to	repair	plasma	membrane	piercing	
[608].	Endocytic	vesicle	rupture	by	adenovirus,	like	a-syn,	results	in	release	of	activated	
cathepsins	and	a	consequent	upregulation	in	mitochondrial	ROS	[609].	Examining	the	
process	of	cellular	infection	by	various	pathogens	or	sterile	damage	in	endocytic	vesicle	
membranes	has	illuminated	similarities	with	the	cellular	invasion	of	a-syn	aggregates,	as	
well	as	highlighted	several	detrimental	cellular	consequences	resulting	from	endocytic	
vesicle	rupture.		
Lysosomal	Membrane	Permeabilization.	
	 Lysosomal	rupture	induced	by	a-syn	aggregates	after	their	endocytic	uptake	is	
one	of	many	diverse	causes	of	lysosomal	membrane	permeabilization	(LMP),	a	common	
programmed	cell	death	pathway	induced	by	various	cytotoxic	stimuli	and	stressful	
cellular	conditions	[610,	611].	Just	as	observed	in	response	to	a-syn	endocytic	uptake	
and	lysosomal	rupture,	the	LMP	pathway	causes	the	release	of	lysosomal	cathepsins	
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and	other	hydrolases	from	the	lumen	to	the	cytosol,	causing	aberrant	digestion	of	vital	
proteins,	oxidative	stress,	and	inflammatory	sequelae	[610].	In	addition	to	endocytic	
vesicle	rupture	by	fibrillar	assemblies	of	amyloid	proteins	or	invading	pathogens,	other	
stimuli	such	as	ROS,	endogenous	cell	death	effectors	like	Bax,	lysosomotropic	
compounds	with	detergent	activity	like	L-leucyl-L-leucine	methyl	ester	(LLOMe),	high	
doses	of	the	quinolone	antibiotic	ciprofloxacin,	uptake	of	mineral	crystals	such	as	silica	
and	monosodium	urate	(MSU),	and	even	adherent	noningested	bacteria	like	Type	1-
fimbriated	Escherichia	coli	also	induce	LMP	[610,	612-615].	There	is	additional	evidence	
that	the	nucleotide-binding	oligomerization	domain-like	receptor	family,	pyrin	domain-
containing	3	(NLRP3)	inflammasome,	activated	in	response	to	many	of	the	same	stimuli	
as	LMP,	may	also	contribute	to	its	induction	[616].		
The	ectopic	presence	of	lysosomal	proteases	in	the	cytosol	resulting	from	LMP	
causes	caspase	activation	indirectly	through	cathepsin-mediated	cleavage	and	activation	
of	Bid,	inducing	mitochondrial	outer	membrane	permeabilization	(MOMP),	cytochrome	
c	release	and	caspase	activation	during	apoptotic	cell	death	[610].	This	induction	of	the	
mitochondrial	apoptotic	pathway	through	Bid	activation	synergizes	with	a	concomitant	
degradation	of	antiapoptotic	Bcl-2,	Bcl-xL,	or	Mcl-1	by	lysosomal	proteases	[614].	
However,	if	LMP	is	massively	increased,	cell	death	can	occur	through	necrosis	in	the	
absence	of	caspase	activation	[610,	617].	This	LMP	cell	death	pathway	can	be	regulated	
under	physiologic	conditions	or	can	contribute	to	cell	death	in	in	pathological	situations,	
including	PD	[611,	618].	In	PD	pathogenesis,	lysosomal	depletion	is	known	to	be	caused	
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by	ROS-mediated	LMP,	which	results	in	defective	clearance	and	subsequent	
accumulation	of	autophagosomes	and	dopaminergic	cell	death	mediated	by	the	
released	lysosomal	proteases	[130].	Additionally,	dysfunctional	lysosomal	degradation	
and	the	resulting	accumulation	of	autophagosomes	leads	to	LB	inclusion	formation,	as	
LBs	contain	markers	of	autophagosomes	in	PD	brain	[130].	These	findings	highlight	the	
important	role	of	LMP	in	neurodegenerative	pathology	as	a	consequence	of	amyloid-
mediated	lysosomal	rupture,	oxidative	stress,	or	a	combination	of	the	two.						
	 LMP	has	been	noted,	similar	to	pathogen-induced	endocytic	vesicle	rupture,	
through	a	variety	of	techniques	that	rely	on	detecting	either	the	release	of	normal	
lysosomal	factors,	such	as	cathepsins	or	fluorescent	dextran,	or	the	localized	
accumulation	of	membrane	damage	sensors	upon	permeabilization,	like	the	enrichment	
of	galectin	puncta	[617,	619-623].	These	methods	have	been	employed	to	determine	
that	cells	can	survive	limited	LMP	that	occurs	at	a	basal,	resting	state,	but	can	also	be	
overwhelmed	by	LMP	and	succumb	to	this	insult	following	more	significant	incidence	
[620].	Following	membrane	permeabilization,	damaged	lysosomes	are	selectively	
engulfed	by	autophagosomes	following	the	recruitment	of	autophagic	machinery	to	the	
site	of	damage,	resulting	in	their	recovery	of	low	pH	and	degradation	capacity	[615].	
This	autophagosomal	clearance	of	damaged	lysosomes	begins	with	lysine	63	(K63)-
linked	ubiquitination	of	damaged	membranes	and	the	recruitment	of	p62,	followed	by	
translocation	of	the	ubiquitin-directed	AAA-ATPase	p97,	which	cooperates	with	
cofactors	UBDX1,	PLAA,	and	the	deubiquinating	enzyme	YOD1	as	components	of	the	
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endolysosomal	damage	response	(ELDR)	to	remove	lysine	48	(K48)-linked	ubiquitin	
conjugates	and	promote	autophagosome	formation	[560].	If	autophagic	degradation	is	
compromised	in	the	setting	of	LMP,	this	causes	inhibition	of	lysosomal	biogenesis	since	
functional,	degradation-competent	lysosomes	cannot	be	regenerated	through	
autophagy	[615].	Particularly	relevant	for	the	cell-to-cell	propagation	of	amyloid	fibrils	
following	entry	via	endocytic	vesicle	rupture,	elevated	intracellular	Ca2+	induced	by	
exogenous	amyloid	proteins	[210,	382,	550,	551,	556,	624]	triggers	lysosomal	exocytosis	
to	repair	membrane	ruptures,	releasing	lysosomal	contents	to	the	extracellular	
environment	[478,	512,	625].	Autophagy,	too,	may	be	involved	in	the	unconventional	
secretion	of	leaderless	cytosolic	proteins	such	as	a-syn	and	Gal3,	as	lysosomal	damage	
leads	to	the	recognition	of	unconventional	secretory	cargo	by	specialized	cytosolic	cargo	
receptors	and	a	dedicated	SNARE	system	to	facilitate	secretion	[626].	Overall,	LMP	has	
important	consequences	for	invading	fibrillar	amyloid	assemblies	that	are	relevant	to	
both	their	impaired	degradation	and	their	pathological	release	from	the	cells	into	which	
they	have	invaded.		
Concluding	Remarks	
	 The	prion-like	characteristics	of	amyloid	proteins	in	various	neurodegenerative	
diseases	not	only	provide	a	platform	for	in-depth	examination	of	disease	pathogenesis,	
but	also	raise	the	possibility	that	similar	therapeutic	strategies	may	be	effective	to	
combat	shared	mechanisms	of	neurotoxicity	in	this	group	of	progressive,	currently	
intractable	diseases.	Misfolded	aggregates	of	a-syn	in	PD,	tau	in	AD,	and	HTTExon1	in	
		
108	
HD	are	considered	“prion-like”	for	their	many	shared	characteristics	with	prions	but	also	
for	the	important	lack	of	transmissibility	between	host	organisms	only	seen	with	true	
prions.	Even	so,	considering	the	pathogenesis	of	these	diverse	proteinopathies	from	the	
cell	biological	perspective	of	host-pathogen	interactions	yields	novel	insight	into	disease	
mechanisms	that	were	previously	poorly	understood.	Although	the	“pathogen”	is	
derived	from	pathological	aggregation	of	a	host	protein,	many	aspects	of	its	cellular	life	
cycle	such	as	cellular	invasion,	amplification,	and	propagation	are	similar	to	an	infection	
by	a	foreign	agent.		
	 Three	aspects	of	prion-like	amyloid	proteins	make	combating	cellular	“infection”	
by	these	protein	aggregates	particularly	challenging.	First,	the	ability	of	misfolded	
amyloid	proteins	to	serve	as	both	seeds	and	templates	for	further	misfolding	of	naïve	
counterparts	represents	the	mechanism	by	which	a	pathologic	protein	aggregate	can	
replicate	and	amplify	its	protein	misfolding	pathology	[197,	200-202,	212,	213,	347,	490,	
492,	525,	526,	533].	Second,	the	ability	of	misfolded	amyloid	proteins	to	interfere	with	
the	very	mechanisms	that	cells	employ	to	degrade	them	represents	a	positive	feedback	
mechanism	for	degradative	dysfunction	and	amyloid	protein	accumulation	[130,	340,	
341,	356,	358].	Finally,	the	ability	of	misfolded	amyloid	proteins	to	propagate	from	
affected	to	naïve	cells	represents	the	mechanism	of	disease	progression	and	
dissemination	[212,	213,	419,	420,	498,	502,	535].		
Endocytic	vesicle	rupture,	an	event	occurring	during	cellular	invasion	by	fibrillar	
amyloid	protein	assemblies,	exerts	influence	on	all	three	challenging	aspects	of	prion-
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like	pathology.	Rupture	of	endocytic	vesicles	represents	the	mechanism	of	amyloid	
protein	vesicular	escape	following	uptake,	an	essential	step	in	the	cell-to-cell	
propagation	pathway,	which	induces	degradative	dysfunction	through	damage	to	
lysosomal	membranes	and	allows	seeding	of	further	aggregation	by	the	escaped	seed	
nucleus.	As	an	event	that	impacts	these	critical	pathological	activities	of	misfolded	
protein	aggregates,	a	clear	understanding	of	its	mechanisms	and	consequences	is	
essential	for	a	complete	understanding	of	disease	pathogenesis.		
The	goal	of	this	dissertation	is	to	better	understand	endocytic	vesicle	rupture	as	
a	mechanism	of	cellular	invasion	for	several	amyloid	proteins,	focusing	for	a-syn	on	
specific	modifications	that	influence	vesicle	rupture	potency	as	well	as	the	effects	of	a-
syn-mediated	rupture	on	cellular	homeostasis	and	aggregate	propagation.	Taken	
together,	these	studies	demonstrate	the	ability	of	fibrillar	amyloid	protein	assemblies	to	
induce	endocytic	vesicle	rupture,	and	provide	a	clear	understanding	of	the	impact	of	this	
damaging	mechanism	of	cellular	invasion	on	the	pathogenesis	and	progression	of	
proteinopathies.		
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CHAPTER	TWO	
MATERIALS	AND	METHODS	
Cell	Lines	and	Media	
The	human	neuroblastoma	cell	line	SH-SY5Y	was	obtained	from	the	American	
Type	Culture	Collection	(ATCC,	Manassas,	VA).	The	rat	dopaminergic	neuronal	cell	line	
N27	was	a	kind	gift	from	Dr.	Anumantha	Kanthasamy	[627].	SH-SY5Y	cells	were	
maintained	in	Dulbecco’s	modified	Eagle’s	medium	(DMEM)	supplemented	with	15%	
fetal	bovine	serum	(FBS)	(Hyclone)	and	100	IU/mL	penicillin,	100	µg/mL	streptomycin,	
and	10	µg/mL	ciprofloxacin.	N27	cells	were	maintained	in	Roswell	Park	Memorial	
Institute	(RPMI)	1640	media	with	10%	FBS	and	the	same	additives	used	for	SH-SY5Y	
cells.	Human	embryonic	kidney	293T	cells	were	cultured	in	DMEM	supplemented	with	
10%	FBS	and	the	same	additives	used	for	SH-SY5Y	cells.	SH-SY5Y	and	N27	cells	were	
plated	on	fibronectin	(Sigma)-treated	glass	coverslips	or	Delta	T	dishes	(Bioptechs)	at	
least	12	hr	prior	to	experiments.	Human	dopaminergic	neurons	differentiated	from	
human	induced	pluripotent	stem	cells	(hiPSC-derived	dopaminergic	neurons)	were	
obtained	from	Cellular	Dynamics	International	(iCell	DopaNeurons,	CDI,	Madison,	WI).	
hiPSC-derived	dopaminergic	neurons	were	grown	on	dishes	pre-coated	with	poly-L-
ornithine	and	laminin	according	to	the	supplier’s	instructions.	One	half	of	the	hiPSC-
derived	dopaminergic	neuron	complete	maintenance	media	was	changed	at	
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24	hr	post	thaw	and	every	other	day	thereafter	until	the	start	of	experiments,	between	
4-14	days	post	thawing.	Cells	were	maintained	in	a	37°C	incubator	with	5%	CO2.	
Generation	of	Stable	Cell	Lines	
	 The	mCherry-galectin	3	(chGal3)	lentiviral	plasmid	was	generated	by	inserting	
the	galectin	3	open	reading	frame	(ORF)	into	a	mCherry-pLVX	backbone	(Takara	Bio	
USA,	Mountain	View,	CA).	Lentiviruses	for	transduction	were	produced	by	
polyethylenimine	(PEI)	(molecular	weight,	25,000;	Polysciences)	transfection	of	293T	
cells	seeded	at	60%	confluency	in	a	15	cm	dish	with	8.33	µg	PLVX	mCherry-Gal3,	8.33	µg	
vesicular	stomatitis	virus	glycoprotein	(VSV-G),	and	8.33	µg	PsPax2	(lentiviral	packaging	
plasmid,	AIDS	Reagent	Repository).	Fresh	media	was	added	24	hr	after	transfection	and	
viruses	were	harvested	48	hr	after	transfection.	Following	filtration	through	a	0.45-µm	
filter	(Millipore),	viruses	were	used	to	transduce	SH-SY5Y,	N27,	and	hiPSC-derived	
dopaminergic	neurons.	Twenty-four	hours	after	infection,	vector	was	removed	and	
replaced	with	fresh	media.	Forty-eight	hours	after	transduction,	SH-SY5YchGal3	or	
N27chGal3	cells	were	selected	in	media	containing	5	µg/mL	puromycin	(Sigma-Aldrich).		
	 The	yellow	fluorescent	protein	(YFP)-LC3	lentiviral	plasmid	was	generated	by	
inserting	the	YFP-LC3	open	reading	frame	into	pLVX	(Takara	Bio	USA,	Mountain	View,	
CA).	Lentiviruses	for	transduction	were	prepared	in	an	identical	fashion	to	above,	and	
used	to	transduce	SH-SY5YchGal3	cells	previously	transduced	to	express	chGal3	with	a	
retroviral	vector	[4].	SH-SY5YchGal3	YFP-LC3	cells	were	selected	in	media	containing	400	
µg/mL	Geneticin	(G418,	Gibco)	and	5	µg/mL	puromycin.		
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Amyloid	Proteins	
Alpha-Synuclein.	
Wild	type	and	familial	mutant	alpha-synuclein	assemblies.	A	pET-28a	plasmid	
containing	human	WT	a-syn	cDNA	was	generously	provided	by	Dr.	Anurag	Tandon	
[280].	Human	a-syn	cDNAs	for	familial	mutants	(A53T,	A30P,	E46K,	and	G51D)	were	
subcloned	into	this	pET-28a	plasmid	using	NcoI	and	HindIII	restriction	sites.	a-syn	was	
purified	as	previously	described	[628].	Briefly,	a-syn	was	overexpressed	in	Escherichia	
coli	BL21	via	an	isopropyl-1-thio-b-D-galactopyranoside	(IPTG)-inducible	T7	promoter.	
The	bacterial	pellet	was	resuspended	in	phosphate-buffered	saline	(PBS)	containing	1	
mM	phenylmethylsulfonyl	fluoride	(PMSF).	The	bacterial	pellet	was	then	sonicated	for	
15	sec	several	times,	boiled	for	15	min,	and	centrifuged	at	10,000	x	g	for	20	min.	The	
supernatant	was	then	ultracentrifuged	at	150,000	x	g	for	30	min.	The	supernatant	
containing	the	heat-stable	a-syn	was	dialyzed	against	50	mM	Tris,	pH	8.3,	loaded	onto	a	
Q-Sepharose	column	(GE	Healthcare),	and	eluted	with	a	0-500	mM	NaCl	linear	gradient.	
Ion	exchange	fractions	were	analyzed	by	sodium	docedyl	sulfate-polyacrylamide	gel	
electrophoresis	(SDS-PAGE)	followed	by	Coomassie	Brilliant	Blue	(CBB)	staining	and	
western	blotting	for	a-syn	to	confirm	purity.	Appropriate	ion	exchange	fractions	were	
pooled,	dialyzed	against	20	mM	Tris,	pH	7.4,	sterile	filtered,	flash	frozen	in	liquid	
nitrogen,	and	stored	at	-80	°C.	Protein	concentration	was	determined	by	spectrometer	
absorbance	at	280	nm	using	an	extinction	coefficient	of	5960	M-1cm-1.		
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	 a-syn	samples	were	prepared	for	aggregation	by	standardizing	protein	and	
solute	concentrations,	as	well	as	total	sample	volume,	across	all	samples	according	to	
our	previously	published	aggregation	conditions	[4,	280].	Specifically,	200	µL	of	purified	
a-syn	(1	mg/mL)	was	prepared	in	a	pH	7.4	buffer	containing	the	following	solute	
concentrations:	323.3	mM	NaCl,	20	mM	Tris-HCl,	9	mM	Na2HPO4,	2.43	mM	KCl,	and	1.62	
mM	KH2PO4.	Sample	preparations	were	then	incubated	for	3	days	at	37	°C	under	
constant	agitation	(300	revolutions	per	minute	(rpm),	Benchmark	Incu-Shaker	Mini),	
followed	by	flash	freezing	in	liquid	nitrogen	and	storage	at	-80	°C.	Assemblies	were	
fluorescently	labeled	with	DyLight488	N-hydroxysuccinimide	(NHS)	ester	fluorophores	
(Thermo	Scientific)	according	to	the	manufacturer’s	protocol	prior	to	use.	Briefly,	100	µL	
of	aggregated	protein	at	1	mg/mL	was	dialyzed	into	0.1	M	sodium	phosphate	buffer,	pH	
8.0,	for	2	hr	at	4°C	using	10,000	molecular	weight	cutoff	(MWCO)	minidialysis	units	
(Thermo	Scientific).	The	protein	solution	was	then	transferred	to	the	vial	containing	the	
dye	and	was	labeled	as	per	the	supplier’s	instructions	for	30	min	at	room	temperature	
(RT).	After	incubation,	the	labeling	reaction	was	quenched	with	40	mM	Tris	(final	
concentration),	and	extensive	dialysis	was	performed	at	4	°C	using	10,000	MWCO	
dialysis	units	into	a	buffer	containing	40	mM	Tris	and	150	mM	NaCl	for	about	24	hr	to	
remove	excess	unlabeled	dye.	Following	labeling,	samples	were	flash	frozen	in	liquid	
nitrogen	and	stored	at	-80°C.	
	 Phosphorylated	serine-129	alpha-synuclein	aggregates.	Recombinant	WT,	A30P,	
and	A53T	a-syn	were	expressed	in	E.	coli	with	or	without	PLK2,	purified	as	described	
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previously	[628],	and	stored	in	20	mM	Tris-Cl,	pH	7.4	at	-80	°C.	Samples	containing	
monomeric	WT,	WT	pS129,	A30P,	A30P	pS129,	A53T,	and	A53T	pS129	a-syn	were	
aggregated	under	identical	protein	and	solute	concentrations	and	in	the	same	volume	
as	for	WT	and	mutant	a-syn	assemblies	above,	followed	by	storage	at	4	°C.	Fluorescent	
labeling	was	also	performed	in	a	manner	identical	to	that	of	WT	and	mutant	a-syn	
assemblies	as	above,	followed	by	storage	at	4	°C.		
	 Alpha-synuclein	polymorphic	assemblies.	To	generate	distinct	fibrillar	
polymorphs	of	a-syn,	the	WT	protein	was	expressed	in	Escherichia	coli	strain	BL21(DE3)	
(Stratagene,	La	Jolla,	CA)	transformed	with	the	expression	vector	pET3a	(NovagenTM)	
encoding	wild-type,	full-length	a-syn.	The	expression	of	a-syn	was	induced	by	0.5mM	
IPTG	for	2	hr	when	the	bacteria	grown	in	lysogeny	broth	(LB)	medium	at	37	°C	reached	
an	optical	density	of	1.0	at	660	nm.	Soluble,	monomeric	a-syn	was	purified	from	the	
bacteria	lysate	as	previously	described	[629].	a-syn	concentration	was	determined	
spectrophotometrically	using	an	extinction	coefficient	of	5960	M-1cm-1	at	280	nm.	Pure	
a-syn	(0.2-0.5mM)	in	50mM	Tris-HCl,	pH	7.5,	150mM	KCl	was	filtered	through	sterile	
0.22-µm	filters	and	stored	at	-80	°C.	To	obtain	on-fibrillar	assembly	pathway	a-syn	
oligomers,	a-syn	was	incubated	at	800	µM	in	50mM	Tris-HCl,	pH	7.5,	150mM	KCl	at	4°C,	
without	shaking,	for	7	days,	followed	by	separation	from	monomeric	a-syn	by	size	
exclusion	chromatography	using	a	Superose6	HR10/30	column	(GE	Healthcare)	
equilibrated	in	PBS	buffer	[210,	382,	556,	630].	To	obtain	the	polymorph	“fibrils”,	a-syn	
(400	µM)	was	assembled	in	50	mM	Tris-HCl,	pH	7.5,	150	mM	KCl	as	described	[305];	to	
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obtain	the	polymorph	“ribbons”,	a-syn	(400	µM)	was	dialyzed	overnight	against	5	mM	
Tris-HCl	pH	7.5	prior	to	assembly	[305];	to	obtain	the	polymorph	“fibrils-91”,	a-syn	(400	
µM)	was	dialyzed	overnight	against	20	mM	KPO4	pH	9.1	prior	to	assembly	as	described	
[309];	to	obtain	the	polymorph	“fibrils-65”,	a-syn	(400	µM)	was	dialyzed	for	3	hours	
against	20	mM	MES	pH	6.5,	150	mM	NaCl	prior	to	assembly.	Assembly	was	achieved	by	
incubating	the	samples	for	one	week	at	37	°C	under	continuous	shaking	in	an	Eppendorf	
Thermomixer	set	at	600	rpm.	Fibrillar	assemblies	were	spun	at	15,000	x	g	for	10	min	and	
resuspended	in	PBS.	Labeling	of	all	polymorphs	was	achieved	by	addition	of	2	molar	
equivalent	of	lysine	reactive	ATTO-488	(ATTO-TEC,	GMBH)	for	1	hr	at	RT.	The	unreacted	
fluorophore	was	removed	from	fibrillar	preparations	by	a	cycle	of	two	centrifugations	at	
15,000	x	g	for	10	min	and	resuspensions	of	the	fibrillar	pellets	in	PBS.	Unreacted	
fluorophore	was	removed	from	oligomeric	preparations	by	size	exclusion	
chromatography.	Fibrillar	preparations	homogenous	in	size	were	obtained	through	
sonication	by	fragmenting	fibrillar	polymorphs	for	20	min	at	a	constant	temperature	
(20°C)	in	2	mL	Eppendorf	tubes	in	a	VialTweeter	powered	by	an	ultrasonic	processor	
UIS250v	(250	watts,	24	kHz,	Hielscher	Ultrasonic,	Teltow,	Germany)	set	at	75%	
amplitude,	0.5	sec	pulses	every	1	sec.	On-fibrillar	assembly	pathway	oligomeric	a-syn	
was	not	fragmented.		
	 Alpha-synuclein	pre-formed	fibrils.	a-syn	monomer	to	generate	PFFs	(Proteos,	
Inc,	Kalamazoo,	MI)	was	prepared	according	to	the	manufacturer’s	protocol	[203].	
Briefly,	a-syn	was	assembled	in	PBS	at	5	mg/mL	by	incubation	for	7	days	at	37	°C	under	
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constant	agitation	(300	rpm,	Benchmark	Incu-Shaker	Mini),	followed	by	flash	freezing	in	
liquid	nitrogen	and	storage	at	-80°C.	Samples	were	fluorescently	labeled	with	Dylight488	
or	Dylight650	NHS	ester	fluorophores	as	above,	with	the	exception	that	pre-labeling	
dialysis	was	omitted	as	samples	could	be	sufficiently	labeled	in	PBS	buffer,	and	post-
labeling	dialysis	was	performed	using	PBS	at	RT.	Following	labeling,	samples	were	flash	
frozen	in	liquid	nitrogen	and	stored	at	-80°C.	Immediately	prior	to	use,	PFFs	were	
generated	from	aliquots	of	Dylight488	or	Dylight	650-labeled	a-syn	assemblies	by	
diluting	each	sample	to	0.1	mg/mL	in	PBS	and	sonicating	with	60	pulses	at	20%	power	
for	0.5	sec	each	using	a	Sonics	Vibra	Cell	sonicator	(VCX	130PB,	Sonics	and	Materials	Inc,	
Newtown,	CT).		
Tau.	
	 Full-length	human	tau	1N3R	and	tau	1N4R	cloned	in	pET14b	vector	were	
expressed	in	E.	coli	BL21	DE3	codon	+	cells	(Stratagene).	Cells	were	grown	in	LB	medium	
to	an	optical	density	of	0.8	absorbancy	units	at	600nm.	Tau	isoform	expression	was	
induced	by	0.5	mM	IPTG	for	3	hr.	The	cells	were	then	centrifuged	(4,000	x	g,	10	min),	
resuspended	in	lysis	buffer	(20	mM	MES	pH	6.8,	500	mM	NaCl,	1	mM	EGTA,	0.2	mM	
MgCl2,	5	mM	dithiothreitol	(DTT),	1	mM	PMSF	+	1	tablet	of	Complete	(Roche))	per	liter	
and	lysed	by	sonication.	Bacterial	homogenates	were	clarified	by	centrifugation	at	
14,000	x	g	for	30	min.	The	supernatant	was	heated	to	80	°C	for	20	min	and	centrifuged	
at	14,000	x	g	for	30	min.	The	supernatant	was	dialyzed	against	100	volumes	of	buffer	A	
(20	mM	MES	pH	6.8,	50	mM	NaCl,	1	mM	EDTA,	1	mM	MgCl2,	2	mM	DTT,	0.1	mM	PMSF)	
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at	4	°C.	The	dialyzed	protein	mixture	was	loaded	on	SP	Sepharose	column	(60	mL	bed	
volume).	Proteins	were	separated	with	a	linear	gradient	of	0	to	100%	buffer	B	(20	mM	
MES	pH	6.8,	1	M	NaCl,	1	mM	EGTA,	1	mM	MgCl2,	2	mM	DTT,	0.1	mM	PMSF).	Fractions	
were	analyzed	on	SDS-PAGE	stained	with	CBB.	Fractions	containing	human	tau	isoforms	
were	pooled	and	dialyzed	against	100	volumes	of	PBS	buffer	containing	1	mM	DTT.	The	
protein	concentration	was	determined	spectrophotometrically	using	an	extinction	
coefficient	of	7450	M-1cm-1	at	280nm.	Tau	1N3R	and	tau	1N4R	at	a	concentration	of	50	
to	100	µM	were	aliquoted	and	stored	at	-80	°C.		Tau	1N3R	and	tau	1N4R	(40	µM)	were	
assembled	in	the	presence	of	10	µM	heparin	at	37	°C	in	an	Eppendorf	Thermomixer	set	
at	600	rpm	for	4	days.	Fibrils	were	spun	for	20	min	at	20	°C,	16,000	rpm.	Tau	assemblies	
were	spun	at	15,000	x	g	for	10	min	and	resuspended	in	PBS,	followed	by	fluorescent	
labeling	in	an	identical	fashion	to	labeling	of	a-syn	polymorphic	assemblies.	Fibrillar	tau	
preparations	homogenous	in	size	were	obtained	through	sonication	as	for	a-syn	
polymorphic	assemblies.		
Huntingtin.	
	 Recombinant	HTTExon1	with	a	polyQ	stretch	of	45	glutamine	residues	
(HTTExon1-Q45)	was	expressed	and	purified	as	described	[631].	For	fibril	formation,	
HTTExon1-Q45	was	incubated	in	assembly	buffer	B	(20	mM	Tris-HCl,	pH	7.5,	150	mM	
KCl,	10%	glycerol)	at	37	°C	without	agitation.	HTTExon1-Q45	assemblies	were	spun	at	
15,000	x	g	for	10	min	and	resuspended	in	PBS,	followed	by	fluorescent	labeling	in	an	
identical	fashion	to	labeling	of	a-syn	polymorphic	assemblies.	Fibrillar	HTTExon1-Q45	
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preparations	homogenous	in	size	were	obtained	through	sonication	as	for	a-syn	
polymorphic	assemblies.		
Electron	Microscopy	
	 WT	and	familial	mutant	a-syn	assemblies	were	diluted	to	0.1	mg/mL	and	added	
to	carbon-coated,	200	mesh	copper	grids	(Electron	Microscopy	Sciences)	for	60	sec.	
Grids	were	stained	with	2%	uranyl	acetate	for	5	seconds.	Grids	were	dried	overnight	and	
transmission	electron	microscopy	(TEM)	performed	on	a	Hitachi	H-600	transmission	
electron	microscope.		
	 The	morphology	of	a-syn,	tau	and	HTTExon1-Q45	polymorphs	was	assessed	by	
TEM	in	a	Jeol	1400	transmission	electron	microscope	following	adsorption	onto	carbon-
coated	200	mesh	grids	and	negative	staining	with	1%	uranyl	acetate.	The	images	were	
recorded	with	a	Gatan	Orius	CCD	camera	(Gatan).	
mCherry-Galectin	3	Relocalization	Assay	
	 At	least	12	hr	following	the	plating	of	SY5YchGal3	or	N27chGal3	cells	onto	
fibronectin-coated	glass	coverslips	or	dishes,	or	at	least	48	hr	following	chGal3	lentiviral	
transduction	of	hiPSC-derived	dopaminergic	neurons,	amyloid	assemblies	were	added	to	
the	cell	culture	media.	For	comparisons	of	the	effect	of	a-syn	missense	mutation	and	
S129	phosphorylation,	WT	and	familial	mutant	a-syn	assemblies	and	pS129	a-syn	
aggregates	were	added	at	a	concentration	of	200	nM.	For	comparisons	of	the	effect	of	
amyloid	strain	conformation,	a-syn	monomer,	oligomers,	fibrils,	ribbons,	fibrils-65,	
fibrils-91,	and	assemblies	of	HTTExon1-Q45,	tau	1N3R	and	tau	1N4R	were	added	at	a	
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concentration	of	660	nM.	Following	24-48	hrs	of	treatment	time	as	specified	for	each	
experiment,	cells	were	either	fixed	to	be	mounted	on	coverslips	or	imaged	directly	via	
live	cell	imaging.		
Immunofluorescence	Microscopy	
	 Cells	were	fixed	with	3.7%	formaldehyde	(Polysciences)	in	0.1	M	piperazine-N,	
N’bis(2-ethanesulfonic	acid)	(PIPES)	buffer,	pH	6.8,	for	5	min.	When	immunofluorescent	
staining	was	performed,	cells	were	stained	with	rabbit	anti-human	LAMP1	antibodies	
(1:1000,	ab24170,	Abcam,	Cambridge,	MA)	in	PBS	with	10%	normal	donkey	serum	(NDS)	
and	0.1%	saponin	(Sigma-Aldrich)	for	1	hr.	Primary	antibodies	were	then	secondarily	
labeled	for	20	mins	with	fluorophore-conjugated	donkey	anti-rabbit	647	antibodies	
(1:400,	Jackson	ImmunoResearch)	at	the	same	time	as	4ʹ,6-diamidine-2ʹ-phenylindole	
(DAPI)	staining.	When	vesicle	rupture	was	examined	in	the	absence	of	
immunofluorescent	staining,	cells	were	stained	with	DAPI	alone	for	20	min	in	PBS.	
Coverslips	were	then	mounted	on	glass	slides	using	Fluoro-Gel	with	Tris	Buffer	(Electron	
Microscopy	Sciences)	and	allowed	to	dry	before	image	acquisition.	Images	were	
collected	with	a	DeltaVision	wide-field	deconvolution	microscope	(Applied	Precision)	
equipped	with	a	digital	camera	(CoolSNAP	HQ	or	Cascade	2	Electron	Multiplying	Charge	
Coupled	Device	(EMCCD);	Photometrics),	using	either	a	1.4-numerical	aperture	(NA)	
100X	oil-immersion	objective	lens	or	a	1.42-NA	60X	oil-immersion	objective	lens	with	
immersion	oil	(N=1.514,	Applied	Precision)	at	RT.	Images	were	then	acquired	and	
constrained	iterative	deconvolution	performed	using	SoftWoRx	software	(Applied	
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Precision).	Tif	images	and	quantification	data	were	collected	from	each	image	data	file	
using	Imaris	software	(Bitplane).	To	exclude	the	possibility	that	the	image	deconvolution	
process	affects	the	quality	of	images	or	localization	pattern	of	any	fluorescent	signal,	an	
image	from	Figure	15	is	displayed	again	in	Figure	33	where	a	single	field,	in	addition	to	
enlarged	inset	images,	is	displayed	as	overlay	or	individual	fluorescent	channels	in	both	
an	undeconvolved	and	deconvolved	setting.		
Live	Cell	Imaging	
	 Images	and	videos	were	acquired	on	a	DeltaVision	wide-field	deconvolution	
microscope	(Applied	Precision)	equipped	with	a	Weather	StationTM	chamber	utilized	to	
maintain	cells	at	37	°C	in	5%	CO2.	Images	were	acquired	using	either	a	1.4-NA	100X	oil-
immersion	objective	lens	or	a	1.42-NA	60X	oil-immersion	objective	lens	and	a	Cascade	2	
EMCCD	(Photometrics)	digital	camera.	Acquisition	was	performed	at	37	°C	using	
immersion	oil	(N=1.520,	Applied	Precision),	and	images	were	deconvolved	as	described	
above.	In	some	experiments	LysoTracker	Deep	Red	(Thermo	Scientific)	was	utilized	to	
identify	acidic	organelles	in	live	cells.	60	min	prior	to	imaging,	cells	were	incubated	in	
the	presence	of	20	nM	LysoTracker	Deep	Red	for	30	min,	washed	with	fresh	media,	and	
imaged	30	min	later.		
Image	Analysis	
	 Deconvolved	images	of	experiments	utilizing	WT	and	familial	mutant	a-syn	
assemblies	as	well	as	polymorphic	assemblies	of	a-syn,	tau,	and	HTTExon1-Q45	were	
analyzed	for	chGal3+	puncta	formation	by	blinded	manual	quantification	using	the	
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Imaris	software	program	(Bitplane).	Each	experiment	collected	at	least	20	images	per	
treatment	type.	Values	for	number	of	chGal3	puncta	per	cell	were	pooled	across	all	
experiments	for	statistical	analysis.	Values	for	mean	number	of	chGal3	puncta	per	cell	
induced	by	each	treatment	type	from	at	least	three	independent	experiments	were	
compared	with	one	another	and	to	unexposed	cells	by	use	of	student’s	t-test	or	one-
way	analysis	of	variance	with	Tukey’s	post-hoc	multiple	comparison	test	as	appropriate	
for	each	data	set,	and	expressed	as	fold	increases	relative	to	unexposed	cells	which	
were	normalized	to	1.	
	 Deconvolved	images	of	experiments	utilizing	pS129	a-syn	aggregates	were	
analyzed	for	puncta	formation	by	use	of	the	Surpass	Mode	of	the	Imaris	software	
package	(Bitplane).	Specifically,	a	three-dimensional	surface	was	created	around	chGal3		
puncta	by	designing	an	algorithm	for	each	experiment	that	specifically	detected	
punctate	events	that	increased	in	intensity	sufficiently	above	background	fluorescence	
(Figure	34).	This	same	algorithm	was	uniformly	applied	to	each	image	in	the	data	set,	
and	the	number	of	surfaces	created	by	the	algorithm	was	divided	by	the	number	of	cells	
in	the	field	to	measure	puncta	per	cell.	Each	experiment	collected	at	least	20	images	per	
treatment	type.	Algorithm-detected	values	for	number	of	chGal3	puncta	per	cell	were	
pooled	across	all	experiments	for	statistical	analysis.	Values	for	mean	number	of	chGal3	
puncta	per	cell	induced	by	each	a-syn	treatment	type	from	at	least	three	independent	
experiments	were	compared	with	one	another	and	to	untreated	cells	by	use	of	one-way	
analysis	of	variance	and	Tukey’s	post	hoc	multiple	comparison	test.	When	mean	number	
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of	chGal3	puncta	per	cell	values	from	each	experiment	are	normalized	for	pS129	a-syn	
isoforms	relative	to	their	non-pS129	counterparts	in	the	same	experiment	(set	to	1),	
unpaired	t	tests	were	performed	to	compare	each	a-syn	pS129	isoform	to	its	non-pS129	
counterpart.	
Parkinson’s	Disease	Brain	Tissue	Imaging	
	 Brains	were	obtained	at	autopsy	from	5	subjects	(4	male,	1	female)	with	a	clinical	
and	neuropathological	diagnosis	of	PD.	All	patients	with	PD	were	diagnosed	by	
neurologists	in	the	Section	of	Movement	Disorders	in	the	Department	of	Neurological	
Sciences	at	Rush	University	Medical	Center.	Post	mortem,	the	clinical	diagnosis	was	
confirmed	by	neuropathologists	at	Rush	University	Medical	Center.	For	PD,	inclusion	
criteria	included	a	history	compatible	with	idiopathic	PD	and	at	least	two	of	the	four	
cardinal	signs	(rest	tremor,	rigidity,	akinesia/bradykinesia,	and	gait	disturbance/postural	
reflex	impairment).	The	Unified	Parkinson's	Disease	Rating	Scale	(UPDRS	“on”)	and	
Hoehn	and	Yahr	staging	(H&Y	“on”)	were	recorded,	and	for	this	study,	tissue	sections	
from	patients	at	H&Y	Stage	5	were	used.	The	pathological	diagnosis	was	based	on	
finding	Lewy	bodies	in	catecholamine	nuclei	such	as	the	SN.	Exclusion	criteria	included	
familial	PD,	dementia	with	Lewy	bodies,	the	Lewy	body	variant	of	AD,	or	the	
combination	of	PD	and	AD.		
	 At	autopsy,	the	brains	were	removed	from	the	calvarium	and	processed	as	
described	previously	[346,	632].	Briefly,	each	brain	was	cut	into	1	cm	coronal	slabs	using	
a	plexiglass	brain	slice	apparatus	and	then	hemisected.	The	slabs	were	fixed	in	4%	
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paraformaldehyde	for	48	hr	at	4	°C.	The	left	side	brain	slabs	were	used	for	pathological	
diagnoses.	The	right	side	brain	slabs	were	cryoprotected	in	0.1	M	PBS	(pH	7.4)	
containing	2%	dimethyl	sulfoxide	(DMSO),	10%	glycerol	for	48	hr	followed	by	2%	DMSO,	
20%	glycerol	in	PBS	for	at	least	2	days	prior	to	sectioning.	The	fixed	slabs	containing	the	
SN	were	cut	into	18	adjacent	series	of	40	µm	thick	sections	on	a	freezing	sliding	
microtome	for	this	study.	All	sections	were	collected	and	stored	in	a	cryoprotectant	
solution	prior	to	processing.		
	 A	double-label	immunofluorescence	procedure	was	employed	to	determine	
whether	Gal3	colocalized	with	a-syn	in	LBs.	The	sections	through	the	SN	from	each	brain	
were	blocked	for	1	hr	in	a	solution	containing	5%	goat	serum,	2%	bovine	serum	albumin	
(BSA),	and	0.3%	TritonX-100	in	Tris	buffered	saline	(TBS)	and	then	incubated	with	a-
synuclein	(pS129)	(EP1536Y,	ab51253;	1:1000;	Abcam,	Cambridge,	MA)	rabbit	
monoclonal	antibody	overnight	at	RT.	Following	6	washes	in	TBS,	the	sections	were	
sequentially	incubated	with	goat	anti-rabbit	antibody	coupled	to	Cy2	(1:200;	Jackson	
ImmunoResearch,	West	Grove,	PA)	for	1	hr.	After	6	washes	in	TBS,	the	sections	were	
blocked	again	for	1	hr	in	a	solution	containing	5%	goat	serum,	2%	BSA,	and	0.3%	Triton	
X-100	in	TBS.	Sections	were	then	incubated	with	Gal3	(1:300;	556904,	BD	Biosciences,	
San	Jose,	CA)	mouse	monoclonal	antibody	overnight	at	RT.	After	6	washes,	the	sections	
were	sequentially	incubated	in	goat	anti-mouse	antibody	coupled	to	Cy5	(1:200;	Jackson	
ImmunoResearch)	for	1	hr.	The	sections	were	mounted	on	gelatin-coated	slides	and	
allowed	to	air	dry	overnight.	To	block	autofluorescence,	the	sections	were	rinsed	in	
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distilled	water,	dehydrated	in	70%	alcohol	for	5	min,	incubated	in	the	autofluorescent	
eliminator	reagent	(Millipore)	for	5	min,	and	immersed	in	three	changes	of	70%	alcohol.	
After	rinsing	in	distilled	water,	the	sections	were	coverslipped	using	polyvinyl	alcohol	
with	1,4-Diazabicyclo[2.2.2]octane	(DABCO)	(Sigma-Aldrich).		
	 Autofluorescence	represents	a	potentially	confounding	factor	using	
immunofluorescence	techniques	in	this	tissue.	However,	we	employed	two	means	to	
effectively	minimize	autofluorescence.	First,	Cy5	is	a	fluorophore	in	the	infrared	range,	
and	the	autofluorescence	from	lipofuscin	is	minimized	within	this	range	of	the	visual	
spectrum.	Second,	use	of	the	autofluorescent	eliminator	reagent	further	blocked	auto-
fluorescence	in	the	tissue	[346].	Immunohistochemical	control	experiments	included	
omission	of	the	primary	antibodies	(which	control	for	the	specificity	of	the	staining	
procedure	and	the	secondary	antibody)	and	inclusion	of	images	taken	in	the	A594	
channel	which	is	between	Cy2	and	Cy5	emission	spectra	(to	control	for	signal	bleed-
through	to	adjacent	channels).	The	control	sections	were	processed	in	a	manner	
identical	to	that	described	above.	All	control	experiments	resulted	in	the	absence	of	
specific	staining.		
	 Brain	sections	were	imaged	using	a	DeltaVision	wide-field	deconvolution	
microscope	equipped	with	a	digital	camera	(CoolSNAP	HQ;	Photometrics),	using	a	1.42-
NA	60X	oil-immersion	objective	lens	and	N=1.515	immersion	oil	(Applied	Precision)	at	
RT.	Images	were	acquired	and	deconvolved	and	tif	images	generated	as	before.	At	least	
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25	images	of	LBs	were	collected	from	each	PD	patient,	and	images	were	analyzed	using	
the	Imaris	software	(Bitplane).	
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CHAPTER	THREE	
SERINE-129	PHOSPHORYLATION	AND	STRAIN	CONFORMATION	DETERMINE	ENDOCYTIC	
VESICLE	RUPTURE	POTENCY	OF	ALPHA-SYNUCLEIN	AMYLOID	ASSEMBLIES	
	
Rationale	
	 As	previously	discussed,	the	prion-like	cell-to-cell	propagation	of	a-syn	
aggregates	underlies	the	spreading	of	PD	pathology	throughout	the	brain	and	results	in	
the	inexorable	progression	of	clinical	symptoms	for	affected	patients.	Understanding	
the	mechanism	by	which	disease-associated	a-syn	aggregates	enter	target	cells	and	
induce	cellular	dysfunction	is	therefore	key	to	understanding	the	progressive	nature	of	
PD	as	a	neurodegenerative	disease,	and	for	developing	effective	disease-modifying	
therapeutic	strategies.	Although	much	has	been	learned	regarding	the	life	cycle	of	a-syn	
aggregates	as	they	accumulate	in	diseased	cells,	traverse	the	extracellular	environment,	
and	come	to	invade	recipient	cells	to	propagate	protein	misfolding	and	neurotoxicity,	
much	remains	to	be	elucidated	about	this	pathological	disease	transmission	[380,	448,	
465,	466,	633-637].		
One	central	aspect	of	a-syn	aggregate-induced	pathology	that	defines	the	prion-
like	designation	of	a-syn	aggregates	is	their	ability	to	serve	as	seeds	and	templates	for	
further	a-syn	misfolding	and	assembly,	and	that	internalization	of	a-syn	seeds	results	in	
the	propagation	and	amplification	of	protein	misfolding	from	diseased	cells	to	their
		
127	
normal	neighbors	when	the	seed	encounters	the	naïve,	expressed	a-syn	in	the	
cytoplasmic	environment	[200,	202,	212,	213,	347,	454].	While	endocytosis	is	the	
predominant	process	for	cellular	uptake	of	a-syn	aggregates	[280,	450,	454],	the	
mechanisms	by	which	misfolded	extracellular	a-syn	aggregates	then	escape	this	
endocytic	compartment	to	access	the	cytosol	and	directly	interact	with	normal	
intracellular	a-syn	remained	poorly	understood	[448,	465].		
By	noting	the	striking	similarity	between	a-syn	infection	and	the	infectious	
mechanism	of	pathogens	like	adenovirus,	Salmonella,	or	Shigella,	our	group	contributed	
an	important	mechanistic	advancement	in	demonstrating	that	a-syn	aggregates	induce	
lysosomal	vesicle	rupture	following	endocytosis,	triggering	cathepsin-mediated	
oxidative	stress	and	inflammasome	activation	[4].	Although	this	finding	provided	the	
mechanism	of	contact	between	extracellular	a-syn	aggregates	internalized	in	the	
endocytic	vesicle	and	soluble	a-syn	monomers	in	the	cytosol,	and	linked	a-syn	spread	
with	known	lysosomal,	autophagic,	oxidative,	and	mitochondrial	stress	in	PD	[326,	346,	
638,	639],	numerous	questions	remain	about	this	damaging	mechanism	of	cellular	
invasion	and	its	contribution	to	PD	pathology.	These	previous	studies	did	not	elucidate	
the	molecular	determinants	of	a-syn-induced	vesicle	rupture	potency	or	pinpoint	the	
specific	aggregate	species	of	a-syn	responsible	for	this	vesicle	damage,	both	of	which	
are	mechanistic	questions	essential	for	a	more	complete	understanding	of	endocytic	
vesicle	rupture	in	the	cell-to-cell	propagation	pathway.		
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With	the	aim	of	determining	specific	modifications	to	a-syn	assemblies	that	
increase	vesicle	rupture	potency,	we	sought	to	examine	the	impact	of	familial	missense	
mutation,	S129	phosphorylation,	and	strain	conformation	on	a-syn-induced	vesicle	
rupture,	hypothesizing	that	these	disease-associated	modifications	will	increase	potency	
of	vesicle	rupture	induced	by	a-syn	assemblies.	To	measure	the	influence	of	these	
modifications	on	the	ability	of	a-syn	to	access	the	cytoplasm	of	cells	following	
endocytosis,	we	employed	the	chGal3	relocalization	assay,	as	previously	described	[4,	
280],	to	demonstrate	enrichment	of	chGal3	at	the	site	of	intracellular	vesicle	rupture	
induced	by	a-syn	aggregates	carrying	each	individual	modification.	This	assay,	as	
described	earlier,	which	we	and	others	have	also	used	to	study	both	cellular	entry	by	
pathogenic	organisms	[576-578,	606]	and	the	LMP	cell	death	pathway	[560,	615,	620],	
exploits	the	ability	of	chGal3	to	bind	target	b-galactosides	present	exclusively	on	the	
outer	leaflet	of	the	plasma	membrane	or	the	topologically-equivalent	inner	leaflet	of	an	
internalized	vesicle.	In	the	context	of	an	intact	vesicular	membrane,	these	b-galactoside	
targets	remain	unavailable	for	binding	and	the	cytoplasmic	localization	of	chGal3	
remains	diffuse.	In	a	situation	of	vesicle	rupture	following	endocytosis	of	an	invading	
pathogen	or	a-syn	fibril,	these	sugars	are	now	exposed	to	the	cytoplasmic	chGal3	
protein,	resulting	in	the	accumulation	of	chGal3	puncta	that	are	visible	by	fluorescent	
microscopy	as	distinct	from	the	diffuse	chGal3	cytoplasmic	expression	(Figure	8).		In	the	
sections	described	below,	we	note	vesicle	rupture	induced	by	fluorescently-labeled	a-
syn	assemblies	carrying	each	modification	as	indicated	by	colocalization	between	chGal3		
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Figure	8.	Schematic	of	chGal3	relocalization	assay.	Galectin	3,	fused	to	an	mCherry-
fluorophore,	recognizes	through	the	CRD	its	target	b-galactoside	sugars	present	on	the	
extracellular	leaflet	of	the	plasma	membrane	or	the	inner	leaflet	of	an	internalized	
vesicle.	In	the	situation	of	an	intact	vesicle	(left),	the	cytoplasmic	localization	of	chGal3	is	
diffuse.	In	the	situation	of	a	ruptured	vesicle	(right),	luminal	b-galactosides	are	now	
exposed	to	the	cytosolic	milieu,	allowing	chGal3	binding	and	the	resulting	localization	of	
chGal3	is	punctate,	with	discrete	puncta	localizing	to	the	site	of	vesicle	rupture.		
	
puncta	and	a-syn	fluorescence.	Upon	quantification	of	vesicle	rupture	induced	by	each	
a-syn	assembly	type,	we	find	that	S129	phosphorylation	and	strain	conformation	dictate	
the	potency	of	a-syn-induced	vesicle	rupture.	These	results	indicate	the	importance	of	
these	a-syn	modifications	for	influencing	a-syn-induced	vesicle	rupture	damage	during	
cell-to-cell	propagation,	and	illuminate	more	details	of	how	endocytic	vesicle	rupture	is	
involved	in	PD	pathology.		
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WT	and	Mutant	Alpha-Synuclein	Assemblies	Exhibit	Similar	Potency	of	
Intracellular	Vesicle	Rupture	
	 We	first	sought	to	determine	if	a-syn	mutations	associated	with	familial	forms	of	
disease	conferred	to	high-molecular	weight	assemblies	of	this	protein	an	increased	
ability	to	induce	vesicle	rupture.	We	hypothesized	that	assemblies	of	mutant	forms	of	a-
syn	associated	with	familial,	autosomal	dominant,	early-onset	PD	would	demonstrate	an	
increased	potency	of	endocytic	vesicle	rupture	compared	to	WT	assemblies,	thereby	
accounting	for	their	increased	pathogenicity.	To	test	this	hypothesis,	we	utilized	
purified,	recombinant	a-syn,	including	WT	a-syn	and	familial	mutants	A53T	[220],	A30P	
[221],	E46K	[222]	and	G51D	[223].	To	assess	the	ability	of	disease-associated	a-syn	
assemblies	to	induce	vesicle	rupture,	we	generated	a-syn	aggregates	by	shaking	
recombinant	a-syn	for	3	days	at	37	°C	under	identical	protein	and	solute	aggregation	
conditions,	followed	by	labeling	of	these	assemblies	with	amine-reactive	fluorophore,	a	
commonly	utilized	technique	to	follow	a-syn	microscopically	[218,	454,	640].	Electron	
microscopic	examination	of	the	reaction	products	revealed	that	following	aggregate	
formation	and	fluorophore	labeling,	fibrillar	species	were	present	in	preparations	of	WT	
and	mutant	a-syn	associated	with	familial	forms	of	disease,	and	a-syn	aggregate	
populations	exhibited	a	similar	size	distribution	(Figure	9).	
Following	the	standardized	in	vitro	aggregation	and	fluorophore	labeling	just	
described,	we	investigated	the	relative	abilities	of	these	a-syn	assemblies	to	induce	
vesicle	rupture	following	endocytosis.	To	test	this	hypothesis,	we	employed	the	chGal3		
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Figure	9.	Structural	characterization	of	WT	and	familial	mutant	a-syn	assemblies.	
Morphologies	of	WT,	E46K,	A53T,	A30P,	and	G51D	a-syn	assemblies.	Representative	
negatively-stained	TEM	of	a-syn	assemblies	before	and	after	Dylight488	labeling.	
Assemblies	were	aggregated	for	3	days	at	37 °C	under	constant	agitation	followed	by	
fluorescent	labeling	with	DyLight488	NHS	ester	fluorophores	as	described	in	the	
Materials	and	Methods.	Images	are	magnified	30,000X,	scale	bar	=	1	µm.	
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relocalization	assay	in	SH-SY5YchGal3	human	neuroblastoma	cells	following	24	hr	
exposure	to	WT,	A53T,	A30P,	E46K,	and	G51D	a-syn	assemblies	in	the	culture	media.	
While	untreated	SH-SY5YchGal3	cells	maintained	a	diffuse	cytosolic	localization	of	the	
chGal3	marker	of	vesicle	rupture	(Figure	10),	cells	that	were	exposed	to	assemblies	
made	of	WT	or	mutant	a-syn	associated	with	familial	forms	of	PD	demonstrated	
pronounced	relocalization	of	chGal3	to	discrete	punctate	or	annular	structures	that	
colocalized	with	a-syn	fluorescence	(Figure	10,	arrowheads).	This	punctate	chGal3	
phenotype	and	colocalization	with	a-syn	is	indicative	of	endocytic	vesicle	rupture	
induced	by	a-syn	assemblies.	Moreover,	consistent	with	the	ability	of	a-syn	to	associate	
with	vesicular	membranes,	Dylight488-labeled	a-syn	aggregates	can	frequently	be	seen	
adopting	a	curved	or	arc-shaped	localization	at	the	periphery	of	chGal3+	ruptured	
vesicles.	Quantification	of	this	vesicle	rupture	by	a-syn	assemblies	revealed	that	WT	and	
mutant	a-syn	associated	with	familial	forms	of	PD	induced	vesicle	rupture	to	the	same	
extent	(2.5-3	fold	increase	relative	to	unexposed	cells,	p<0.0001)	(Figure	11).	These	
results	demonstrate	that	endocytic	vesicle	rupture	induced	by	a-syn	assemblies	is	not	
tightly	dependent	on	mutations	associated	with	early	disease	onset.	
Serine-129	Phosphorylation	Increases	Potency	of	Alpha-Synuclein-Induced		
Vesicle	Rupture	
	 The	experiments	above	suggest	that	individual	familial	disease-associated	
mutations	do	not	substantially	influence	the	ability	of	aggregated	a-syn	to	induce	
vesicle	rupture	following	endocytosis.	However,	a-syn	can	also	be	modified	by	multiple		
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Figure	10.	Vesicle	rupture	induced	by	WT	and	familial	mutant	a-syn	assemblies.	
SY5YchGal3	cells	were	subjected	to	24	hr	exposure	in	the	culture	media	to	200nM	
exogenous	Dylight488-labeled	assemblies	of	WT,	E46K,	A53T,	A30P,	or	G51D	a-syn,	
followed	by	fixation	and	DAPI	staining	in	PBS.	a-Syn-induced	vesicle	rupture	
(arrowheads)	identified	by	chGal3	puncta	colocalizing	with	a-syn.	Left	panel	inset	box	is	
enlarged	and	separated	in	right	panels.	Images	representative	of	at	least	20	images	per	
treatment	in	4	independent	experiments.	Scale	bar=10	µm	(left),	1	µm	(right	3	panels).	
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Figure	11.	WT	and	familial	mutant	a-syn	assemblies	exhibit	similar	potency	of	vesicle	
rupture.	Manual	quantification	of	fold	change	in	mean	number	of	chGal3	puncta	per	cell	
+/-	standard	error	of	the	mean	(SEM)	induced	by	each	treatment	type	relative	to	
unexposed	cells,	with	N>190	cells	per	type	in	total	from	4	independent	experiments.	
ANOVA	p	<0.0001,	*	denotes	significance	(p<0.0001)	compared	to	unexposed	cells	as	
determined	by	Tukey’s	post-hoc	multiple	comparison	test.	
	
covalent	PTMs	and	truncations	that	may	affect	both	aggregation	and	cell-to-cell	
propagation	by	influencing	a-syn	conformation	and	modifying	membrane	association,	
complex	formation,	and	degradation	[259].	Perhaps	the	most	ubiquitous	PTM	is	S129	
phosphorylation	[260,	641],	and	given	the	fact	that	almost	90%	of	a-syn	in	LBs	is	
phosphorylated	at	S129	while	only	5%	of	a-syn	in	normal	brains	carries	this	PTM	[119-
122],	S129	phosphorylation	is	tightly	associated	with	pathological	a-syn	forms.	We	
therefore	utilized	the	chGal3	relocalization	assay	to	investigate	the	ability	of	
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endocytosed	non-phosphorylated	and	phosphorylated	a-syn	to	rupture	vesicular	
membranes	and	to	test	the	hypothesis	that	this	PTM	alone	or	in	combination	with	
disease-associated	familial	missense	mutations	can	differentially	affect	the	potency	of	
a-syn	entry	via	this	disruptive	mechanism.	We	again	generated	a-syn	aggregates	by	
shaking	recombinant	WT,	A30P,	or	A53T	a-syn	in	either	their	non-phosphorylated	or	
pS129	forms	for	3	days	at	37	°C	under	identical	protein	and	solute	aggregation	
conditions,	followed	by	labeling	of	these	assemblies	with	amine-reactive	fluorophore.	
SY5YchGal3	cells	were	then	exposed	in	the	cell	culture	medium	for	24	hr	to	these	
labeled	non-pS129	or	pS129	a-syn	aggregates,	followed	by	an	assessment	of	the	
formation	of	chGal3	puncta	as	a	measurement	of	vesicle	rupture	induction.	Again,	each	
type	of	a-syn	was	able	to	induce	chGal3	relocalization	to	intracellular	punctate	
structures	when	compared	with	the	diffuse	cytoplasmic	localization	in	unexposed	cells	
(Figure	12),	and	the	profound	co-localization	of	a-syn	and	chGal3	puncta	implicates	a-
syn	as	the	causative	agent	of	membrane	permeabilization.	a-Syn	aggregates	again	
adopted	curved	or	arc-shaped	appearances	at	the	periphery	of	chGal3+	ruptured	
vesicles	in	many	instances.		
	 To	quantify	vesicle	rupture	in	a	semi-automated,	unbiased	fashion	and	to	
compare	the	relative	abilities	of	each	a-syn	species	to	cause	this	membrane	
permeabilization,	algorithm-assisted	identification	of	chGal3	puncta	was	employed	in	
unexposed	and	exposed	cells.	This	algorithm	reliably	identified	cytoplasmic	chGal3	
puncta	(Figure	34).	When	the	mean	number	of	chGal3	puncta	per	cell	values	were		
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Figure	12.	Vesicle	rupture	induced	by	WT	and	familial	mutant	a-syn	assemblies	with	or	
without	S129	phosphorylation.	SY5YchGal3	cells	were	subjected	to	24	hr	exposure	in	
the	culture	media	to	200nM	exogenous	Dylight488-labeled	aggregates	of	WT,	A30P,	and	
A53T	a-syn	with	and	without	pS129,	followed	by	fixation	and	DAPI	staining	in	PBS.	a-
Syn-induced	vesicle	rupture	(arrows)	identified	by	chGal3	puncta	colocalizing	with	a-
syn.	Left	panel	inset	box	is	enlarged	and	separated	in	right	panels.	Images	
representative	of	at	least	20	images	per	treatment	in	3	independent	experiments.	Scale	
bar=10	µm	(left),	3	µm	(right	3	panels).	Reproduced	with	permission	from	[280].	
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normalized	so	that	pS129	a-syn	isoforms	were	expressed	as	a	fold	change	relative	to	
their	non-pS129	counterparts	within	the	same	experiments,	all	pS129	a-syn	types	show	
an	approximately	50%	increase	in	the	mean	number	of	chGal3	puncta	per	cell	relative	to	
their	non-pS129	counterparts	(Figure	13).	Although	pS129	A30P	asyn	was	the	only	
pS129	a-syn	aggregate	to	induce	a	statistically	significant	increase	in	chGal3	puncta	per	
cell	relative	to	its	non-pS129	counterpart,	both	pS129	WT	a-syn	and	pS129	A53T	a-syn	
showed	trends	above	their	non-pS129	counterparts,	although	not	reaching	statistical	
significance.	This	finding	suggests	that	S129	phosphorylation	impacts	the	potency	of	
vesicle	rupture	following	endocytosis	regardless	of	the	influence	of	familial	missense	
mutation,	and	thus	significantly	contributes	to	neurotoxicity	in	the	a-syn	cell-to-cell	
propagation	pathway.		
Alpha-Synuclein	Strain	Conformation	Dictates	Vesicle	Rupture	Potency	
	 While	previous	results	suggest	that	S129	phosphorylation	significantly	increases	
the	potency	of	a-syn-induced	vesicle	rupture,	and	that	a-syn	familial	mutation	has	little	
effect	on	membrane	damage	following	endocytosis	even	when	combined	with	S129	
phosphorylation,	the	size	and	structural	heterogeneity	of	the	aggregates	generated	in	
the	manner	described	above	prevents	the	identification	of	specific	high-molecular	
weight	oligomeric	or	fibrillar	species	capable	of	inducing	vesicle	rupture.	To	more	
precisely	define	a-syn	high-molecular	weight	species	responsible	for	endocytic	vesicle	
rupture,	we	utilized	structurally	well-defined	WT	a-syn	assemblies	and	the	chGal3	
relocalization	assay	in	SY5YchGal3	cells	following	24	hr	exposure	to	a-syn	assemblies	in	
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Figure	13.	S129	Phosphorylation	increases	potency	of	a-syn-induced	vesicle	rupture.	
Algorithm-based	quantification	of	fold	change	in	mean	number	of	chGal3	puncta	per	cell	
+/-	SEM	induced	by	each	treatment	type	relative	to	non-pS129	counterpart,	with	N>	200	
cells	per	type	in	total	from	3	independent	experiments.*	denotes	significance	(p<0.05)	
compared	to	non-pS129	counterpart	as	determined	by	unpaired	t	test.	Reproduced	with	
permission	from	[280].		
	
the	culture	media.	Generated	in	vitro	by	varying	the	aggregation	conditions	for	
recombinant	monomeric	a-syn,	the	7-day	aggregation	protocol	results	in	fully	elongated	
a-syn	assemblies	of	varying	strain	conformations	which	are	then	fragmented	by	
sonication,	resulting	in	structurally	well-characterized,	homogenous	assembly	
populations	of	a	smaller	size	distribution	capable	of	cellular	uptake	by	endocytosis	
(Figure	14).	This	preparation	protocol	resembles	that	of	a-syn	PFFs,	whose	fibrillar	
conformation	and	smaller	size	distribution	make	it	the	a-syn	species	most	efficient	for		
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Figure	14.	Structural	characterization	of	WT	α-syn	polymorphs.	Morphologies	of	a-syn	
oligomers	and	fibrillar	assemblies/strains.	Representative	negatively	stained	TEM	of	a-
syn	on-fibrillar	assembly	pathway	oligomers,	fibrils,	ribbons,	fibrils-65,	and	fibrils-91,	
shown	before	and	after	fragmentation	for	all	except	oligomers	which	were	not	
fragmented.	Fibrillar	assemblies	were	fragmented	for	20	min	at	a	constant	temperature	
(20	°C)	in	2	mL	Eppendorf	tubes	in	a	VialTweeter	powered	by	an	ultrasonic	processor	
UIS250v	(250	watts,	24	kHz,	Hielscher	Ultrasonic,	Teltow,	Germany)	set	at	75%	
amplitude,	0.5	s	pulses	every	1	s.	Scale	bar,	200	nm.	
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inducing	seeding,	propagating	from	cell-to-cell,	and	causing	neurotoxicity	[129,	200,	
202-204,	209-213,	219,	389-395,	439,	441,	442].	When	a-syn	monomers	and	on-fibrillar	
assembly	pathway	oligomers	were	assessed	in	the	chGal3	relocalization	assay,	these	a-
syn	forms	were	unable	to	induce	significant	vesicle	rupture.	Cells	exposed	to	these	
forms	of	a-syn	exhibited	a	predominantly	diffuse	phenotype	of	chGal3	fluorescence	
resembling	that	of	untreated	cells	(Figure	15).	
	 a-syn	has	been	previously	shown	to	assemble	into	fibrils	that	exhibit	different	
intrinsic	structures,	surfaces,	seeding	and	persistence	propensities	[305].	These	distinct	
fibrillar	polymorphs	yield	different	synucleinopathies	when	injected	into	recipient	
animals	[218].	We	hypothesized	that	differences	in	the	surface	and	physical	properties	
of	the	distinct	fibrils	will	influence	their	vesicle	rupture	potency.	We	therefore	examined	
the	relative	ability	of	four	different	a-syn	fibrillar	polymorphs,	fluorescently	labeled	and	
fragmented	to	produce	fibrillar	assemblies	with	uniform	size	distribution	(Figure	14),	to	
induce	vesicle	rupture	following	endocytosis.	We	observed	that	a-syn	fibrils,	ribbons,	
fibrils-65,	and	fibrils-91	potently	induced	endocytic	vesicle	rupture	in	target	SY5YchGal3	
cells	as	demonstrated	by	chGal3	relocalization	to	punctate	or	annular	structures	that	
colocalize	with	a-syn	fluorescence	(Figure	15,	arrowheads).	Interestingly,	quantification	
of	chGal3+	ruptured	vesicles	per	cell	revealed	that	a-syn	fibrils,	fibrils-65,	and	fibrils-91	
significantly	induced	vesicle	rupture	compared	to	unexposed	cells	(2.5-4	fold	increase,	
p<0.0001	for	fibrils	and	fibrils-65;	p=0.0047	for	fibrils-91),	whereas	a-syn	ribbons	were	
unable	to	demonstrate	a	similar	significant	induction	of	vesicle	rupture	(p=0.2646).		
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Figure	15.	Vesicle	rupture	induced	by	WT	a-syn	polymorphs.	SY5YchGal3	cells	were	
subjected	to	24	hr	exposure	to	660nM	exogenous	Atto488-labeled	fragmented	
assemblies	of	WT	a-syn	fibrils,	ribbons,	fibrils-65,	and	fibrils-91,	as	well	as	a-syn	
monomers	and	oligomers	in	the	culture	media,	followed	by	fixation	and	DAPI	staining	in	
PBS.	a-Syn-induced	vesicle	rupture	(arrowheads)	identified	by	chGal3	puncta	
colocalizing	with	a-syn.	Left	panel	inset	box	is	enlarged	and	separated	in	right	panels.	
Images	representative	of	at	least	20	images	per	treatment	in	3	independent	
experiments.	Scale	bar=15	µm	(left),	3	µm	(right	3	panels).	
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Furthermore,	a-syn	fibrils	were	shown	to	be	significantly	more	potent	in	their	induction	
of	vesicle	rupture	compared	to	a-syn	monomers,	on-fibrillar	assembly	pathway	
oligomers,	and	ribbons	(p=0.0009	compared	to	monomers,	p<0.0001	compared	to	
oligomers,	p=0.0004	compared	to	ribbons),	and	a-syn	fibrils-65	were	shown	to	be	
significantly	more	potent	compared	to	a-syn	oligomers	(p<0.0001)	(Figure	16).	While	a-
syn	ribbons	failed	to	demonstrate	a	statistically	significant	increase	in	vesicle	rupture	
induction	compared	to	unexposed	cells,	we	did	observe	instances	where	chGal3+	
ruptured	vesicles	colocalized	with	a-syn	ribbons	(Figure	15).	These	data	demonstrate	
that	the	fibrillar	nature	of	a-syn	assemblies	is	an	essential	but	not	sufficient	factor	for	
the	induction	of	endocytic	vesicle	rupture	by	a-syn	assemblies,	and	that	the	intrinsic	
structural	conformation	of	a-syn	fibrillar	polymorphs	dictates	the	potency	with	which	
this	endocytic	vesicle	rupture	occurs.	Furthermore,	given	that	distinct	a-syn	strains	are	
associated	with	different	synucleinopathies,	strain-specific	differences	in	disease	
phenotype	may	arise	from	varying	levels	of	vesicle	rupture	potency	induced	by	each	a-
syn	strain.	Overall,	the	potency	of	a-syn	aggregate-induced	vesicle	rupture	is	
determined	by	a	unique	combination	of	aggregate	size	and	conformation	that	initiates	
membrane	damage	following	endocytosis.		
Significance	
	 The	above	findings	reveal	new	information	regarding	the	ability	of	a-syn	
aggregates	to	induce	vesicle	rupture	during	the	cell-to-cell	propagation	pathway.	
Transmission	of	a-syn	aggregates	from	diseased	cells	and	brain	regions	to	unaffected		
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Figure	16.	a-Syn	strain	conformation	dictates	vesicle	rupture	potency.	Manual	
quantification	of	fold	change	in	mean	number	of	chGal3+	puncta	per	cell	+/-	SEM	
induced	by	each	treatment	type,	with	N>412	cells	per	type	in	total	from	3	independent	
experiments.	ANOVA	p	<0.0001,	*	denotes	significance	compared	to	unexposed	cells	
(p<0.0001	for	fibrils	and	fibrils-65,	p=0.0047	for	fibrils-91),	#	denotes	significance	
compared	to	monomer	(p=0.0009	for	fibrils),	+	denotes	significance	compared	to	
oligomer	(p<0.0001),	and	^	denotes	significance	(p=0.0004)	compared	to	ribbons	as	
determined	by	Tukey’s	post-hoc	multiple	comparison	test.	
	
ones	underlies	the	widespread	pathological	progression	of	PD	and	the	onset	of	
increasingly	severe	symptoms	affecting	an	ever-growing	number	of	brain	functions	[542,	
642,	643].	Additionally,	the	infiltration	of	a-syn	pathology	into	previously	healthy	brain	
regions	may	also	contribute	to	the	failure	of	striatal	dopaminergic	neuronal	grafts	as	a	
potential	therapeutic	replacement	for	degenerating	dopaminergic	innervation	in	PD	
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[426,	644].	Insights	into	the	mechanisms	of	cell-to-cell	propagation	have	enormous	
potential	to	uncover	new	therapeutic	targets	that	could	be	used	to	stem	the	tide	of	a-
syn	deadly	spread	[448,	635,	645].		
	 Prior	to	the	work	of	our	group,	there	was	an	unaddressed	disconnect	between	
the	uptake	of	a-syn	amyloid	aggregates	via	endocytosis	and	the	seeding	of	further	a-syn	
aggregation	in	the	cytosol	[448,	465].	Since	the	endocytic	pathways	results	in	uptake	of	
a-syn	aggregates	sequestered	within	the	vesicular	compartment,	the	process	by	which	
exogenous	a-syn	aggregates	escape	this	compartment	to	contact	cytosolic	a-syn	and	
serve	as	misfolded	templates	was	unclear.	Our	group	was	the	first	to	directly	address	
this	question	of	a-syn	aggregate	vesicular	escape	by	employing	the	chGal3	relocalization	
assay,	a	novel	approach	to	investigating	a-syn	vesicular	membrane	damage	having	
previously	been	used	only	in	the	investigation	of	cellular	invasion	by	infectious	
pathogens	[576-578,	606].	The	application	of	this	assay	from	the	world	of	infectious	
diseases	is	particularly	appropriate	given	the	parallels	between	a-syn	aggregate	cell-to-
cell	propagation	and	the	infectious	mechanism	of	prions	in	TSEs.	Just	as	bacteria	or	
viruses	need	to	escape	the	vesicular	compartment	of	entry	to	propagate	their	infection	
by	hijacking	host	replication	machinery	in	the	cytosol,	so	too	must	an	a-syn	aggregate	
leave	the	endocytic	vesicle	to	contact	its	own	“replication	machinery”,	the	pool	of	naïve	
monomeric	a-syn	expressed	in	the	cytosol.	The	demonstration	that	a-syn	aggregates	
are	capable	of	inducing	lysosomal	rupture	following	endocytosis	explained	the	
disconnect	between	the	method	of	entry	and	the	seeding	of	aggregation	[4],	although	
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many	questions	remained	about	which	a-syn	species	is	most	capable	of	this	entry	
mechanism	and	if	various	modifications	to	a-syn	aggregates	may	modulate	the	potency	
of	rupture.		
	 The	above	results	illuminate	the	a-syn	species	most	capable	of	inducing	
endocytic	vesicle	rupture,	short	fragments	of	a-syn	fibrils,	and	determined	that	S129	
phosphorylation	and	strain	conformation	influence	vesicle	rupture	potency.	Using	
several	variations	of	in	vitro	a-syn	aggregates	prepared	from	recombinant	forms	of	WT	
or	familial	mutant	a-syn,	also	with	S129	phosphorylation	in	some	cases,	we	have	
demonstrated	that	all	forms	of	fibrillar	a-syn	aggregates	were	capable	of	inducing	
chGal3	relocalization	to	the	site	where	they	caused	vesicle	rupture.	Consistent	with	our	
previous	findings	[4],	this	vesicle	rupture	phenomenon	is	not	induced	in	response	to	
treatment	with	a-syn	monomers.	We	extend	the	nuances	of	vesicle	rupture	
determinants	by	showing	specific	a-syn	structures	such	as	on-fibrillar	assembly	pathway	
oligomers	that	also	do	not	induce	vesicle	rupture	in	target	cells.	Despite	the	early-onset	
of	PD	associated	with	familial	missense	mutations	in	a-syn,	aggregates	created	from	a-
syn	monomers	carrying	these	mutations	did	not	exhibit	changes	in	vesicle	rupture	
potency	compared	with	WT	a-syn	aggregates,	but	instead	were	each	capable	of	
endocytic	vesicle	rupture	to	an	equal	extent.	In	contrast,	aggregates	created	from	a-syn	
monomers	phosphorylated	at	S129	were	shown	to	be	more	potent	compared	with	non-
pS129	forms,	implicating	this	PTM	in	increasing	a-syn	aggregate	pathogenicity	in	the	
cell-to-cell	propagation	pathway.	That	pS129	a-syn	aggregates	are	more	potent	
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inducers	of	endocytic	vesicle	rupture	and	the	resulting	neurotoxicity	may	underlie	the	
enrichment	of	this	PTM	in	pathological	a-syn	LB	inclusions.	Finally,	the	conformation	
with	which	a-syn	monomers	pack	into	a	larger	fibrillar	assembly	is	a	critical	modifier	of	
endocytic	vesicle	rupture	potency,	and	highlights	one	mechanism	for	the	variations	in	
disease	phenotype	caused	by	distinct	a-syn	strains.	These	findings	are	significant	for	the	
new	insights	they	bring	into	the	damaging	mechanism	of	cellular	invasion	by	aggregates	
of	a-syn	in	their	cell-to-cell	transmission	life	cycle.		
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CHAPTER	FOUR	
AMYLOID	ASSEMBLIES	OF	TAU	AND	POLYGLUTAMINE-EXPANDED	HUNTINGTIN	INDUCE	
ENDOCYTIC	VESICLE	RUPTURE	
	
Rationale	
	 In	addition	to	its	relevance	for	a-syn	in	synucleinopathies,	the	prion-like	cell-to-
cell	propagation	of	amyloid	proteins	has	also	been	implicated	in	the	pathogenesis	and	
progression	of	numerous	other	neurodegenerative	proteinopathies	such	as	AD,	CTE,	HD,	
and	ALS,	where	it	has	been	blamed,	as	in	PD,	for	contributing	to	worsening	pathology	
and	increasingly	debilitating	symptomatology	[3,	42,	505,	522,	642,	646-650].	Although	
the	monomeric	protein	building	blocks	differ,	there	are	many	similarities	among	the	
higher-order	amyloid	assemblies	of	each	causative	protein,	and	mechanistic	insight	
regarding	the	cell-to-cell	propagation	of	one	amyloid	protein	form	may	be	relevant	for	
understanding	the	pathological	behavior	of	others.	Many	aspects	of	the	intracellular	and	
intercellular	life	cycle	of	amyloid	proteins	are	yet	to	be	fully	understood,	but	the	
prospect	of	translating	insight	from	one	proteinopathy	to	others	holds	enormous	
promise	toward	developing	a	potential	therapeutic	strategy	to	stem	the	progressive	tide	
of	numerous	incurable	neurodegenerative	diseases.		
	 In	the	case	of	tau	in	tauopathies	and	polyglutamine-expanded	huntingtin	in	HD,	
these	proteins	also	perform	prion-like	seeding	and	templating	of	additional	monomeric	
constituents	in	the	cytosol	of	naïve	cells	
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[201,	489-491,	493,	494,	498,	502,	505,	508,	510,	531,	533,	534].	Faithful	templating	of	
misfolded	structure	and	subsequent	intracellular	inclusion	formation	necessitates	direct	
contact	between	exogenous	tau	or	HTTExon1	seeds	and	soluble	cytosolic	monomers,	
and	this	direct	contact	has	been	demonstrated	for	exogenous	and	expressed	versions	of	
tau,	using	FRET,	and	HTTExon1,	using	BiFC	[510,	534].	Endocytosis	is	again	the	
predominant	mechanism	for	cellular	uptake	of	amyloid	assemblies	of	tau	and	HTTExon1	
[498,	506,	531],	although	like	a-syn,	its	mechanism	of	vesicular	escape	remains	an	
enigma	[465,	522,	531].	Because	all	the	aforementioned	fibrillar	a-syn	polymorphs	
exhibited	the	ability	to	induce	vesicle	rupture	in	target	cells,	we	explored	whether	this	
damaging	mechanism	of	cellular	invasion	was	a	specific	consequence	of	a-syn	aggregate	
cellular	entry,	or	if	other	neurodegenerative-related	proteins	could	also	induce	vesicle	
rupture.	Endocytic	vesicle	rupture	induced	by	these	amyloid	aggregates	would	provide	
an	explanation	for	contact	between	extracellular	seeds	and	intracellular	expressed	
monomers,	and	in	a	manner	similar	to	a-syn,	also	contribute	to	degradative,	
mitochondrial,	and	oxidative	stress	in	diseased	cells.		
	 With	the	aim	of	determining	the	conserved	nature	of	amyloid	cellular	invasion	
through	endocytic	vesicle	rupture,	we	sought	to	examine	the	cellular	uptake	of	fibrillar	
assemblies	composed	of	full-length	WT	tau	isoforms	1N4R	and	1N3R	and	HTTExon1-
Q45,	hypothesizing	that	short	fibrillar	forms	of	these	prion-like	amyloid	proteins	would	
also	induce	vesicle	rupture	following	endocytosis.	Investigation	of	this	form	of	cellular	
entry	by	assemblies	of	HTTExon1	is	entirely	novel,	and	while	a	limited	number	of	reports	
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have	examined	the	vesicle	rupture	capability	of	tau	aggregates	[507,	560],	no	other	
study	has	thus	far	utilized	multiple	isoforms	of	WT	full-length	tau	in	a	neuronal	model,	
let	alone	employed	rigorous	assembly	characterization	to	ensure	specificity	of	effect.	To	
measure	vesicle	rupture	induced	by	tau	and	HTTExon1-Q45	amyloid	assemblies,	we	
again	employed	the	chGal3	relocalization	assay	in	SH-SY5Y	human	neuroblastoma	cells	
following	exposure	to	well-defined	exogenous	fluorescently-labeled	assemblies	of	these	
proteins.	In	the	sections	below,	we	note	vesicle	rupture	induced	by	tau	and	HTTExon1-
Q45	as	indicated	by	colocalization	between	chGal3	puncta	and	fluorescently-labeled	
amyloid	assemblies.	Furthermore,	we	find	a	significant	increase	in	vesicle	rupture	
potency	for	assemblies	composed	of	tau	1N4R	compared	with	those	composed	of	tau	
1N3R,	implicating	differences	in	vesicle	rupture	potency	as	contributors	to	specific	
disease	phenotypes	for	distinct	tau	isoform	strains.	These	findings	highlight	the	
conserved	nature	of	endocytic	vesicle	rupture	in	the	cell-to-cell	propagation	pathway	of	
amyloid	proteins	composed	of	multiple	neurodegenerative	disease-related	proteins.		
Multiple	Isoforms	of	Wild-Type	Full-Length	Tau	Induce	Endocytic	Vesicle	Rupture	
	 In	the	diverse	set	of	diseases	characterized	by	tau	inclusions,	some	diseases	like	
AD,	CTE,	and	TD	are	characterized	by	inclusions	of	both	3R	and	4R	tau	isoforms,	whereas	
inclusions	of	3R	isoforms	predominate	in	PiD	and	4R	isoforms	predominate	in	PSP,	CBD,	
and	AGD	[488].	Because	various	isoform	compositions	can	result	in	unique	strain	
conformations	that	induce	distinct	disease	phenotypes	upon	cell-to-cell	propagation,	we	
hypothesized	that	assemblies	of	tau1N4R	and	tau1N3R	would	both	induce	vesicle	
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rupture,	but	that	differences	in	the	potency	of	vesicle	rupture	induction	may	underlie	
strain-specific	disease	phenotypes	as	they	do	for	a-syn	strains	in	PD.	To	test	this	
hypothesis,	we	generated	in	vitro	fibrillar	assemblies	of	full-length	WT	tau	1N4R	and	tau	
1N3R	from	recombinant	purified	protein	in	a	fashion	similar	to	a-syn	fibrillar	polymorph	
production,	including	prolonged	assembly	reactions,	fluorophore	labeling,	and	
fragmentation	by	sonication	to	produce	homogenous	preparations	of	tau	fibrils	of	a	
smaller	size	distribution	to	be	taken	up	by	endocytosis	in	target	cells.	This	species	of	tau	
assembly	was	chosen	not	only	because	of	the	efficacy	of	this	amyloid	assembly	form	for	
a-syn-induced	vesicle	rupture,	but	also	to	allow	a	direct	comparison	with	vesicle	rupture	
induced	by	a-syn	assemblies	of	a	similar	size	distribution,	so	that	only	protein	
composition	and	conformation	differ.	TEM	analysis	revealed	that	the	assemblies	were	of	
fibrillar	nature	following	aggregation,	and	maintained	this	fibrillar	architecture	following	
fragmentation	despite	the	decrease	in	fibril	size	(Figure	17).	SY5YchGal3cells	were	then	
exposed	for	24	hr	to	these	fibrillar	tau	assemblies,	followed	by	an	assessment	of	chGal3	
relocalization	to	indicate	endocytic	vesicle	rupture	as	for	asyn	assemblies.	We	noted	
chGal3	relocalization	to	a	punctate	phenotype	upon	exposure	of	cells	to	fibrillar	
assemblies	of	full-length	WT	tau	1N4R	and	1N3R	isoforms,	whereas	chGal3	remained	
diffuse	in	unexposed	cells	(Figure	18).	We	observed	robust	colocalization	between	
chGal3+	ruptured	vesicles	and	both	isoforms	of	fluorescently-labeled	fibrillar	tau	(Figure	
18,	arrowheads).	This	observation	strongly	suggests	that	fibrils	composed	of	multiple	
isoforms	of	WT	full-length	tau	cause	vesicular	membrane	damage	upon	cellular	entry.		
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Figure	17.	Structural	characterization	of	WT	full-length	tau	polymorphs.	Morphologies	
of	tau	1N4R	and	tau	1N3R	assemblies/strains.	Representative	negatively	stained	TEM	of	
tau	1N4R	and	tau	1N3R	polymorphs,	shown	before	and	after	fragmentation.	Fibrillar	
assemblies	were	fragmented	for	20	min	at	a	constant	temperature	(20	°C)	in	2	mL	
Eppendorf	tubes	in	a	VialTweeter	powered	by	an	ultrasonic	processor	UIS250v	(250	
watts,	24	kHz,	Hielscher	Ultrasonic,	Teltow,	Germany)	set	at	75%	amplitude,	0.5	s	pulses	
every	1	s.	Scale	bar,	200	nm.	
	
Quantification	of	punctate	chGal3	clearly	indicates	that	both	isoforms	of	fibrillar	full-
length	WT	tau	rupture	endocytic	vesicles	to	a	significant	extent	compared	to	unexposed	
cells,	with	a	further	significant	increase	in	rupture	potency	induced	by	fibrillar	tau	1N4R		
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Figure	18.	Vesicle	rupture	induced	by	multiple	isoforms	of	wild-type	full-length	tau.	
SY5YchGal3	cells	were	subjected	to	24	hr	exposure	to	660nM	exogenous	Atto488-
labeled	fragmented	assemblies	of	tau	1N3R	or	tau	1N4R	in	the	culture	media,	followed	
by	fixation	and	DAPI	staining	in	PBS.	Tau-induced	vesicle	rupture	(arrowheads)	identified	
by	chGal3	puncta	colocalizing	with	tau.	Left	panel	inset	box	is	enlarged	and	separated	in	
right	panels.	Images	representative	of	at	least	20	images	per	treatment	in	3	
independent	experiments.	Scale	bar=10	µm	(left),	1	µm	(right	3	panels).	
	
compared	to	1N3R	(Figure	19).	These	findings	provide	the	first	demonstration	that	fibrils	
composed	of	multiple	full-length	wild-type	tau	isoforms	1N4R	and	1N3R	are	capable	of	
inducing	vesicle	rupture	following	endocytosis,	and	like	a-syn,	that	the	intrinsic	isoform	
composition	and	structural	conformation	of	tau	fibrillar	polymorphs	dictates	endocytic	
vesicle	rupture	potency.	We	have	again	implicated	variations	in	vesicle	rupture	potency		
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Figure	19.	Tau	isoform	composition	and	strain	conformation	dictate	vesicle	rupture	
potency.	Manual	quantification	of	fold	change	in	mean	number	of	chGal3+	puncta	per	
cell	+/-	SEM	induced	by	assemblies	of	tau	isoforms,	with	N>135	cells	per	type	in	total	
from	3	independent	experiments.	ANOVA	p	<0.0001,	*	denotes	significance	compared	
to	unexposed	cells	(p<0.0001)	and	#	denotes	significance	compared	to	tau	1N3R	
(p<0.0001)	as	determined	by	Tukey’s	post-hoc	multiple	comparison	test.	
	
in	strain-specific	differences	in	pathology.	This	observation	underscores	the	importance	
of	this	conserved	endocytic	vesicle	rupture	event	as	essential	in	the	cell-to-cell	
propagation	life	cycle	of	tau	amyloid	assemblies	in	diverse	tauopathies.	
Assemblies	of	Polyglutamine-Expanded	Huntingtin	Induce	Vesicle	Rupture	
	 CAG	repeat	expansion	in	HTTExon1	yields	a	polyglutamine-rich	huntingtin	
protein	with	an	increased	propensity	to	spontaneously	aggregate	into	a	fibrillar	amyloid	
morphology	when	the	polyglutamine	tract	expands	to	37	glutamine	residues	or	beyond	
(HTTExon1-Q³37)	[524],	causing	HD	in	patients	with	this	dominantly-inherited	genetic	
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mutation	[523].	Because	HTTExon1	amyloid	assemblies	also	propagate	from	cell-to-cell	
in	a	prion-like	manner	and	serve	as	seeds	and	templates	for	further	aggregation,	we	
hypothesized	that	assemblies	of	HTTExon1	containing	a	polyglutamine	tract	of	
pathologic	length	(Q45)	would	induce	vesicle	rupture	following	endocytosis.	To	test	this	
hypothesis,	we	again	generated	in	vitro	fibrillar	assemblies	of	HTTExon1-Q45	from		
recombinant	purified	protein,	just	as	for	a-syn	and	tau	fibrillar	polymorphs,	using	
prolonged	assembly	reactions	combined	with	subsequent	fragmentation	to	produce	
homogenous	small	fibrillar	preparations	of	HTTExon1	fibrils	of	an	equivalent	size	
distribution	to	fragmented	polymorphs	of	a-syn	and	tau.	Because	of	this	preparation	
scheme,	the	size	distribution	of	HTTExon1	assemblies	is	standardized	with	that	of	a-syn	
and	tau	fibrillar	polymorphs,	allowing	comparisons	of	vesicle	rupture	ability	based	only	
on	protein	composition	and	conformation	in	the	preparation	form	most	potent	for	
inducing	vesicle	rupture,	short	amyloid	fibrils.	TEM	analysis	revealed	that	HTTExon1-Q45	
assemblies	are	composed	of	amyloid	fibrils	just	as	assemblies	of	a-syn	and	tau,	and	
short	fibrillar	preparations	are	induced	by	sonication	(Figure	20).	As	for	other	amyloid	
preparations,	we	also	utilized	amine-reactive	fluorophore	labeling	of	HTTExon1	fibrils	
for	fluorescent	microscopic	detection,	but	despite	the	presence	of	four	reactive	primary	
amine	groups	within	the	HTTExon1	amino	acid	sequence,	we	were	unable	to	achieve	
sufficient	fluorescent	labeling	perhaps	due	to	the	limited	accessibility	of	these	amine	
groups	within	the	fibrillar	aggregate.		
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Figure	20.	Structural	characterization	of	HTTExon1-Q45	polymorph.	Morphology	of	
HTTExon1-Q45	assemblies/strain.	Representative	negatively	stained	TEM	of	HTTExon1-
Q45	polymorph,	shown	before	and	after	fragmentation.	Fibrillar	assemblies	were	
fragmented	for	20	min	at	a	constant	temperature	(20	°C)	in	2	mL	Eppendorf	tubes	in	a	
VialTweeter	powered	by	an	ultrasonic	processor	UIS250v	(250	watts,	24	kHz,	Hielscher	
Ultrasonic,	Teltow,	Germany)	set	at	75%	amplitude,	0.5	s	pulses	every	1	s.	Scale	bar,	200	
nm.	
	
	 SY5YchGal3cells	were	exposed	for	24	hr	to	these	fibrillar	HTTExon1-Q45	
assemblies,	and	chGal3	relocalization	was	assessed	as	an	indicator	of	endocytic	vesicle	
rupture	in	target	cells	following	their	uptake	of	amyloid	fibrils.	We	noted	chGal3	
relocalization	to	a	punctate	phenotype	upon	cellular	exposure	to	HTTExon1-Q45	fibrillar	
assemblies,	whereas	chGal3	again	remained	diffuse	in	unexposed	cells	(Figure	21).	This	
observation	strongly	implies	that	amyloid	fibrils	composed	of	HTTExon1	with	a	
pathologic	stretch	of	polyglutamine	residues	also	cause	endocytic	vesicular	rupture	just	
like	amyloid	fibrils	of	asyn	and	tau.	Due	to	the	insufficient	labeling	of	fibrillar	HTTExon1-
Q45,	we	were	unable	to	visualize	colocalization	of	assemblies	with	chGal3+	ruptured		
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Figure	21.	Vesicle	rupture	induced	by	HTTExon1-Q45	polymorph.	SY5YchGal3	cells	
were	subjected	to	24	hr	exposure	to	660nM	exogenous	Atto488-labeled	fragmented	
assemblies	of	HTTExon1-Q45	in	the	culture	media,	followed	by	fixation	and	DAPI	
staining	in	PBS.	HTTExon1-Q45-induced	vesicle	rupture	identified	by	chGal3	puncta.	Left	
panel	inset	box	is	enlarged	and	separated	in	right	panel.	Images	representative	of	at	
least	20	images	per	treatment	in	5	independent	experiments.	Scale	bar=15	µm	(left),	3	
µm	(right).	
	
vesicles.	However,	quantification	of	punctate	chGal3	clearly	indicates	that	fibrillar	
HTTExon1-Q45	induces	significant	vesicle	rupture	as	compared	to	unexposed	cells	
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(Figure	22).	These	findings	provide	the	first	demonstration	that	fibrils	composed	of	
HTTExon1	with	pathologic	polyglutamine	repeats	are	capable	of	inducing	vesicle	rupture	
following	endocytosis	as	a	means	of	propagating	their	misfolded	amyloid	structure	from	
the	extracellular	to	the	intracellular	environment.	This	observation	is	of	critical	
importance	for	understanding	HD	progression,	and	the	conserved	nature	of	vesicle	
rupture	induced	following	endocytosis	of	a-syn,	tau,	and	HTTExon1	amyloid	assemblies	
raises	the	possibility	that	therapeutic	strategies	targeting	this	pathologic	cellular	entry	
mechanism	may	be	applied	to	reverse	or	prevent	numerous	proteinopathies.		
Significance	
	 The	above	results	have	uncovered	a	conserved	role	for	endocytic	vesicle	rupture	
as	a	mechanism	of	cellular	invasion	by	amyloid	assemblies	of	multiple	
neurodegenerative	disease-related	proteins.	Just	as	for	a-syn	in	PD,	amyloid	assemblies	
of	tau	and	HTTExon1	are	known	to	propagate	from	one	cell	to	another,	templating	their	
misfolded	conformation	onto	soluble	constituent	monomers	and	inducing	neurotoxicity	
through	a	variety	of	mechanisms	in	the	cells	encountered	along	the	transmission	
pathway	[465,	488,	522].	Much	remains	to	be	determined	regarding	the	mechanisms	
employed	by	amyloid	protein	assemblies	during	this	pathological	progression,	especially	
to	understand	if	any	mechanisms	are	shared	between	these	prion-like	amyloid	proteins	
or	if	each	transmission	process	is	as	distinct	as	the	respective	etiological	protein.	Given	
that	the	propagation	of	amyloid	proteins	underlies	pathological	disease	progression,		
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Figure	22.	HTTExon1-Q45	assemblies	induce	significant	increase	in	vesicle	rupture	
compared	to	unexposed	cells.	Manual	quantification	of	fold	change	in	mean	number	of	
chGal3+	puncta	per	cell	+/-	SEM	induced	by	assemblies	of	HTTExon1-Q45,	with	N>441	
cells	per	type	in	total	from	5	independent	experiments.	*	denotes	significance	
compared	to	unexposed	cells	(p<0.0001)	by	unpaired	student’s	t	test.	
	
insights	into	their	intracellular	and	intercellular	life	cycle	are	incredibly	important	for	a	
more	complete	picture	of	disease	pathogenesis.		
	 Critically,	the	incongruity	between	the	cellular	uptake	of	exogenous	aggregates	
into	the	endocytic	vesicle	and	the	seeding	of	further	aggregation	in	the	cytosol	is	shared	
among	the	propagation	pathways	of	a-syn,	tau,	and	HTTExon1	amyloid	aggregates	[448,	
465,	522,	531].	Given	the	common	ability	of	a-syn	aggregates	to	rupture	endocytic	
vesicles	as	a	means	of	escape,	and	the	utility	of	the	chGal3	relocalization	assay	to	
provide	a	reliable	indication	of	this	vesicular	damage	[4,	280,	619,	620],	we	examined	
the	vesicle	rupture	capability	of	tau	and	HTTExon1	amyloid	assemblies.	This	process	of	
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cellular	invasion	has	never	been	investigated	for	HTTExon1	amyloids,	and	even	for	
amyloid	aggregates	of	tau,	the	studies	examining	its	vesicle	rupture	capability	have	
significant	limitations	to	the	scope	of	their	conclusions.	One	study	found	an	ability	of	
P301L	mutant	tau	aggregates	to	induce	vesicle	rupture	in	rat	primary	neurons	
expressing	chGal3,	although	the	assembly	form	of	exogenous	tau	was	poorly	
characterized	since	fluorescently-labeled	whole	cell	lysates	from	HEK293	cells	
expressing	P301L	mutant	tau	were	used	as	a	treatment	[507].	Another	study	utilized	
full-length	WT	2N4R	tau	assemblies	generated	in	vitro	from	recombinant	purified	
protein,	although	these	preparations	were	heterogeneous	and	of	high	molecular	weight	
given	that	fragmentation	was	not	performed,	observing	that	these	preparations	induce	
vesicle	rupture	as	seen	by	chGal3	relocalization	in	a	non-neuronal	HeLa	cell	model	[560].	
Both	studies	are	limited	in	that	the	exogenous	tau	assemblies	used	to	demonstrate	
vesicle	rupture	induction	are	not	characterized	to	an	extent	that	allows	determination	
of	a	specific	effect	of	distinct	tau	assembly	species.	We	employed	in	vitro	generation	of	
tau	assemblies	composed	of	multiple	isoforms	of	WT	full-length	tau,	followed	by	
sonication	to	homogenize	the	assembly	population	size	distribution	by	fragmenting	
larger	fibrillar	assemblies	into	smaller	amyloid	fibrils	more	readily	taken	up	through	
endocytosis	into	target	cells.	The	structurally	well-defined	nature	of	these	WT	full-length	
tau	assemblies	guarantees	the	specific	measurement	of	vesicle	rupture	induced	by	short	
fibrillar	tau	assemblies.	
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	 In	demonstrating	that	fibrillar	assemblies	of	tau	1N4R,	tau	1N3R,	and	HTTExon1-
Q45	rupture	endocytic	vesicles	following	cellular	uptake,	we	have	provided	an	
explanation	for	the	invasion	mechanism	by	which	exogenous	fibrils	contact	intracellular	
monomers.	The	shared	ability	of	a-syn,	tau,	and	HTTExon1	assemblies	to	induce	
endocytic	vesicle	rupture	implies	that	this	pathological	activity	is	a	result	of	the	fibrillar	
amyloid	architecture	common	to	many	aggregation-prone	proteins.	Endocytic	vesicle	
rupture	is	a	shared	mechanism	of	cellular	invasion	by	these	diverse	prion-like	amyloid	
proteins,	despite	differences	in	conformations	and	compositions,	because	of	the	short	
fibrillar	amyloid	structure	standardized	among	a-syn,	tau,	and	HTTExon1	preparations,	
enabling	endocytic	uptake,	vesicle	rupture,	seeding,	and	cell-to-cell	propagation.	We	
have	further	demonstrated	that	assemblies	of	tau	isoform	1N4R	are	significantly	more	
potent	in	their	induction	of	vesicle	rupture	compared	with	assemblies	of	tau	isoform	
1N3R,	indicating	that	unique	combinations	of	tau	composition	and	conformation	dictate	
vesicle	rupture	potency	just	as	for	a-syn-induced	rupture.	These	variations	in	vesicle	
rupture	potency	between	different	tau	isoform	strains	may	contribute	to	the	variety	of	
disease	phenotypes	displayed	by	tauopathies.	These	findings	are	significant	because	of	
the	determination	that	endocytic	vesicle	rupture,	conserved	for	fibrillar	assemblies	of	
amyloid	proteins	in	multiple	neurodegenerative	diseases,	is	a	key	mechanism	during	the	
cellular	invasion	phase	of	the	cell-to-cell	propagation	life	cycle.
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CHAPTER	FIVE	
ENDOCYTIC	VESICLE	RUPTURE	CONTRIBUTES	TO	INCLUSION	FORMATION	AND	CELL-TO-
CELL	PROPAGATION	IN	PARKINSON’S	DISEASE	PATHOLOGY	
	
Rationale	
	 With	the	clear	understanding	that	endocytic	vesicle	rupture	is	a	conserved	
mechanism	of	cellular	invasion	by	fibrillar	assemblies	of	amyloid	proteins,	we	next	
sought	to	determine	the	relevance	of	this	damaging	mechanism	of	cellular	invasion	in	
PD,	investigating	the	contribution	of	a-syn-mediated	endocytic	vesicle	rupture	and	its	
consequences	to	established	aspects	of	PD	pathology	and	propagation.	Despite	the	
highly	reproducible	nature	of	our	findings	demonstrating	the	induction	of	vesicle	
rupture	by	multiple	fibrillar	amyloid	assemblies	in	recipient	SY5YchGal3	cells,	this	
immortalized	human	neuroblastoma	cell	line	is	not	the	model	system	most	
representative	of	neuronal	physiology,	and	thus	conclusions	drawn	from	the	use	of	this	
cell	line	leave	doubt	as	to	the	occurrence	of	a-syn	mediated	endocytic	vesicle	rupture	in	
authentic	disease.	SH-SY5Y	cells,	widely	used	as	a	neuron-like	cell	line,	are	comprised	of	
a	mixed	phenotypic	culture	derived	from	a	metastatic	bone	tumor	biopsy,	and	despite	
the	expression	of	tyrosine	hydroxylase	(TH)	characteristic	of	dopaminergic	neurons,	
numerous	caveats	exist	when	using	cells	derived	from	malignant	tumors	[651].	
Alternatively,	human	midbrain	dopaminergic	neurons	differentiated	from	hiPSCs	are	
post-mitotic	and	display	typical	physiological	characteristics	and	responses	of	
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dopaminergic	neurons.	These	cells	are	>90%	neurons	(MAP2+/nestin-)	of	a	
dopaminergic	identity	(>85%	FoxA2+,	>75%	TH+),	and	exhibit	spontaneous	and	evoked	
action	potentials	and	excitatory	post-synaptic	currents.	As	such,	hiPSC-derived	
dopaminergic	neurons	expressing	the	chGal3	marker	of	vesicle	damage	represent	a	
model	system	representative	of	human	PD	wherein	to	examine	the	process	of	a-syn-
mediated	endocytic	vesicle	rupture.	With	the	aim	of	determining	the	occurrence	of	
endocytic	vesicle	rupture	in	a	more	physiologically-relevant	model	system,	we	sought	to	
examine	chGal3	relocalization	in	hiPSC-derived	dopaminergic	neurons	following	a-syn	
aggregate	exposure,	hypothesizing	that	a-syn	assemblies	would	also	induce	endocytic	
vesicle	rupture	in	this	model	system.		
	 Among	the	known	consequences	of	endocytic	vesicle	rupture	are	the	production	
of	damaged	vesicular	debris	needing	to	be	cleared	through	autophagic	degradation	and	
the	dysfunctional	lysosomal	degradation	resulting	from	LMP.	Given	that	a-syn	
aggregates	invade	target	cells	that	may	already	be	experiencing	some	degree	of	
degradative	dysfunction	for	a	variety	of	reasons	in	PD	[340-343],	the	effect	of	endocytic	
vesicle	rupture	on	normal	intracellular	vesicle	trafficking	and	degradation	processes	is	
relevant	for	disease	pathogenesis.	Vesicles	damaged	by	pathogen	invasion	are	targeted	
for	autophagic	degradation	[560,	570,	576,	579,	597-600,	602,	603,	615],	significantly	
increasing	the	burden	of	autophagic	substrates	in	need	of	clearance.	Furthermore,	LMP	
itself	directly	depletes	the	pool	of	lysosomes	competent	to	ultimately	perform	the	
clearance	of	autophagic	substrates,	resulting	in	accumulation	of	autophagosomes	and	
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eventual	neuronal	degeneration	because	this	degradative	dysfunction	[130,	615].	This	
dual	effect	whereby	the	mechanism	of	cellular	invasion	both	increases	the	substrate	
burden	for	degradative	processes	while	at	the	same	time	inducing	degradative	
dysfunction	is	expected	to	be	at	work	with	a-syn	cellular	invasion,	and	represents	a	
significant	challenge	to	functional	proteostasis.	With	the	aim	of	defining	the	impact	of	
a-syn-mediated	endocytic	vesicle	rupture	on	normal	vesicular	trafficking	and	
degradation,	we	sought	to	examine	the	phenotype	of	ruptured	vesicles	as	well	as	their	
recruitment	to	the	ALP,	hypothesizing	that	ruptured	lysosomes	and	their	a-syn	cargo	
become	targets	for	autophagic	degradation.	
	 As	the	proposed	mechanism	for	the	vesicular	escape	of	exogenous	fibrillar	
amyloid	seeds	to	interact	with	cytosolic	expressed	monomeric	constituents	and	
template	further	aggregation,	the	relationship	between	amyloid-induced	endocytic	
vesicle	rupture	and	further	seeding	and	inclusion	formation	needs	more	clarity.	
Interestingly,	the	very	same	small	fragmented	amyloid	fibrils	that	are	most	potent	for	
inducing	endocytic	vesicle	rupture	in	our	studies	are	known	to	also	be	most	potent	for	
seeding	and	templating	of	further	aggregation	[209-211].	Theories	on	the	formation	of	
cytosolic	proteinaceous	inclusions	such	as	LBs	center	around	the	idea	of	aggresomes	
representing	a	protective	response	of	cells	overwhelmed	by	the	burden	of	misfolded	
proteins	and	their	inability	to	effectively	degrade	them	[118,	124].	Condensing	
misfolded	protein	aggregates	into	a	larger	inclusion	may	be	a	cellular	effort	to	increase	
efficiency	of	autophagic	clearance,	although	failure	of	autophagy	results	in	the	recycling	
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locus	becoming	a	junkyard	instead	[118].	Consistent	with	this	idea,	LBs	are	known	to	
contain	a-syn-associated	vesicles	as	well	as	dysfunctional	lysosomes	and	
autophagosomes	[128,	131,	134].	While	the	merging	of	misfolded	a-syn	aggregates	and	
associated	degradative	vesicles	may	be	originally	intended	to	facilitate	degradation,	
dysfunction	in	degradative	processes	instead	results	in	agglomerations	becoming	
pathological	LB	inclusions.	With	the	aim	of	determining	the	influence	of	a-syn-induced	
endocytic	vesicle	rupture	on	pathologic	inclusion	formation,	we	sought	to	examine	a-
syn-containing	LB	inclusions	in	cultured	cells	and	in	PD	brain,	hypothesizing	that	Gal3	
localization	would	indicate	involvement	of	endocytic	vesicle	rupture	in	the	formation	of	
these	intracellular	proteinaceous	inclusions.	
	 Finally,	because	the	same	cellular	stressors	induced	by	endocytic	vesicle	rupture,	
such	as	ALP	dysfunction	and	oxidative	stress,	are	also	well-known	causes	of	a-syn	
release	and	intercellular	propagation,	the	influence	of	endocytic	vesicle	rupture	on	a-
syn	cell-to-cell	spreading	is	an	important	unanswered	question.	Diverse	cellular	
stressors	prompt	a-syn	release	from	cells	affected	by	its	aggregation	and	accumulation	
[294,	468-471,	473,	479,	484,	485],	raising	the	possibility	that	consequences	of	the	
endocytic	vesicle	rupture	entry	mechanism	may	contribute	to	mechanisms	of	release.	
Many	of	the	non-classical	a-syn	release	mechanisms	involve	an	association	between	a-
syn	and	vesicles;	within	intracellular	vesicles	or	autophagosomes	that	fuse	with	the	
plasma	membrane	to	release	their	contents	[468-471],	on	the	internal	or	external	leaflet	
of	exosomes	[473,	478,	479],	or	within	lysosomes	that	traffic	to	neighboring	cells	inside	
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TNTs	[445].	Since	Gal3	is	also	released	from	cells	through	a	non-classical	mechanism	
[591-593],	some	a-syn	release	could	be	in	association	with	Gal3+	ruptured	vesicles	it	
induces	during	its	cellular	invasion.	With	the	aim	of	elucidating	the	contribution	of	
endocytic	vesicle	rupture	to	a-syn	cell-to-cell	propagation,	we	sought	to	examine	the	
extracellular	localization	and	intercellular	movement	of	a-syn	aggregates	following	
invasion	via	rupture,	hypothesizing	that	the	damaging	consequences	of	endocytic	
vesicle	rupture	would	promote	pathologic	a-syn	release	in	association	with	ruptured	
vesicles.		
	 In	the	sections	below,	we	utilize	a	combination	of	approaches	to	demonstrate	
that	a-syn-induced	ruptured	lysosomes	are	targeted	for	autophagic	degradation,	that	
merging	of	ruptured	vesicles	containing	a-syn	promotes	LB	inclusion	formation,	and	
that	ruptured	vesicles	may	act	as	both	a	stimulus	and	a	vector	for	a-syn	cell-to-cell	
propagation.	These	findings	illustrate	the	impact	of	endocytic	vesicle	rupture	in	PD	
pathology	and	raise	new	possibilities	for	therapeutic	targets	based	on	its	involvement	
and	consequences.	
Alpha-Synuclein	Induces	Vesicle	Rupture	in	Human	Dopaminergic	Neurons	Derived	
From	Induced	Pluripotent	Stem	Cells	
	 Given	the	consistency	of	our	observation	that	fibrillar	assemblies	of	amyloid	
proteins	induce	endocytic	vesicle	rupture	in	recipient	cells,	we	sought	to	extend	our	
findings	by	performing	the	chGal3	relocalization	assay	in	an	authentic	human	
dopaminergic	neuron	to	determine	the	occurrence	of	endocytic	vesicle	rupture	induced	
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by	a-syn	following	endocytosis	in	this	model.	We	hypothesized	that	a-syn	induced	
vesicle	rupture	would	be	a	conserved	phenotype	in	multiple	cellular	model	systems.	To	
confirm	our	observations	in	a	setting	more	representative	of	that	in	human	PD,	we	
utilized	hiPSC-derived	dopaminergic	neurons	as	a	model	of	neuronal	physiology.	hiPSC-
derived	dopaminergic	neurons	stably	overexpressed	the	chGal3	marker	of	vesicle	
rupture	using	lentiviral	transduction,	and	we	exposed	these	cells	for	48hr	to	fragmented	
WT	a-syn	PFFs.	We	observed	chGal3	relocalization	to	distinct	puncta,	and	many	chGal3+	
ruptured	vesicles	colocalized	with	a-syn	fibrils	fluorescence	(Figure	23).	This	observation	
demonstrates	that	a-syn	assemblies	induce	endocytic	vesicle	rupture	in	hiPSC-derived	
dopaminergic	neurons,	and	validates	our	earlier	results	obtained	in	the	SY5YchGal3	
model	of	vesicle	rupture.	
Lysosomes	Ruptured	by	Alpha-Synuclein	are	Targeted	for	Autophagic	Degradation	
	 It	is	known	that	recognition	of	ruptured	vesicles	by	cytosolic	galectins	targets	
these	vesicles	for	autophagic	degradation	[560,	570,	576,	579,	597-600,	602,	603,	615].	
However,	it	remains	unclear	to	what	degree	a-syn	can	prevent	these	ruptured	vesicles	
from	re-establishing	a	low	pH	during	autophagic	degradation,	and	how	lysosomal	
rupture	by	a-syn	affects	normal	vesicular	trafficking	in	the	ALP.	We	hypothesized	that	
ruptured	lysosomes	would	also	become	autophagic	substrates	just	like	their	aggregated	
a-syn	cargo.	To	more	deeply	understand	the	effect	of	lysosomal	rupture	on	vesicular	
trafficking	and	degradation	pathways,	we	first	sought	to	determine	the	degree	to	which	
ruptured	lysosomes	become	incorporated	into	autophagosomes.	In	agreement	with	our		
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Figure	23.	a-Syn	induces	vesicle	rupture	in	human	dopaminergic	neurons	derived	from	
induced	pluripotent	stem	cells.	hiPSC-derived	chGal3	dopaminergic	neurons	were	
subjected	to	48	hr	treatment	with	200	nM	exogenous	Dylight488-labeled	WT	a-syn	PFFs	
in	the	culture	media,	followed	by	live	cell	imaging	to	identify	vesicle	rupture.	Treatment	
with	a-syn	induced	vesicle	rupture	and	subsequent	chGal3	relocalization	to	discrete	
puncta	that	colocalized	with	a-syn	fluorescence	(arrowheads).	Inset	box	in	top	left	
image	is	enlarged	and	separated	in	other	panels	into	Overlay,	a-syn	fluorescence,	or	
chGal3	fluorescence.	Images	are	representative	of	at	least	10	images	from	3	
independent	experiments.	Scale	bar	=	10	µm	for	left	panel	and	3	µm	for	inset-enlarged	
panels.	
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previously	published	data	[4],	we	observed	that	chGal3+	ruptured	vesicles	containing	a-
syn	fibrils	colocalized	with	the	lysosomal	marker	lysosome-associated	membrane	
protein	1	(LAMP1)	upon	immunofluorescent	labeling	(Figure	24A).	We	generated	SH-
SY5Y	cells	expressing	both	the	chGal3	marker	of	ruptured	vesicles	and	a	YFP-LC3	
construct	to	identify	autophagosomes.	Upon	exposure	of	these	cells	to	Dylight650-
labeled	WT	a-syn	PFFs	for	24	hr	in	the	culture	media,	we	observed	that	many	chGal3+	
ruptured	vesicles	containing	a-syn	colocalized	with	YFP-LC3+	autophagosomes,	
although	a-syn-containing	ruptured	vesicles	and	autophagosomes	existed	
independently	as	well	(Figure	24B).	While	these	findings	indicate	that	a-syn-induced	
ruptured	lysosomes	become	targeted	to	autophagic	degradation,	they	do	not	allow	a	
real-time	monitoring	of	vesicular	pH	and	membrane	integrity	throughout	the	duration	
of	this	pathway.		
	 To	follow	the	fate	of	vesicles	ruptured	by	a-syn	in	real-time,	we	performed	live	
cell	imaging	using	the	LysoTracker	Deep	Red	dye	to	label	and	track	acidic	organelles	in	
live	cells.	This	fluorescent	acidotropic	probe	selectively	accumulates	in	cellular	
compartments	with	low	internal	pH.	Whereas	the	presence	of	chGal3	demonstrates	that	
an	individual	vesicle	has	been	previously	ruptured,	the	accumulation	of	LysoTracker	in	
ruptured	vesicles	to	mark	a	low	pH	indicates	re-establishment	of	a	pH	gradient	through	
the	autophagic	degradation	system.	At	single	time	points,	individual	Z-stack	images	
were	acquired	to	determine	the	degree	of	colocalization	of	Dylight488-labeled	WT	a-syn	
assemblies,	chGal3,	and	LysoTracker.	These	images	revealed	that	a	subset	of	a-syn+,		
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Figure	24.	Lysosomes	ruptured	by	a-syn	are	targeted	for	autophagic	degradation.	
Vesicular	identity	and	pH	status	of	a-syn-induced	chGal3+	ruptured	vesicles	identified	
by	(A)	24	hr	exposure	of	SY5YchGal3	cells	to	660nM	exogenous	Atto488-labeled	WT	α-
syn	fibrils	followed	by	fixation	and	staining	for	LAMP1,	(B)	24	hr	exposure	of	SY5YchGal3	
YFP-LC3	cells	to	660nM	exogenous	Dylight650-labeled	WT	α-syn	PFFs	followed	by	live	
cell	imaging,	and	(C)	24	hr	exposure	of	SY5YchGal3	cells	to	200nM	exogenous	
Dylight488-labeled	WT	α-syn	assemblies	followed	by	loading	of	Lysotracker	Deep	Red	
dye	and	live	cell	imaging.	Inset	box	from	top	image	is	enlarged	and	separated	in	below	
images.	Colocalization	between	all	three	channels	shown	with	arrowheads.	Images	are	
representative	of	at	least	10	images	from	3	independent	experiments.	Scale	bar	=	15	µm	
for	top	panel	and	3	µm	for	inset-enlarged	lower	panels.		
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chGal3+	ruptured	vesicles	were	additionally	LysoTracker+,	indicating	a	re-establishment	
of	the	pH	gradient	during	autophagic	degradation	of	ruptured	vesicles.	In	these	cells,	
instances	of	a-syn+,	chGal3+	vesicles	were	also	observed,	as	were	a-syn	puncta	that	did	
not	colocalize	with	either	chGal3	or	LysoTracker	(Figure	24C).	Additionally,	live	cell	
imaging	of	chGal3-expressing	N27	rat	dopaminergic	neuronal	cells	exposed	to	
DyLight488-labeled	WT	a-syn	assemblies	in	the	presence	of	Lysotracker	indicated	the	
accumulation	of	multiple	smaller	a-syn-containing	ruptured	vesicles	within	a	larger	low	
pH	compartment	(Figure	25,	arrowheads).	This	observation	indicates	ongoing	
autophagic	recruitment	of	ruptured	vesicles	induced	by	a-syn	endocytic	uptake.	These	
findings	demonstrate	that	lysosomes	ruptured	by	fibrillar	amyloid	assemblies	of	a-syn	
are	targeted	for	autophagic	degradation	and	thus	re-establish	a	low	pH	gradient.	The	
damaged	vesicles	and	vesicular	debris	created	by	lysosomal	rupture	following	a-syn	
endocytosis	therefore	add	to	the	cellular	burden	of	substrates	needing	to	be	degraded	
through	the	ALP.	
Fusion	of	Ruptured	Vesicles	Leads	to	the	Formation	of	Large	Cytoplasmic		
Inclusions	of	Alpha-Synuclein	
	 We	next	used	live	cell	imaging	to	monitor	the	intracellular	trafficking	of	vesicles	
ruptured	by	a-syn	assemblies	to	determine	their	relationship	with	the	subsequent	
formation	of	cytoplasmic	a-syn-containing	LB	inclusions.	Because	endocytic	vesicle	
rupture	is	the	damaging	mechanism	whereby	exogenous	a-syn	seeds	come	into	contact	
with	expressed	monomeric	a-syn	in	the	cytosol	and	can	subsequently	template	further		
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Figure	25.	Ruptured	vesicles	containing	a-syn	present	in	large	low	pH	compartment.		
N27chGal3	cells	were	subjected	to	24	hr	treatment	with	200nM	exogenous	Dylight488-
labeled	WT	a-syn	assemblies	in	the	culture	media,	followed	by	live	cell	imaging	to	
identify	vesicle	rupture.	chGal3+	ruptured	vesicles	(red)	can	be	observed	colocalizing	
with	a-syn	assemblies	(green)	and	low	pH	compartments	(Lysotracker,	blue)	in	this	
snapshot	of	the	live	cell	movie.	Additionally,	large	low	pH	compartments	are	seen	
containing	multiple	smaller	ruptured	vesicles	that	colocalize	with	a-syn	(arrowheads).	
Scale	bar	is	10	µm.		
	
aggregation	and	LB	formation	[200,	202,	209-213,	347],	we	hypothesized	that	endocytic	
vesicle	rupture	would	be	involved	in	the	formation	of	a-syn	LB	inclusions.	Time	lapse	
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imaging	revealed	that	colocalization	between	α-syn	assemblies	and	the	chGal3	marker	
of	vesicle	rupture	was	maintained	as	the	ruptured	vesicles	and	a-syn	cargo	trafficked	
considerable	distances	throughout	the	cell.	In	many	instances,	colocalizing	vesicles	
could	be	observed	trafficking	throughout	both	the	soma	and	cellular	projections	of	
chGal3-expressing	hiPSC-derived	dopaminergic	neurons,	SH-SY5Y	cells,	and	N27	cells.	
We	also	observed	evidence	of	vesicle	fusion	in	which	multiple	smaller	vesicles	
containing	both	a-syn	assemblies	and	chGal3	appear	to	merge	together	into	a	larger	
inclusion	during	the	acquisition	period.	In	N27chGal3	cells	exposed	to	Dylight488-
labeled	WT	a-syn	assemblies	and	loaded	with	Lysotracker,	multiple	smaller	low	pH	
compartments	each	containing	a-syn	and	the	chGal3	marker	of	previous	membrane	
rupture	merge	together	into	a	larger	compartment	(Figure	26).	This	merging	of	a-syn-
containing	ruptured	vesicles	also	occurred	in	SY5YchGal3	cells	exposed	to	Dylight488-
labeled	WT	a-syn	assemblies	(Figure	27).	This	merging	of	ruptured	vesicles	containing	
chGal3	and	a-syn	assemblies	produced	larger	structures	that	substantially	exceeded	the	
size	of	the	individual	ruptured	vesicles	from	which	they	were	derived.	Such	structures	
were	also	observed	in	fixed	cell	images	following	exposure	of	SY5YchGal3	cells	to	
exogenous	Dylight-488	labeled	a-syn	assemblies,	and	in	some	cases	these	larger	
structures	assumed	the	appearance	of	a	LB	in	which	a	large	perinuclear	a-syn	inclusion	
was	surrounded	by	a	peripheral	border	of	chGal3	(Figure	28).	This	phenotype	of	chGal3	
enrichment	at	the	periphery	of	a-syn	LB	inclusions	indicates	previous	membrane	
rupture	in	the	a-syn-containing	endocytic	vesicles	that	subsequently	merged	together		
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Figure	26.	Fusion	of	ruptured	vesicles	containing	a-syn	in	N27chGal3	cells.	N27chGal3	
cells	(red)	were	incubated	with	Dylight488-conjugated	WT	a-syn	assemblies	(green)	for	
24	hr.	Prior	to	live	cell	imaging,	cells	were	incubated	with	20	nM	Lysotracker	(blue)	for	
30	minutes.	Colocalization	between	these	three	channels	is	seen	in	white.	Inset	box	at	
top	left	is	enlarged	in	other	panels,	and	timed	snapshots	of	this	region	are	shown	with	
the	time	stamp	in	the	bottom	left	of	each	frame.	Z-stack	images	were	acquired	at	~28	
second	intervals	for	12	minutes.	Scale	bars	are	20	µm	in	top	left	and	3	µm	in	panels	
enlarged	from	inset	box.	
	
into	a	larger	inclusion.	Despite	the	degradative	intention	behind	the	merging	of	vesicles	
and	a-syn	aggregates	into	aggresomes,	this	process	ultimately	facilitates	LB	inclusion		
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Figure	27.	Fusion	of	ruptured	vesicles	containing	a-syn	in	SY5YchGal3	cells.	SY5YchGal3	
cells	(red)	were	incubated	with	Dylight488-conjugated	WT	a-syn	assemblies	(green)	for	
24	hr.	Timed	snapshots	are	shown	with	the	time	stamp	in	the	bottom	left	of	each	frame.	
Z-stack	images	were	acquired	at	~13	second	intervals	for	10	minutes.	Scale	bar	=	5	μm.	
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Figure	28.	a-Syn	LB	inclusion	surrounded	by	corona	of	chGal3	in	SY5YchGal3	cells.	
SY5YchGal3	cells	(red)	were	subjectd	to	24h	exposure	to	200nM	exgenous	Dylight488-
labeled	A53T	a-syn	assemblies	(green),	followed	by	fixation	and	DAPI	staining	(blue)	in	
PBS.	Image	separated	into	overlay,	chGal3,	and	a-syn	fluorescence.	Scale	bar	=	10	µm.	
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formation	when	degradation	becomes	compromised	[118].	Gal3	presence	around	the	LB	
is	an	indicator	of	the	accumulation	of	ruptured	vesicles	unable	to	be	degraded	in	
aggresomes.	These	findings	highlight	the	close	relationship	between	ruptured	vesicles	
and	a-syn	LB	inclusions,	where	fusion	of	a-syn-containing	ruptured	vesicles	and	the	
specific	enrichment	of	chGal3	surrounding	a	larger	LB	inclusion	implicate	endocytic	
vesicle	rupture	in	the	formation	of	pathologic	intracellular	a-syn	inclusions.		
Vesicle	Rupture	Markers	Surround	Alpha-Synuclein	in	Lewy	Bodies	
	 The	data	above	suggest	that	the	failed	degradation	of	a-syn	fibrils	within	the	
autophagic	compartment	following	vesicle	rupture	leads	to	the	gradual	fusion	of	these	
vesicles	into	structures	resembling	LBs.	To	determine	the	influence	of	endocytic	vesicle	
rupture	on	LB	inclusion	formation	in	authentic	PD,	we	examined	a-syn-containing	LBs	in	
human	post	mortem	SN	tissue	sections	from	PD	patients,	hypothesizing	that	
endogenous	Gal3	localization	would	also	implicate	endocytic	vesicle	rupture	in	LB	
formation	in	vivo.	To	determine	if	LBs	present	in	PD	patients	exhibit	a	similar	phenotype	
to	that	in	SY5YchGal3	cells	exposed	to	exogenous	a-syn	assemblies,	we	performed	
immunofluorescence	microscopic	analysis	on	SN	sections,	staining	these	sections	with	
antibodies	specific	for	pS129	a-syn	as	a	marker	of	LBs	and	endogenous	Gal3,	detected	
by	secondary	antibodies	conjugated	to	Cy2	and	Cy5,	respectively.	In	these	sections,	we	
observed	numerous	examples	of	pS129	a-syn+	inclusions	that	closely	resembled	LBs.	
Many	of	these	LBs	demonstrated	a	characteristic	peripheral	outward-radiating	
filamentous	halo	of	pS129	a-syn	and	a	dim	center,	consistent	with	other	published	
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reports	detailing	the	ultrastructure	of	LBs	where	a-syn	staining	comprises	a	peripheral	
halo	surrounding	a	dense	granular	core	with	a	high	abundance	of	ubiquitin	staining	
[117,	118].	Additionally,	we	observed	that	a	majority	of	the	LBs	present	in	these	sections	
exhibited	a	corona	of	Gal3	surrounding	the	aggregated	pS129	a-syn	within	the	LB	
(Figure	29).	Of	the	305	LBs	identified	in	samples	from	5	PD	patients,	170	(~56%)	of	these	
LBs	exhibited	a	discernable	Gal3	corona.	No	similar	fluorescent	pattern	was	observed	in	
the	neighboring	fluorescent	channel	(Cy3)	under	identical	acquisition	conditions	or	in	
tissue	sections	from	the	same	patient	stained	with	secondary	antibodies	alone,	
demonstrating	that	this	observation	is	not	due	to	signal	bleedthrough	or	tissue	
autofluorescence.	The	presence	of	Gal3	at	the	periphery	of	LBs	suggests	that	this	region	
contains	membrane	components	where	the	lectin	ligands	present	on	the	luminal	leaflet	
of	vesicles	had	been	previously	exposed	to	the	cytoplasm.	Notably,	normal	autophagic	
degradative	mechanisms	do	not	result	in	the	cytoplasmic	exposure	of	these	lectin	
ligands.	Thus,	the	Gal3	corona	around	LBs	is	evidence	of	previous	membrane	
perturbations	having	occurred	in	the	lipid	components	which	form	the	periphery	of	
these	structures.	This	observation	implicates	endocytic	vesicle	rupture	in	the	formation	
of	LBs	in	authentic	PD,	meaning	that	the	cellular	response	of	merging	ruptured	vesicles	
and	a-syn	cargo	to	facilitate	degradation	instead	promotes	pathologic	inclusion	
formation	when	degradative	mechanisms	are	dysfunctional.		
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Figure	29.	LB	inclusions	from	PD	brain	surrounded	by	corona	of	Gal3.	Brain	sections	
from	H&Y5	PD	patients	were	immunostained	for	pS129	a-syn	(FITC,	green)	and	Gal3	
(Cy5,	red),	and	additionally	imaged	in	the	Cy3	channel	to	detect	tissue	autofluorescence	
(blue).	Six	representative	images	of	LBs	are	shown	from	three	PD	patients,	and	left	
Overlay	panel	is	separated	into	single	channels	for	a-syn	fluorescence,	Gal3	
fluorescence,	and	autofluorescence	to	appreciate	the	degree	of	partial	colocalization	
between	Gal3	corona	and	radiating	halo	of	pS129	a-syn	within	LBs.	Scale	bar	=	5	µm.	
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Ruptured	Vesicles	Containing	Alpha-Synuclein	are	Released	and		
Propagate	Between	Cells	
	 In	addition	to	the	intracellular	consequence	of	promoting	pathologic	LB	inclusion	
formation,	endocytic	vesicle	rupture	is	also	known	to	induce	cellular	stressors	that	can	
stimulate	a-syn	release	and	cell-to-cell	propagation	[294,	468-471,	473,	479,	484,	485].	
With	this	fact	in	mind,	we	aimed	to	clarify	the	contribution	of	a-syn	induced	endocytic	
vesicle	rupture	to	its	cell-to-cell	propagation.	We	hypothesized	that	a-syn-mediated	
lysosomal	rupture	and	its	consequences	would	prompt	a-syn	cellular	release	in	
association	with	ruptured	vesicles.	To	test	this	hypothesis,	we	examined	both	the	
extracellular	localization	and	the	intercellular	movement	of	exogenous	a-syn	aggregates	
using	a	combination	of	fixed	and	live	cell	imaging.	Under	identical	conditions	to	those	
that	produce	intracellular	vesicle	rupture	following	endocytosis	of	exogenous	a-syn	
aggregates,	we	observe	instances	where	chGal3+	ruptured	vesicles	containing	a-syn	are	
present	in	the	extracellular	environment	(Figure	30).	Given	that	this	now	extracellular	a-
syn	aggregate	remains	associated	with	a	lipid	vesicle	exhibiting	an	enrichment	of	chGal3	
derived	from	the	cytosol	of	the	original	recipient	cell,	this	finding	indicates	the	existence	
of	a	process	for	the	cellular	release	of	a-syn-containing	ruptured	vesicles.	Using	live	cell	
imaging	of	hiPSC-derived	chGal3	dopaminergic	neurons	exposed	to	Dylight488-labeled	
a-syn	PFFs,	we	have	also	observed	the	intercellular	movement	of	a-syn	aggregates	
contained	within	ruptured	vesicles	(Figure	31),	indicating	that	this	process	of	a-syn	
cellular	release	within	ruptured	vesicles	can	facilitate	cell-to-cell	propagation.	While		
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Figure	30.	Ruptured	vesicles	containing	a-syn	observed	in	the	extracellular	
environment.	Annular	chGal3+	ruptured	vesicle	containing	a-syn	found	in	the	
extracellular	environment	adjacent	to	SY5YchGal3	cell	affected	by	a-syn-induced	vesicle	
rupture.	SY5Y	chGal3	cells	were	treated	for	24	hr	with	Dylight488-labeled	a-syn	
aggregates.	Highlighted	extracellular	vesicle	within	inset	box	is	not	connected	to	any	
portion	of	adjacent	cell	or	its	processes.	Inset	box	in	merged	panel	(left)	is	enlarged	and	
separated	by	channel	(right)	to	emphasize	co-localization.	Blue	DAPI-stained	nucleus	
shown.	Scale	bar	=	10	µm	left,	1.5	µm	right.			
	
much	remains	to	be	understood	regarding	the	specific	factors	that	stimulate	this	release	
of	ruptured	vesicles	and	a-syn	cargo	as	well	as	its	mechanistic	underpinnings,	these		
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Figure	31.	Ruptured	vesicles	containing	a-syn	propagate	between	hiPSC-derived	
chGal3	dopaminergic	neurons.	hiPSC-derived	chGal3	dopaminergic	neurons	(red)	were	
subjected	to	48	hr	treatment	with	200	nM	exogenous	Dylight488-labeled	WT	a-syn	PFFs	
(green)	in	the	culture	media,	followed	by	live	cell	imaging	to	identify	vesicle	rupture.	
Ruptured	vesicles	containing	a-syn	seen	in	yellow.	Inset	box	enlarged	at	bottom	right,	
with	timed	snapshots	shown	at	the	times	indicated	in	the	bottom	right	of	each	frame.	
Scale	bar	=	15	µm.		
	
results	indicate	that	endocytic	vesicle	rupture	and	its	consequences	can	act	as	both	a	
stimulus	and	a	vector	for	pathologic	a-syn	cell-to-cell	propagation.	
Significance	
	 The	above	results	have	established	the	contribution	of	endocytic	vesicle	rupture	
to	dysfunctional	degradative	processes,	intracellular	inclusion	formation,	and	
intercellular	aggregate	transmission,	making	this	damaging	mechanism	of	cellular	
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invasion	clearly	relevant	for	PD	pathology	and	progression.	Although	much	remains	to	
be	determined	regarding	the	life	cycle	of	a-syn	within	and	between	diseased	neurons,	
this	examination	of	the	intersection	of	endocytic	vesicle	rupture	and	established	aspects	
of	PD	pathology	brings	the	research	endeavor	one	step	closer	to	an	understanding	of	
pathogenesis	necessary	for	effective	therapeutic	intervention.	Beginning	with	the	
demonstration	that	a-syn	aggregates	induce	endocytic	vesicle	rupture	in	hiPSC-derived	
chGal3	dopaminergic	neurons	just	as	they	do	in	SH-SY5YchGal3	cells	verifies	the	
occurrence	of	this	invasion	mechanism	in	a	model	system	more	representative	of	
neuronal	physiology.	This	validation	establishes	the	utility	of	the	chGal3	relocalization	
assay	for	detecting	this	vesicle	damage,	and	again	underscores	the	conserved	nature	of	
endocytic	vesicle	rupture	as	a	mechanism	of	amyloid	protein	escape	from	the	vesicular	
compartment	during	the	propagation	pathway.	Furthermore,	these	findings	confirm	
that,	just	like	those	ruptured	by	invading	pathogens	or	sterile	damage	[560,	570,	597,	
601-603,	615],	lysosomes	ruptured	by	a-syn	become	targets	of	autophagy,	adding	to	
the	cellular	burden	of	substrates	requiring	clearance	via	the	ALP.	The	combination	of	
lysosomal	dysfunction	induced	by	a-syn	mediated	LMP	[4]	and	the	addition	of	damaged	
or	destroyed	lysosomal	vesicles	to	the	already	overwhelming	buildup	of	ALP	substrates	
in	PD	[130]that	now	also	include	the	invading	misfolded	a-syn	aggregates	themselves	is	
a	clear	cause	of	dysregulated	proteostasis.	
	 Two	of	the	most	problematic	aspects	of	proteinopathies	include	the	prion-like	
seeding	and	templating	of	further	amyloid	misfolding	upon	cellular	invasion	and	the	cell-
		
183	
to-cell	propagation	of	amyloid	aggregates	[3,	465,	647,	648].	With	our	findings,	we	have	
established	a	role	for	endocytic	vesicle	rupture	as	contributing	to	both.	We	first	
examined	the	trafficking	of	ruptured	vesicles	and	their	a-syn	cargo,	and	noted	the	
merging	or	coalescence	of	multiple	smaller	ruptured	vesicles	into	larger	low	pH	
compartments	representing	ongoing	autophagic	degradation.	However,	the	presence	of	
Gal3	at	the	periphery	of	LB	inclusions	in	SY5YchGal3	cells	and	in	PD	SN	brain	tissue	
suggests	that	degradative	mechanisms	fail	to	cope	with	the	accumulation	of	ruptured	
vesicles	and	misfolded	protein,	which	instead	results	in	LB	inclusion	formation.	
Moreover,	understanding	that	the	increased	lysosomal,	autophagic,	and	oxidative	stress	
resulting	from	endocytic	vesicle	rupture	is	known	to	contribute	to	a-syn	release	and	
intercellular	spreading	[468,	469,	479,	485],	we	identified	a	process	of	a-syn	cellular	
release	within	ruptured	vesicles	that	is	competent	to	shuttle	a-syn	aggregate	cargo	
between	cells.	These	observations	implicate	the	mechanism	of	endocytic	vesicle	rupture	
as	contributing	to	inclusion	formation	and	cell-to-cell	propagation	in	PD,	providing	both	
the	substance	and	the	stimulus	for	both	pathological	processes.	We	have	provided	an	
explanation	for	how	the	damaging	mechanism	of	cellular	invasion	through	endocytic	
vesicle	rupture	directly	contributes	to	PD	pathology	and	progression,	and	these	findings	
are	significant	because	the	multifaceted	nature	of	this	invasion	mechanism	and	its	
consequences	could	provide	numerous	new	therapeutic	targets	for	reversing	or	
preventing	disease.	
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CHAPTER	SIX	
CONCLUSIONS	
	
Introduction	
	 No	disease	modifying	therapy	exists	for	numerous	neurodegenerative	diseases	
characterized	and	defined	by	the	accumulation	of	misfolded	amyloid	proteins.	a-
Synucleinopathies,	tauopathies,	and	polyglutamine	expansion	diseases	each	encompass	
several	diverse	neurodegenerative	diseases	exhibiting	the	accumulation	of	insoluble	
fibrillar	amyloid	aggregates	of	a-syn,	tau,	and	polyglutamine-containing	proteins	
respectively.	These	diverse	proteinopathies	have	also	been	referred	to	as	prionopathies	
for	their	numerous	similarities	to	prion	diseases	[42].	As	prion-like	proteins,	amyloid	
assemblies	of	a-syn,	tau,	and	HTTExon1	exhibit	misfolding	into	an	insoluble,	fibrillar	b-
sheet-rich	amyloid	structure,	induce	seeding	and	templating	of	additional	misfolding	in	
their	cytosolic	monomeric	constituent	proteins,	and	undergo	spreading	from	affected	to	
naïve	cells	throughout	the	nervous	system	[488,	522,	634].	Given	that	the	prion-like	
mechanisms	for	amyloid	protein	aggregation	and	propagation	are	remarkably	conserved	
between	neurodegenerative	diseases,	and	even	that	the	fibrillar	amyloid	structure	itself	
occurring	as	a	final	product	of	constituent	assembly	is	structurally	very	similar	in	these	
diseases	despite	being	composed	of	different	proteins,	there	is	a	possibility	that	
understanding	the	mechanisms	underlying	a	single	disease	may	lead	to	insights	about	
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many,	forming	the	foundation	for	future	disease-modifying	therapeutic	strategies	[3].	
To	realize	this	potential,	much	remains	to	be	learned	about	the	mechanisms	by	which	
misfolded	amyloid	aggregates	corrupt	their	soluble	counterparts,	disrupt	cellular	
homeostasis,	and	transmit	their	pathologic	protein	misfolding	from	cell-to-cell.		
	 Examining	the	specific	steps	in	the	intracellular	and	intercellular	life	cycle	of	
amyloid	proteins	through	the	lens	of	host-pathogen	interactions	is	beneficial	for	
understanding	the	consequences	of	and	cellular	response	to	this	prion-like	process.	
Using	the	situation	of	a-syn	in	PD,	our	group	was	the	first	to	demonstrate	that	fibrillar	
protein	aggregates	cause	lysosomal	rupture	following	their	endocytic	uptake,	occurring	
in	a	fashion	identical	to	infection	by	bacterial	or	viral	pathogens	[4,	280].	Despite	the	
new	insight	gained	from	this	finding,	many	key	questions	remained	about	its	
mechanism,	its	contribution	to	cellular	dysfunction,	and	its	relevance	to	the	pathology	
of	PD	and	other	proteinopathies.	The	studies	discussed	in	this	dissertation	aimed	to	
address	the	above	questions,	with	the	goal	of	exploring	endocytic	vesicle	rupture	as	a	
mechanism	of	cellular	invasion	for	several	amyloid	proteins.	Furthermore,	focusing	on	
a-syn	in	PD,	we	aimed	to	define	specific	protein	modifications	that	influence	vesicle	
rupture	potency,	as	well	as	determine	the	effect	of	a-syn-mediated	vesicle	rupture	on	
cellular	homeostasis	and	aggregate	propagation.	Below	we	revisit	key	findings	identified	
in	each	chapter	and	discuss	how	they	contribute	to	an	enhanced	understanding	of	
amyloid	protein	propagation	in	neurodegenerative	disease.	We	also	point	out	questions	
that	remain	unanswered	and	needing	to	be	addressed	in	future	work.	With	more	insight	
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into	the	pathological	life	cycle	of	misfolded	amyloid	proteins,	new	therapeutic	targets	
are	identified	that	may	allow	future	treatment	targeted	to	disease	pathogenesis.		
Endocytic	Vesicle	Rupture	is	a	Conserved	Mechanism	of	Cellular	Invasion	by		
Amyloid	Proteins	
	 Building	from	our	earlier	work	demonstrating	that	heterogeneous	aggregates	of	
a-syn	rupture	lysosomes	following	their	endocytic	uptake,	we	next	sought	to	determine	
if	this	endocytic	vesicle	rupture	phenomenon	is	a	specific	effect	of	a-syn	aggregates,	or	
if	aggregates	of	other	neurodegenerative	disease-associated	amyloid	proteins	were	also	
capable	of	inducing	this	type	of	vesicular	membrane	damage	following	endocytosis.	The	
rationale	for	this	hypothesis	was	that	misfolded	higher-order	aggregates	of	many	
aggregation-prone	neurodegenerative	disease-associated	proteins	adopt	a	stable,	
protease-resistant,	detergent-insoluble	fibrillar	b-sheet	rich	architecture	known	as	
amyloid	that	is	very	similar	despite	these	protein	aggregates	being	composed	of	
different	proteins	for	each	disease	[2,	3,	465,	647,	652].	This	characteristic	amyloid	
structure	also	defines	the	disease-associated	prion	PrPSc	[6,	11,	12],	and	it	is	this	
structure	that	imparts	to	prions	the	ability	to	corrupt	like	monomeric	constituents	
through	templating	and	seeding	of	further	aggregation	[17].	Thus,	given	the	similarities	
in	their	structure,	we	hypothesized	that	amyloid	assemblies	of	tau	and	HTTExon1	would	
also	induce	endocytic	vesicle	rupture	following	their	cellular	uptake	by	endocytosis.		
	 Endocytosis	is	the	predominant	mechanism	for	the	cellular	uptake	of	fibrillar	
assemblies	of	a-syn,	tau,	and	HTTExon1,	being	too	large	for	direct	translocation	across	
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the	plasma	membrane	[448-450,	498,	506-508,	531].	However,	if	these	fibrillar	amyloid	
proteins	are	very	elongated	and/or	tightly	bundled	with	many	other	fibrils	due	to	
ongoing	aggregation,	then	these	elongated	or	grouped	fibrils	are	too	large	to	enter	cells	
via	endocytosis.	Instead,	smaller	fibrillar	forms	such	as	fragments	of	longer	a-syn,	tau,	
or	prion	fibrils	are	the	assembly	species	most	efficiently	taken	up	by	endocytosis	[45,	
200,	509].	Following	cellular	entry	in	this	manner,	the	question	of	how	amyloid	
aggregates	escape	from	the	vesicular	compartment	was	unanswered	for	assemblies	of	
tau	and	HTTExon1	just	as	it	had	been	for	a-syn	prior	to	our	demonstration	of	a-syn	
induced	vesicle	rupture	[448,	465,	522,	531].	To	properly	assess	this	possibility	of	
endocytic	vesicle	rupture	representing	a	shared	invasion	mechanism	for	these	various	
aggregated	amyloid	proteins,	we	employed	an	in	vitro	aggregation	protocol	of	
recombinant	purified	a-syn,	tau,	and	HTTExon1	that	relies	on	the	combination	of	
extended	aggregation	times	to	produce	elongated	fibrils	and	the	subsequent	
fragmentation	of	these	elongated	fibrils	by	sonication	to	produce	homogenous	
populations	of	smaller	fibrillar	assemblies	that	retain	their	original	b-sheet-rich	
architecture	that	had	been	present	in	the	elongated	fibril	after	aggregation.	Not	only	
does	this	aggregation	scheme	allow	for	a	homogenous,	uniform	population	of	similar	
size	distribution	between	samples	of	a-syn,	tau,	and	HTTExon1	(Figures	14,	17,	20),	
standardizing	the	variable	of	aggregate	size	for	the	comparison	of	vesicle	rupture,	the	
fragmentation	of	larger	fibrils	to	smaller	fibrillar	forms	matches	the	species	of	amyloid	
proteins	known	to	best	invade	recipient	cells	through	endocytosis.		
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	 When	we	incubated	small	fibrillar	forms	of	a-syn,	tau,	and	HTTExon1	with	our	
SY5YchGal3	cell	model	of	vesicle	rupture,	we	observed	a	shared	ability	of	these	fibrillar	
amyloid	proteins	to	induce	chGal3	relocalization	indicative	of	endocytic	vesicle	rupture	
(Figures	15,	18,	21).	The	specific	enrichment	of	cytosolic	chGal3	at	the	site	of	ruptured	
vesicles	colocalized	strikingly	with	the	fluorescence	from	internalized	amyloid	
assemblies	of	a-syn	and	tau,	although	we	were	unable	to	visualize	this	colocalization	of	
ruptured	vesicles	with	assemblies	of	HTTExon1	due	to	technical	limitations	of	the	
fluorescent	labeling	approach.	To	extend	and	validate	the	observation	of	amyloid-
induced	endocytic	vesicle	rupture	in	a	more	physiologically-relevant	model	system,	we	
utilized	hiPSC-derived	dopaminergic	neurons	expressing	the	chGal3	construct	as	more	
closely	resembling	authentic	neuronal	physiology.	In	this	system,	hiPSC-derived	
dopaminergic	neurons	that	successfully	expressed	the	chGal3	protein	indicated	clear	
relocalization	of	its	expression	to	cytosolic	punctate	structures	that	colocalized	with	the	
fluorescence	of	exogenous	a-syn	PFFs,	indicating	the	induction	of	endocytic	vesicle	
rupture	in	these	neurons	just	as	in	SY5YchGal3	cells	(Figure	23).	These	findings	allow	us	
to	confidently	conclude	that	endocytic	vesicle	rupture	is	the	mechanism	by	which	
fibrillar	assemblies	of	amyloid	proteins	escape	from	the	vesicular	compartment	
following	their	uptake,	and	the	recruitment	of	cytosolic	chGal3	is	a	reliable	indicator	of	
this	damage	caused	during	invasion	(Figure	32,	middle).		
	 The	pattern	of	colocalization	between	exogenous	fluorescently-labeled	amyloid	
protein	assemblies	and	the	chGal3	indicator	of	vesicle	rupture	warrants	further		
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Figure	32.	Schematic	of	amyloid-induced	vesicle	rupture	and	its	consequences.	Fibrillar	
amyloid	protein	assembly	(green)	taken	up	into	endocytic	vesicle	along	with	b-
galactoside	sugars	(orange)	from	the	outer	leaflet	of	the	plasma	membrane	now	on	the	
inner	leaflet	of	the	internalized	vesicle.	Endocytic	vesicle	rupture	induced	by	amyloid	
protein	aggregates	is	indicated	by	the	enrichment	of	cytosolic	Gal3	(red	cytoplasm,	red	
dots)	at	the	site	of	membrane	damage	where	it	binds	to	b-galactoside	sugars	exposed	
upon	vesicle	rupture	(middle).	Colocalization	(yellow)	can	be	observed	between	amyloid	
assembly	fluorescence	and	chGal3	in	inset	middle	image.	Cellular	homeostasis	depends	
on	the	balance	between	amyloid	protein	degradation	(left)	and	amyloid	protein	
accumulation	(right).	Degradation	of	ruptured	vesicles	and	amyloid	protein	cargo	occurs	
via	autophagy	(left),	where	ruptured	vesicles	containing	a-syn	can	be	observed	in	low	
pH	compartments	positive	for	the	autophagic	marker	LC3	(inset	left	images).	
Accumulation	of	ruptured	vesicles	and	amyloid	protein	cargo	occurs	when	degradative	
mechanisms	are	dysfunctional	or	overwhelmed	(right),	prompting	both	inclusion	
formation,	where	the	presence	of	Gal3	at	the	periphery	indicates	merging	of	previous	
ruptured	vesicles	into	the	larger	cytoplasmic	inclusion	(inset	right	images),	and	cellular	
release	of	ruptured	vesicles	and	amyloid	protein	cargo.			
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investigation.	We	often	observe	localization	of	fluorescent	amyloid	assemblies	to	curved	
or	comma-shaped	structures	at	the	periphery	of	larger	annular	or	ring-like	intracellular	
ruptured	vesicles,	closely	associated	with	the	vesicular	membrane	rather	than	occupying	
the	visible	vesicular	lumen	(Figure	32,	inset	middle	image).	In	addition,	smaller	punctate	
or	dot-like	structures	are	also	observed,	where	more	exact	overlap	between	amyloid	
assembly	and	chGal3	fluorescence	is	observed	(Figure	32,	inset	middle	image).	While	
both	phenotypes	of	intracellular	vesicles	exhibit	rupture	as	indicated	by	chGal3	
enrichment,	their	dramatically	different	appearances	suggest	involvement	of	diverse	
intracellular	vesicle	phenotypes	in	the	process	of	endocytic	vesicle	rupture.	Our	previous	
work	demonstrated	vesicle	rupture	of	endosomes	and	lysosomes	by	a-syn	aggregates,	
with	a	higher	number	of	ruptured	vesicles	exhibiting	a	lysosomal	phenotype	[4].	The	
results	presented	here	validate	the	observation	of	lysosomal	rupture,	and	demonstrate	
that	ruptured	lysosomes	are	recruited	to	autophagosomes	for	degradation	(Figure	24).	
The	chGal3	relocalization	assay	does	not	allow	us	to	distinguish	if	one	vesicular	
phenotype	is	more	predominantly	affected	by	amyloid-mediated	vesicle	rupture,	as	the	
recruitment	of	cytosolic	galectins	is	an	all-or-none	phenomenon	that	occurs	
immediately	following	rupture	and	the	presence	of	this	indicator	would	persist	as	
vesicles	move	through	intracellular	trafficking	and	degradative	pathways.	Thus,	
additional	study	must	be	performed	to	more	completely	understand	the	stage	within	
the	endocytic	pathway	when	endocytic	vesicle	rupture	is	induced	by	exogenous	amyloid	
assemblies.	This	question	has	important	implications	for	the	consequences	of	amyloid-
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mediated	vesicle	rupture,	as	early	egress	from	the	endocytic	pathway	during	the	
endosomal	stage	is	employed	by	pathogens	such	as	adenovirus	which	have	an	
evolutionary	pressure	to	avoid	lysosomal	degradation	[575,	606,	609].	Early	endocytic	
vesicle	rupture	thus	causes	fewer	LMP	events	and	avoids	the	more	severe	proteolytic	
toxicity	and	oxidative	stress	resulting	from	cathepsin	leakage.	It	is	possible	that	various	
amyloid	protein	assemblies	induce	vesicle	rupture	at	different	endocytic	stages,	and	
thus	would	be	expected	to	have	very	different	consequences	for	the	host	cell.		
	 With	the	finding	that	endocytic	vesicle	rupture	is	a	conserved	mechanism	of	
cellular	invasion	by	aseemblies	of	numerous	amyloid	proteins,	we	have	contributed	an	
important	advance	in	the	understanding	of	the	amyloid	cell-to-cell	propagation	
pathway.	Although	the	existence	of	a	mechanism	to	physically	disrupt	the	endocytic	
vesicle	compartment	had	been	hypothesized,	and	always	assumed	to	exist	given	the	
induction	of	intracellular	aggregation	by	exogenous	seeds,	such	a	mechanism	had	never	
been	specifically	demonstrated	for	aggregates	of	a-syn,	tau,	and	HTTExon1	prior	to	this	
work.	Future	studies	will	expand	these	observations	and	the	understanding	of	the	
endocytic	vesicle	rupture	entry	mechanism	by	examining	the	cell-to-cell	propagation	
pathway	of	additional	amyloid	proteins	such	as	Ab,	SOD-1,	and	TDP-43.	Probing	this	
cellular	invasion	mechanism	for	specific	factors	that	increase	or	decrease	its	potency	
may	reveal	mechanisms	whereby	it	can	be	inhibited,	and	thus	represent	attractive	
future	therapeutic	targets	to	prevent	or	reverse	disease	progression.		
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Alpha-Synuclein	Serine-129	Phosphorylation	and	Assembly	Strain	Conformation	
Determine	Endocytic	Vesicle	Rupture	Potency	
	 Given	the	conserved	nature	of	endocytic	vesicle	rupture	in	the	cellular	invasion	
of	amyloid	proteins	during	neurodegenerative	disease,	we	next	sought	to	determine	
specific	protein	modifications	that	dictate	the	potency	of	this	cellular	entry	mechanism.	
We	focused	this	effort	on	amyloid	assemblies	of	a-syn	in	PD,	examining	familial	
missense	mutation,	pS129	phosphorylation,	and	strain	conformation	as	three	factors	
highly	implicated	in	disease	pathogenesis.	An	increased	understanding	of	the	vesicle	
rupture	entry	mechanism	from	the	perspective	of	factors	that	increase	or	decrease	its	
potency	may	generate	new	therapeutic	targets	to	intervene	on	amyloid	protein	cell-to-
cell	propagation.	
	 We	began	by	investigating	the	influence	of	missense	mutations	in	the	a-syn	
protein	associated	with	familial,	early-onset	PD,	with	the	hypothesis	that	an	increased	
potency	of	endocytic	vesicle	rupture	induced	by	amyloid	assemblies	of	these	mutants	
may	account	for	their	earlier	disease	onset.	Although	only	10%	of	PD	cases	have	a	
genetic	cause	and	the	remaining	90%	are	idiopathic	cases	[229,	230],	examination	of	a-
syn	familial	missense	mutants	is	valuable	because	the	onset	of	PD	is	directly	attributable	
to	alterations	in	the	a-syn	protein,	and	insights	gained	from	examining	these	forms	of	a-
syn	may	lead	to	new	information	about	the	behavior	of	WT	a-syn	becoming	misfolded	
and	causing	toxicity	in	the	vast	majority	of	PD	cases.	When	we	produced	aggregates	of	
WT,	E46K,	A53T,	A30P,	and	G51D	a-syn	in	vitro	from	recombinant	purified	protein	
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(Figure	9),	and	exposed	target	SY5YchGal3	cells	to	these	exogenous	aggregates	in	the	
culture	media,	we	noted	clear	vesicle	rupture	as	indicated	by	the	colocalization	of	a-syn	
aggregates	with	distinct	chGal3	puncta	at	the	site	of	vesicle	damage	(Figure	10).	
Quantification	of	this	phenomenon	revealed	an	identical	propensity	to	induce	vesicle	
rupture	between	WT	and	familial	mutant	a-syn	(Figure	11),	indicating	that	individual	
amino	acid	missense	mutations	do	not	alter	the	structural	characteristics	of	the	
resulting	amyloid	aggregate	enough	to	influence	its	vesicle	rupture	potency.	Although	
this	finding	again	emphasizes	the	conserved	nature	of	endocytic	vesicle	rupture	induced	
by	a	variety	of	amyloid	protein	assemblies,	we	were	unable	to	observe	a	significant	
change	in	vesicle	rupture	potency	with	assemblies	composed	of	any	missense	mutant	
form	of	a-syn.	These	findings	are	limited,	though,	in	the	preparation	scheme	utilized	to	
generate	amyloid	aggregates.	The	intermediate	aggregation	period	and	lack	of	
fragmentation	utilized	in	these	studies	results	in	a	heterogeneous	population	of	
aggregates	that	may	contain	large,	small,	or	even	monomeric	forms	of	a-syn.	Future	
studies	will	examine	the	impact	of	familial	disease-associated	a-syn	missense	variants	in	
the	context	of	assembly	populations	of	a	homogenous	size	distribution.		
	 Given	the	preferential	and	consistent	upregulation	of	S129	phosphorylation	in	
PD	[260],	and	the	fact	that	90%	of	a-syn	in	pathological	LB	inclusions	is	phosphorylated	
at	S129	compared	to	less	than	5%	of	soluble	a-syn	exhibiting	this	PTM	[119-122],	we	
next	investigated	the	influence	of	S129	phosphorylation	on	endocytic	vesicle	rupture	
potency	alone	or	in	combination	with	a-syn	familial	missense	mutations.	Despite	the	
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prevalence	of	this	a-syn	PTM,	its	influence	on	a-syn	pathology	is	still	poorly	understood.	
Even	the	question	of	whether	S129	phosphorylation	is	a	cause	or	a	consequence	of	a-
syn	toxicity	is	unanswered.	We	reasoned	that	S129	phosphorylation	would	affect	
aggregate	structure,	membrane	binding,	or	both	in	such	a	way	that	increases	the	
endocytic	vesicle	rupture	potency	of	assemblies	exhibiting	this	PTM.	To	address	this	
hypothesis,	we	generated	aggregates	of	recombinant	purified	WT,	A30P,	and	A53T	a-
syn	that	had	been	expressed	in	E.coli	with	or	without	PLK2,	which	induces	specific	
phosphorylation	only	at	S129.	Incubation	of	recipient	SY5YchGal3	cells	with	these	
exogenous	aggregates	results	in	clear	induction	of	endocytic	vesicle	rupture	as	shown	by	
relocalization	of	chGal3	to	the	site	of	vesicle	rupture	and	colocalization	with	a-syn	
fluorescence	(Figure	12).	Quantification	of	this	experimental	data,	which	had	been	
acquired	and	analyzed	in	a	blinded	fashion,	revealed	a	consistent	50%	increase	in	vesicle	
rupture	potency	induced	by	S129	phosphorylation	(Figure	13).	Our	observation	that	
S129	phosphorylation	increases	the	potency	of	endocytic	vesicle	rupture,	combined	
with	the	specific	enrichment	of	this	PTM	in	pathologic	LB	inclusions,	raises	the	
possibility	that	these	two	events	are	linked,	and	that	increases	in	endocytic	vesicle	
rupture	potency	by	pathologic	pS129	a-syn	increases	the	likelihood	of	LB	inclusion	
formation.	Whether	S129	phosphorylation	occurs	to	cause	a-syn	pathological	behavior	
or	simply	results	from	already	increased	pathological	characteristics,	once	a-syn	
aggregates	become	phosphorylated,	before	or	after	their	assembly,	S129	
phosphorylation	induces	more	toxicity	because	of	increased	vesicle	rupture	potency.		
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	 Finally,	given	the	fact	that	distinct	a-syn	strain	conformations	underlie	the	
tremendous	heterogeneity	of	disease	phenotypes	in	the	a-synucleinopathy	diseases	PD,	
DLB,	and	MSA	[304],	we	next	examined	the	influence	of	a-syn	strain	conformation	on	
endocytic	vesicle	rupture	potency	with	the	hypothesis	that	differences	in	rupture	
potency	induced	by	distinct	a-syn	strains	may	result	in	strain-specific	differences	in	
disease	phenotype.	Distinct	a-syn	strains	exhibiting	different	structures,	levels	of	
toxicity,	and	seeding	and	propagation	properties	have	been	generated	in	vitro	by	
varying	the	conditions	of	aggregation	[218,	305-310,	315],	and	the	existence	of	distinct	
strains	in	vivo	has	been	verified	with	PD	and	MSA	samples	[312-314].	Strain	diversity	is	
encoded	by	variable	conformations	of	PrP,	a-syn,	tau,	and	HTTExon1	in	their	respective	
proteinopathies,	and	these	differences	may	account	for	differences	in	disease	pattern	as	
even	slight	changes	to	aggregate	conformation	may	have	a	big	impact	on	biological	
behavior.	We	hypothesized	that	variable	strain	conformations	exposing	different	
surfaces	and	exhibiting	distinct	physical	properties	would	dictate	membrane	association	
and	subsequent	endocytic	vesicle	rupture	potency.	To	test	this	hypothesis,	distinct	a-
syn	strains	generated	in	vitro	from	WT	a-syn	and	fragmented	to	produce	smaller	sized	
fibrillar	assemblies	(Figure	14)	were	used	as	a	treatment	for	recipient	SY5YchGal3	cells,	
and	their	relative	abilities	to	induce	vesicle	rupture	were	quantified.	We	observed	
vesicle	rupture	in	response	to	endocytosis	of	all	fibrillar	strains	of	a-syn	examined,	
although	vesicle	rupture	was	not	observed	in	response	to	treatment	with	a-syn	
monomers	or	oligomers	(Figure	15).	Quantification	revealed	significant	increases	in	
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vesicle	rupture	induced	by	a-syn	fibrils,	fibrils-65,	and	fibrils-91,	but	a-syn	ribbons	were	
unable	to	induce	a	significant	increase	in	vesicle	rupture	compared	to	unexposed	cells	
(Figure	16)	despite	observing	instances	of	a-syn	ribbons	fluorescence	colocalizing	with	
chGal3	puncta	just	as	for	other	a-syn	fibrillar	strains.	These	findings	indicate	that	the	
fibrillar	nature	of	a-syn	assemblies	is	necessary	but	not	sufficient	for	the	ability	to	
induce	vesicle	rupture,	and	the	intrinsic	conformation	of	a-syn	fibrillar	polymorphs	
dictates	endocytic	vesicle	rupture	potency.	Because	a-syn	fibrils	have	been	shown	to	
induce	higher	levels	of	toxicity	in	vitro	[305]	and	in	vivo	[218]	compared	with	a-syn	
ribbons,	and	these	two	polymorphs	yield	different	synucleinopathies	when	injected	into	
recipient	animals	[218],	we	believe	that	differences	in	endocytic	vesicle	rupture	potency	
may	account	for	strain-specific	differences	in	disease	pathology.	Additionally,	in	the	
setting	of	endocytic	vesicle	rupture	induced	by	multiple	isoforms	of	full-length	WT	tau,	
we	observed	a	significant	increase	in	vesicle	rupture	potency	for	tau	isoform	1N4R	
compared	with	tau	isoform	1N3R	(Figure	19),	indicating	that	vesicle	rupture	induction	
may	also	underlie	phenotypic	variability	among	tauopathies	just	as	for	a-
synucleinopathies.	Finally,	in	an	intriguing	turn	of	events,	since	the	completion	of	our	
work	examining	the	effect	of	S129	phosphorylation	on	vesicle	rupture	potency,	another	
study	found	that	pS129	a-syn	assembles	into	a	unique	strain	conformation	distinct	from	
non-pS129	a-syn	[316],	offering	an	explanation	for	our	observed	increase	in	vesicle	
rupture	potency	with	S129	phosphorylation	based	on	the	existence	of	a	unique	strain	
conformation	that	may	be	capable	of	more	potent	endocytic	vesicle	rupture	induction.		
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	 Our	work	examining	the	mechanism	of	endocytic	vesicle	rupture	induced	by	
fibrillar	amyloid	protein	assemblies	forms	the	basis	for	the	established	induction	of	
seeding	and	templating	of	expressed	proteins	by	invading	exogenous	assemblies.	In	the	
life	cycle	of	amyloid	protein	cell-to-cell	propagation,	exogenous	amyloid	assemblies	
need	to	break	out	of	the	endocytic	vesicle	to	access	the	cytosolic	“replication	
machinery”,	additional	monomeric	constituent	building	blocks.	Such	a	mechanism	is	
deviously	employed	by	intracellular	bacteria	and	viruses,	which	escape	the	vesicular	
compartment	and	evade	cellular	defense	responses,	sometimes	even	using	these	
responses	to	their	advantage	[572].	Bacteria	and	viruses	have	an	evolutionary	pressure	
to	develop	these	characteristics	or	else	face	extinction.	Aggregated	amyloid	proteins	do	
not	have	this	evolutionary	pressure	or	agenda.	These	proteins	are	pulled	away	from	
their	endogenous	roles	when	they	become	misfolded	and	aggregated,	and	their	
accumulation	results	in	highly-stable	protein	aggregates	whose	behavior	is	dictated	only	
by	the	environmental	conditions	they	experience.	Seeding	of	additional	monomeric	
misfolding	is	part	of	the	definition	of	prion-like	proteins,	and	this	seeding	process	
cannot	occur	unless	the	exogenous	amyloid	seed	contacts	intracellular	naïve	monomeric	
constituents	to	serve	as	a	template	for	further	misfolding.	While	many	groups	have	
separately	established	the	importance	of	both	uptake	by	endocytosis	[448-450,	498,	
506-508,	531]	and	induction	of	intracellular	seeding	[18,	19,	21,	197,	200-202,	212,	213,	
347,	478,	490,	498,	510,	525,	526,	534],	these	two	essential	aspects	of	the	amyloid	
protein	propagation	pathway	have	never	been	linked	[448,	465,	522,	531].	No	study,	
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until	our	prior	work	[4],	had	directly	assessed	the	ability	of	amyloid	proteins	to	escape	
the	endocytic	compartment.	Additionally,	building	on	these	previous	findings,	the	
specific	aggregate	species	involved	and	the	molecular	determinants	of	rupture	potency	
remained	to	be	determined.	We	have	established	that	short	fragments	of	fibrillar	
amyloid	assemblies	represent	the	aggregate	species	most	potent	for	inducing	vesicle	
rupture,	perfectly	aligning	with	the	prevailing	view	that	these	same	species	most	easily	
enter	recipient	cells	via	endocytosis	[45,	200,	509],	most	effectively	disrupt	artificial	
liposomes	[557],	most	potently	induce	seeding	[22-25,	209-211,	525,	527,	653]	and	
toxicity	[129,	389-393],	and	most	efficiently	propagate	from	one	cell	to	another	[202,	
203,	212,	213,	219,	439,	441,	442].	These	findings	add	endocytic	vesicle	rupture	to	the	
list	of	characteristics	of	prion-like	amyloid	proteins,	with	its	amyloid	structure	imparting	
this	function	just	as	it	does	for	seeding/templating	and	propagation.	Due	to	the	
conserved	nature	of	endocytic	vesicle	rupture	for	the	cellular	entry	of	amyloid	protein	
assemblies	from	multiple	neurodegenerative	diseases,	there	may	be	a	shared	
therapeutic	approach	that	could	have	a	broad	impact.		
Affected	Cells	Target	Ruptured	Vesicles	and	Alpha-Synuclein	Cargo	to	Autophagy	
	 Knowing	that	endocytic	vesicle	rupture	represents	the	mechanism	for	the	
cellular	invasion	of	exogenous	amyloid	assemblies,	we	next	sought	to	examine	the	
impact	of	this	vesicle	damage	on	vesicular	trafficking	and	degradation	processes.	
Although	we	have	exploited	their	properties	as	PRRs,	recognizing	exposed	b-galactoside	
sugars	abnormally	present	in	the	cytosol	[570,	571],	for	the	fluorescent	microscopic	
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detection	of	endocytic	vesicle	rupture	events[619,	620],	cytosolic	galectins	such	as	Gal3	
and	Gal8	play	an	integral	role	in	degradative	and	innate	immune	defense	responses	
within	cells	affected	by	endocytic	vesicle	rupture	[570,	579,	587-589,	602,	603].	In	the	
context	of	infectious	pathogens	or	sterile	damage	that	cause	endocytic	vesicle	rupture	
in	an	identical	fashion	to	that	induced	by	invading	amyloid	protein	assemblies,	it	is	
known	that	ruptured	vesicles	become	recognized	by	the	autophagic	machinery	for	
degradation	[570,	576,	579,	597-600,	603],	and	as	a	result	of	recruitment	to	the	ALP	can	
subsequently	recover	a	low	pH	despite	their	previous	rupture	[560,	615].	We	examined	
the	situation	of	a-syn-induced	endocytic	vesicle	rupture	to	learn	if	this	process	of	
autophagic	recruitment	of	ruptured	vesicles	also	occurs	in	the	context	of	a-syn	invasion,	
or	if	ongoing	membrane	damage	would	prevent	autophagic	recruitment	and	re-
establishment	of	a	low	pH	environment.	To	do	this,	we	utilized	immunofluorescent	
detection	of	the	lysosomal	marker	LAMP1	in	addition	to	live	cell	imaging	of	YFP-labeled	
LC3	and	the	identification	of	low	pH	compartments	labeled	by	Lysotracker	in	
SY5YchGal3	cells	exposed	to	a-syn	assemblies.	We	confirmed	our	previous	finding	that	
lysosomes	are	ruptured	by	a-syn	aggregates	[4]	by	demonstrating	colocalization	of	
chGal3+	ruptured	vesicles	containing	a-syn	with	LAMP1	(Figure	24).	Furthermore,	we	
also	confirmed	that,	like	ruptured	vesicles	caused	by	invading	pathogens	or	sterile	
damage,	lysosomes	ruptured	by	a-syn	aggregates	are	recruited	to	LC3+	
autophagosomes	and	re-establish	a	low	pH	gradient	(Figure	24,	25).	This	recruitment	of	
damaged	vesicles	and	a-syn	cargo	to	the	ALP	counteracts	accumulation	of	misfolded	
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proteins	and	dysfunctional	organelles	(Figure	32,	left),	but	would	also	be	expected	to	
add	to	the	overall	burden	of	substrates	needing	to	be	cleared	through	this	degradative	
mechanism,	causing	an	increased	workload	for	this	system	to	maintain	proteostasis.	
Future	studies	will	examine	the	signaling	cascades	that	mediate	this	targeting	of	
ruptured	vesicles	to	the	ALP,	and	determine	if	enhancing	their	detection	and	
recruitment	and/or	boosting	the	overall	degradative	capacity	of	the	pathway	may	have	
therapeutic	efficacy	for	tipping	the	scale	back	in	the	direction	of	equilibrium.		
Endocytic	Vesicle	Rupture	Can	Promote	Inclusion	Formation	
	 As	the	mechanism	for	exogenous	pre-formed	amyloid	assemblies	to	trigger	the	
aggregation	and	intracellular	inclusion	formation	of	expressed	naïve	constituents,	
endocytic	vesicle	rupture	delivers	the	seed	to	the	cytoplasm	where	it	continues	its	
prion-like	cascade.	Additionally,	rupture	of	lysosomes	by	invading	amyloid	assemblies	
directly	impairs	lysosomal	degradation	by	causing	cathepsin	leakage	and	produces	
oxidative	stress	[4].	Given	these	roles,	endocytic	vesicle	rupture	is	uniquely	positioned	
to	provide	both	the	substance,	misfolded	seeds	and	damaged	vesicles,	and	the	stimulus,	
degradative	dysfunction,	for	pathologic	proteinaceous	inclusion	formation.	The	
prevailing	hypothesis	regarding	the	formation	of	LB	inclusions	of	a-syn	is	that	this	
process	is	related	to	the	formation	of	aggresomes,	agglomerations	of	degradative	
substrates	occurring	as	a	protective	mechanism	of	the	cell	to	more	efficiently	facilitate	
degradation	[118,	124].	This	observation	is	supported	by	numerous	demonstration	of	
LBs	as	clusters	of	vesicles	containing	lysosomal	and	autophagic	markers	and	proteolytic	
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enzymes	[128-135].	Additionally,	activation	of	autophagy	can	facilitate	the	dissolution	of	
larger	inclusions,	increasing	the	number	of	smaller	cytoplasmic	aggregates	[327].	
Alternatively,	mature	fibrillar	inclusion	bodies	are	known	to	be	refractory	to	lysosomal	
or	autophagic	clearance	[134,	334],	exemplified	by	the	buildup	of	dysfunctional	
lysosomes	and	autophagosomes	[131,	339,	346].	When	degradative	mechanisms	are	
dysfunctional,	the	merging	of	substrates	into	aggresome-like	structures	instead	
facilitates	LB	inclusion	formation	[118,	124]	(Figure	32,	right).	Given	the	nature	of	
vesicles	ruptured	by	a-syn	as	targeted	for	autophagic	degradation	just	like	their	
misfolded	protein	aggregate	cargo,	and	the	contribution	of	a-syn-mediated	LMP	to	
degradative	dysfunction,	we	reasoned	that	endocytic	vesicle	rupture	may	contribute	to	
pathological	inclusion	formation.	To	test	this	hypothesis,	we	examined	intracellular	
trafficking	of	ruptured	vesicles	for	the	presence	and	formation	of	intracellular	inclusions,	
and	investigated	the	localization	of	endogenous	Gal3	in	PD	post-mortem	SN	tissue.	Live-
cell	imaging	of	ruptured	vesicles	containing	a-syn	demonstrated	instances	where	
multiple	smaller	ruptured	vesicles	merged	into	larger	low	pH	inclusions	(Figure	25,	26,	
27),	and	large	perinuclear	inclusions	of	exogenous	a-syn	identified	by	fixed	cell	imaging	
exhibited	a	corona	of	chGal3	fluorescence	around	the	periphery	of	the	inclusion,	
indicating	rupture	in	the	vesicles	that	merged	to	create	the	inclusion	(Figure	28,	32	right	
inset	image).	Finally,	immunofluorescent	detection	of	pS129+	LBs	and	endogenous	Gal3	
in	the	post-mortem	SN	of	PD	patients	also	demonstrated	Gal3	localization	as	a	corona	
surrounding	pathological	LB	inclusions,	indicating	a	history	of	previous	membrane	
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rupture	as	preceding	LB	formation	(Figure	29,	32	right	inset	image).	The	observation	
that	Gal3	is	trapped	within	the	majority	of	LBs	(≥55%)	in	the	brains	of	PD	patients	
suggests	that	these	proteinaceous	inclusions	do	not	originate	solely	from	the	
aggregation	of	expressed,	misfolded	α-syn,	but	rather	have	as	their	origin	the	invasion	
of	exogenous	a-syn	fibrils	through	endocytic	vesicle	rupture.	Indeed,	the	trafficking	of	
exogenous	fibrils	from	affected	to	naïve	cells,	either	naked	or	encapsulated	within	
intracellular	vesicles,	would	lead	through	vesicle	rupture	to	their	accumulation	into	LBs	
and	the	trapping	of	Gal3	within	these	LBs.	While	these	findings	demonstrate	that	
endocytic	vesicle	contributes	to	pathological	inclusion	formation	in	authentic	PD,	we	
have,	to	date,	only	characterized	LB	inclusions	in	5	separate	patients,	all	of	whom	were	
in	a	very	advanced	H&Y5	stage	of	PD.	Future	studies	will	expand	this	work	by	including	
more	patient-derived	samples	from	various	disease	stages	and	brain	regions,	and	focus	
on	characterizing	the	involvement	of	vesicle	rupture	in	the	stages	of	LB	development	in	
various	brain	regions.	Also,	pathological	examination	of	endocytic	vesicle	rupture	in	
fetal	dopaminergic	graft	tissue	implanted	into	the	brains	of	PD	patients	would	provide	
an	elegant	way	to	focus	our	analysis	exclusively	on	a-syn	pathology	arising	from	
exogenous	amyloid	aggregates,	as	young	fetal	dopaminergic	grafts	would	not	be	
expected	to	develop	LB	pathology	spontaneously.	The	finding	that	~55%	of	SN	LBs	
exhibit	a	discernable	Gal3	corona	that	indicates	vesicle	rupture	may	increase	if	the	
source	of	LB	pathology	is	exclusively	exogenous,	and	would	need	to	induce	endocytic	
vesicle	rupture	to	trigger	inclusion	formation	in	recipient	cells.		
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Endocytic	Vesicle	Rupture	Can	Promote	Alpha-Synuclein	Cell-to-Cell	Propagation	
	 Many	of	the	same	stimuli	prompting	intracellular	inclusion	formation,	such	as	
lysosomal	or	autophagic	dysfunction	and	oxidative	stress,	are	also	known	to	promote	
the	pathological	release	and	cell-to-cell	transmission	of	amyloid	protein	aggregates	
[294,	468-471,	473,	479,	485,	518]	(Figure	32,	right).	We	aimed	to	determine	if	
endocytic	vesicle	rupture	could	fulfill	this	criterion	as	well.	Interestingly	given	the	
association	of	the	invading	amyloid	aggregate	with	an,	albeit	ruptured,	intracellular	
vesicle,	there	have	been	numerous	mechanisms	of	non-classical	secretion	proposed	for	
both	a-syn	and	Gal3	that	raise	the	possibility	that	a-syn	aggregates	may	be	released	
into	the	extracellular	environment	through	fusion	of	intracellular	vesicles	with	the	
plasma	membrane	or	through	release	of	vesicles	as	exosomes	[468-473,	478,	480,	591-
593].	These	types	of	non-classical	release	mechanisms	have	also	been	demonstrated	for	
amyloid	assemblies	of	tau	and	HTTExon1	[444,	516-519].	Interestingly,	prions	and	
amyloid	assemblies	of	a-syn,	tau,	and	HTTExon1	have	each	been	shown	to	traffick	from	
affected	to	naïve	cells	within	TNTs,	and	also	to	upregulate	the	cellular	expression	of	
TNTs	to	facilitate	their	own	transmission	[47,	48,	445,	520,	521,	535].	In	the	case	of	a-
syn,	TNT-mediated	transmission	was	shown	to	occur	within	the	lumen	of	lysosomes,	
raising	the	intriguing	possibility	that	ruptured	lysosomes	containing	a-syn	may	be	
involved	in	this	process	[445].	Finally,	the	same	small	fibrillar	forms	of	amyloid	
assemblies	most	potent	for	inducing	vesicle	rupture	are	most	often	the	species	
responsible	for	cell-to-cell	propagation	[202,	203,	212,	213,	219,	439,	441,	442],	
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suggesting	that	cellular	invasion	and	release	may	be	intertwined	when	induced	by	these	
pathogenic	amyloid	species.	To	assess	the	involvement	of	endocytic	vesicle	rupture	in	
the	cellular	release	and	intercellular	propagation	of	a-syn	aggregates,	we	examined	the	
extracellular	localization	and	the	intercellular	movement	of	a-syn	containing	ruptured	
vesicles.	We	observed	ruptured	vesicles	containing	a-syn	present	in	the	extracellular	
environment	(Figure	30),	and	we	furthermore	captured	an	instance	of	a-syn	
intercellular	trafficking	between	chGal3-expressing	hiPSC-derived	dopaminergic	neurons	
that	revealing	a-syn	propagation	occurring	within	a	ruptured	vesicle	(Figure	31).	While	
these	findings	are	preliminary	and	in	need	of	additional	verification,	our	observation	
that	a-syn	release	and	cell-to-cell	propagation	can	occur	in	association	with	ruptured	
vesicles	has	great	importance	for	understanding	disease	pathogenesis.	Future	work	will	
focus	on	characterizing	the	population	of	free	and	membrane-associated	a-syn,	
investigating	the	cellular	factors	that	facilitate	release,	and	examining	the	potential	
chaperone	or	facilitative	role	for	Gal3	in	recognizing	ruptured	vesicle	damage	and	
trafficking	with	a-syn	to	the	extracellular	environment	and	to	neighboring	cells.	We	
believe	that	the	damaging	mechanism	of	cellular	invasion	by	a-syn	assemblies	and	other	
aggregated	amyloid	proteins	through	endocytic	vesicle	rupture	sets	into	a	motion	a	
positive	feedback	loop	whereby	the	cellular	stressors	induced	by	this	damage	lead	to	
the	inability	of	the	damaged	vesicle	and	its	a-syn	cargo	to	be	degraded	via	autophagy	
and	instead	result	in	pathological	inclusion	formation,	amyloid	protein	release,	and	cell-
to-cell	propagation	of	misfolded	protein	pathology.		
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Concluding	Remarks	
	 The	above	results	have	uncovered	a	conserved	role	for	endocytic	vesicle	rupture	
in	the	cell-to-cell	propagation	pathway	of	fibrillar	amyloid	protein	assemblies.	In	the	
intracellular	and	intercellular	life	cycle	of	misfolded	amyloid	protein	aggregates,	thought	
to	underlie	the	inexorable	progression	of	numerous	neurodegenerative	diseases,	the	
mechanism	by	which	amyloid	aggregates	escape	from	the	vesicular	compartment	
following	their	endocytic	uptake	was	unknown.	We	have	characterized	this	process	in	
multiple	model	systems,	observing	its	occurrence	as	a	common	mechanism	of	amyloid	
aggregate	invasion	in	immortalized	cells	and	hiPSC-derived	dopaminergic	neurons.	
Furthermore,	in	a	fashion	resembling	the	cellular	infection	by	bacterial	and	viral	
pathogens,	lysosomes	ruptured	by	a-syn	are	targeted	for	autophagic	degradation,	but	
not	before	their	problematic	permeabilization	releases	proteolytic	cathepsins	and	
mitochondrial	ROS	creating	an	environment	of	oxidative	and	degradative	stress.	
Dysfunctional	degradative	processes	may	fail	to	cope	with	the	burden	of	misfolded	
protein	aggregates	and	damaged	vesicles,	instead	causing	pathological	inclusion	
formation	and	cellular	release	of	pathologic	a-syn	species.	The	localization	of	Gal3	to	
the	periphery	of	LB	inclusions	in	PD	brain	implicates	amyloid	assembly-mediated	
endocytic	vesicle	rupture	as	occurring	in	authentic	human	disease,	and	provides	a	
unique	opportunity	for	further	assessment	of	this	phenomenon	as	a	therapeutic	target	
to	prevent	or	reverse	neurodegenerative	proteinopathies.		
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Figure	33.	chGal3+	ruptured	vesicles	containing	a-syn	observed	in	undeconvolved	and	
deconvolved	fluorescent	microscopic	images.	Image	of	SY5YchGal3	cells	exposed	to	WT	
a-syn	fibrils	from	Figure	15,	shown	as	undeconvolved	and	deconvolved	images.	As	in	
Figure	15,	Overlay	images	are	separated	into	separate	channels	for	either	a-syn	
fluorescence	or	chGal3	fluorescence,	and	inset	box	in	top	images	is	enlarged	in	bottom	
images.	Arrowheads	indicate	colocalization	between	chGal3+	ruptured	vesicles	
appearing	as	discrete	puncta	and	a-syn	assemblies,	observed	in	both	undeconvolved	
and	deconvolved	image	sets.	
	
	
	
Figure	34.	Three-dimensional	surfaces	encapsulating	a-syn-containing	chGal3+	
ruptured	vesicles	superimposed	onto	deconvolved	fluorescent	microscopic	images.	
Image	of	SY5YchGal3	cells	exposed	to	A53T	a-syn	assemblies	from	Figure	12,	analyzed	
for	puncta	formation	by	use	of	the	Surpass	Mode	of	the	Imaris	software	package	
(Bitplane).	A	three-dimensional	surface	was	created	around	chGal3	puncta	by	designing	
an	algorithm	for	each	experiment	that	specifically	detected	punctate	events	that	
increased	in	intensity	sufficiently	above	background	fluorescence.	Algorithm-detected	
semi-spherical	chGal3+	puncta	are	seen	in	gray,	either	superimposed	on	fluorescent	
image	in	left	panel	or	alone	in	right	panel.			
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